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Abstract 
The platelet collagen receptor GPVI has been shown to activate platelets through an 
ITAM (immunoreceptor based activatory motif) signalling pathway mediated by 
sequential activation of Src and Syk tyrosine kinases leading to activation of PLC2.  
The recently discovered C-type lectin CLEC-2 has been shown to activate platelets 
using an ITAM-like sequence in its cytoplasmic tail that is also dependent on Src and 
Syk tyrosine kinases, but this shows a partial rather than an absolute dependence on 
adapter SLP-76 for activation of PLC2.  The aim of this thesis is to understand some of 
the key differences in these two signalling pathways. 
 
GPVI is found in a complex with FcRwhich contains the ITAM sequence consisting 
of two conserved tyrosine residues (Yxx(L/I)x6-12Yxx(L/I)).  These two tyrosines, when 
phosphorylated, provide a docking site for the tandem SH2 domains of the tyrosine 
kinase Syk, which plays a critical role in downstream signalling and platelet activation.  
In this thesis I show that CLEC-2 signalling through Syk is mediated by 
phosphorylation of the single CLEC-2 YxxL sequence and involves receptor 
dimerisation and cross-linking by the tandem SH2 domains in Syk.  I also show that the 
differential requirement for the adaptor protein SLP-76 between GPVI and CLEC-2 is 
not mediated by the adaptor Gads, which is a constitutive SLP-76 binding partner and 
plays a similar, weak partial role in platelet activation by both receptors.  Both 
signalling pathways also show a similar, partial dependency for the transmembrane 
adaptor protein LAT, although its role is more substantive that that of Gads.  I also 
show that a novel membrane adapter protein, G6f, is not able to substitute for LAT in 
this signalling pathway and also exclude the LAT-family proteins PAG, LIME, LAX 
  
and NTAL as potential LAT replacements in platelet activation by GPVI.  Thus, these 
results extend our understanding of the mode of platelet activation by CLEC-2 in 
comparison to GPVI, with the major difference being that the former induces activation 
of Syk through a novel dimerisation pathway.  The events that lie downstream of 
activation of Syk by CLEC-2 and GPVI on the other hand appear to largely similar. 
  
  
Publications arising from this thesis 
Hughes, C. E., A. Y. Pollitt, J. Mori, J. A. Eble, Michael G. Tomlinson, John H. 
Hartwig, Chris A. O‟Callaghan, Klaus Fütterer and S. P. Watson (2010). 
"CLEC-2 activates Syk through dimerisation." Blood (in press). 
 
Hughes, C. E., J. M. Auger, J. McGlade, J. A. Eble, A. C. Pearce and S. P. Watson 
(2008). "Differential roles for the adapters Gads and LAT in platelet activation 
by GPVI and CLEC-2." J Thromb Haemost 6(12): 2152-9. 
 
Garcia, A., Y. A. Senis, R. Antrobus, C. E. Hughes, R. A. Dwek, S. P. Watson and N. 
Zitzmann (2006). "A global proteomics approach identifies novel 
phosphorylated signalling proteins in GPVI-activated platelets: involvement of 
G6f, a novel platelet Grb2-binding membrane adapter." Proteomics 6(19): 5332-
43.  
  
 
 
“…all that is of the body is as coursing waters, all that is of the soul as dreams and 
vapours; life a warfare, a brief sojourning in an alien land; and after repute, oblivion.  
Where, then, can man find the power to guide and guard his steps?  In one thing and one 
alone: the love of knowledge.” 
Marcus Aurelius 
 
 
“We are just an advanced breed of monkeys on a minor planet of a very average star.  
But we can understand the Universe.  That makes us something very special.” 
Stephen Hawking 
 
 
“When you are courting a nice girl an hour seems like a second.  When you sit on a red-
hot cinder a second seems like an hour.  That's relativity.” 
Albert Einstein 
  
  
Acknowledgments 
First and foremost I would like to thank my supervisor Steve Watson who has been, and 
continues to be a constant source of encouragement and support.  It has been thanks to 
his help that I feel like I can call myself a scientist.  Thanks also to Mike Tomlinson, my 
second supervisor who has also been a source of great help and advice.  Thanks to the 
University of Birmingham for our lab space and to the Wellcome Trust for funding. 
Many thanks to our collaborators for reagents, mice and the use of their lab space and 
equipment.  In particular Dr. Burkhart Schraven and Dr. Mauro Togni for allowing me 
to work in their lab in Magdeburg, Germany and for the use of many of their knock-out 
mice.  Thanks to Dr. Jane McGlade for sending the Gads knock-out mice from Canada.  
Thanks to Dr. Chris O‟Callaghan and his lab in Oxford for teaching me how to use their 
Biacore T-100 and thanks to Dr. Klaus Fütterer for his help with protein expression, 
ITC and tryptophan fluorescence in the School of Bioscience.  Thanks also to John 
Herbert for his bioinformatical know how. 
Thanks also to members of the Watson lab, both past and present; it wouldn‟t have been 
the same without you all.  In no particular order, Andy for being a mentor and a great 
bloke.  Gemma for being posh.  Teresa for teaching me the geography of Europe, and 
for being a great friend.  Simon aka Cpt. Starch Boy for consistently beating me at 
squash.  Stevie T for consistently losing to me at squash, and for being my chauffer, and 
also being a great bloke.  Yotis for making offers people cannot refuse.  Mark and Jen 
for both being stalwart Pub Quizzers.  Majd for being a computer whiz.  Neil for 
making me feel like a cool, calm and collected individual.  Jun for being funny, and for 
fitting underneath her desk.  Sonia and Alex for teaching me about France.  Dario for 
punching me, a lot, still to this day without any real explanation.  Alice for being one of 
the nicest people to work with and for introducing me to studio cycling without ruining 
my butch image.  Banjo for being a cross between a mother and a child.  Jossy for 
laughing.  Stuart for being the first Man Utd fan from Manchester I‟ve met. Craig for 
being a great sport.  Dean for the love.  Ian aka Swerve for being an enigma.  The 
Marmite Sandwiches for good times and the most fun I‟ve had loosing at football, and 
last but definitely not least, Gayle for being easy to scare. 
Also, thanks to Andy for being not only a great bloke but also a Best Man, and to both 
Andy and Gemma for countless evenings/nights/early mornings, for going on holiday 
with us, and for being Ben‟s Godparents.  Birmingham just isn‟t the same without you 
two.  To Kings Norton RFC for allowing me an outlet for my stress and making me feel 
like a sportsman. 
To Mom, Dad, Emma and Brian, thanks for all your love and support.  Hopefully Dad 
can now say “Thank you Doctor” without it being entirely erroneous.  And finally to my 
loving wife Clare, and my son Benjamin.  For your support and understanding and 
putting up with me through this from day one, you have made this thesis possible.  I 
dedicate it to you. 
 
 
  
  
Abbreviations 
 
5-HT 5-hydroxytryptamine (serotonin) 
ACD Acid citrate dextrose 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ATP Adenosine triphosphate 
BCR B-cell receptor 
BSA Bovine serum albumin 
cAMP Cyclic adenosine monophosphate 
cGMP Cyclic guanosine monophosphate 
CLEC-2 C-type lectin-like receptor 2 
CRD Carbohydrate recognition domain 
CTLD C-type lectin-like domain 
CRP Collagen related peptide 
DAG Diacylglycerol 
DIC Differential interference contrast 
DMEM Dulbecco‟s modified eagle medium 
DMSO Dimethylsulfoxide 
ECL Enhanced chemiluminescence 
EDTA Ethylenediamine tetra-acetic acid 
EGTA Ethylene glycol tetra-acetic acid 
FAK Focal adhesion kinase 
FcR Fc receptor 
Gads Grb2 adaptor downstream of Shc 
GDP Guanine diphosphate 
GEF Guanine nucleotide exchange factor 
GEMs Glycolipid enriched microdomains 
GPVI Glycoprotein VI 
Grb2 Growth factor receptor bound protein-2 
GST Glutathione-S-transferase 
GTP Guanine triphosphate 
HRP Horseradish peroxidase 
Ig Immunoglobulin 
IP Immunoprecipitation 
IP3 Inositol-1,4,5-trisphosphate 
ITC Isothermal titration calorimetry 
ITAM Immunoreceptor tyrosine based activation motif 
ITIM Immunoreceptor tyrosine based inhibition motif 
ITSM Immunoreceptor tyrosine based switch motif 
kDa Kilodalton 
LAT Linker for activation of T-cells 
mAb Monoclonal antibody 
pAb Polyclonal antibody 
PAR Protease activated receptor 
PAS Protein A sepharose 
PBS Phosphate buffered saline 
PGI2 Prostaglandin I2 
PGS Protein G sepharose 
  
PH Pleckstrin homology 
PI-3 kinase Phosphatidyl inositol-3 kinase 
PIP2 Phosphatidyl inositol-4,5-bisphosphate 
PIP3 Phosphatidyl inositol-3,4,5-trisphosphate 
PKA Protein kinase A 
PKC Protein kinase C 
PKG Protein kinase G 
PLA Phospholipase A 
PLC Phospholipase C 
PMA Phorbol myristate acetate 
PRP Platelet rich plasma 
PS Phosphatidyl serine 
PTB Phosphotyrosine binding 
PVDF Polyvinyl difluoride 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SH2 Src homology 2 
SH3 Src homology 3 
SLP-76 SH2 containing leukocyte protein of 76 kDa 
SPR Surface plasmon resonance 
Sulfo-EGS Ethylene glycol bis (sulfosuccinimidylsuccinate) 
TBS-T Tris buffered saline-Tween 
TCR T-cell receptor 
TPO Thrombopoietin 
TxA2 Thromboxane A2 
VWF Von Willebrand Factor 
WT Wild type  
  
Contents 
 
1   General introduction 
1.1  Platelet physiology 
 1.1.1 Platelet overview      2 
 1.1.2 Platelet genesis      2 
 1.1.3 Platelet anatomy      5 
 1.1.4 Platelet function in haemostasis    6 
 1.1.5 Platelet activation and inhibition    11 
1.2  Platelet ITAM signalling 
 1.2.1 The GPVI-Fc receptor -chain complex   18 
 1.2.2 The GPVI receptor signalling pathway   21 
 1.2.3 FcRIIA – a second platelet ITAM receptor   27 
 1.2.4 Integrin IIb3       28 
 1.2.5 The role of GEMs in platelet ITAM signalling  30 
 1.2.6 ITAM signalling in other haematopoietic cells  31 
1.3  The C-type lectin CLEC-2 in platelets 
 1.3.1 CLEC-2       33 
 1.3.2 Rhodocytin       36 
 1.3.3 The CLEC-2 signalling pathway    37 
 1.3.4 Other platelet C-type lectin receptors    39 
 1.3.5 Endogenous CLEC-2 ligands     41 
 1.3.6 Dectin-1 and CLEC9A     49 
1.4  Aims of the thesis      55 
 
2   Materials and methods 
 2.1  Materials 
  2.1.1 Antibodies and reagents     57 
  
  2.1.2 Plasmids and constructs     60 
  2.1.3 Mice        63 
 2.2  Platelet preparation 
  2.2.1 Human washed platelet preparation    63 
  2.2.2 Mouse washed platelet preparation    64 
 2.3  Platelet functional studies 
  2.3.1 Aggregation and stimulation for biochemistry  65 
  2.3.2 ATP secretion       66 
  2.3.3 Static adhesion and spreading     66 
  2.3.4 P-Selectin exposure      67 
  2.3.5 In vitro flow adhesion      67 
 2.4  Cell culture 
  2.4.1 Cell culture       68 
  2.4.2 Transfection       68 
 2.5  Cell line reporter assay 
  2.5.1 NFAT-luciferase assay     69 
  2.5.2 -galactosidase assay      70 
  2.5.3 Flow cytometry      70 
 2.6  Protein biochemistry 
  2.6.1 Immunoprecipitation and pull-downs    70 
  2.6.2 SDS-PAGE and Western Blotting    71 
  2.6.3 Platelet surface protein cross-linking    72 
2.6.4 GST-fusion proteins 
   2.6.4.1 Expression      73 
   2.6.4.2 Purification      73 
 2.7  Surface plasmon resonance     74 
 2.8  Isothermal titration calorimetry    75 
 2.9  Tryptophan fluorescence titration    75 
 2.10  Analysis of data      76 
  
3 A CLEC-2 dimer is capable of ITAM-like 
signalling through Syk tyrosine kinase 
 3.1  Introduction       78 
 3.2  Results 
3.2.1 Structure-function relationships of the CLEC-2   82
 cytoplasmic tail and Syk tandem SH2 domains 
3.2.2 Dominant negative effect of Y7F CLEC-2 on signalling  88
 by WT CLEC-2 
3.2.3 CLEC-2 oligomers are present on the platelet surface 90 
3.2.4 Affinity measurements of Syk SH2 domains for CLEC-2 93 
3.2.5 GPVI requires both FcR YxxL sequences to signal  100 
 3.3  Discussion       102 
 
4 Differential roles for the adapters Gads and 
LAT in platelet activation by GPVI and 
CLEC-2 
 4.1  Introduction       108 
 4.2  Results 
4.2.1 Comparison of the role of Gads and LAT in platelet aggregation 
and secretion       112 
4.2.2 Platelet aggregation on collagen at arteriolar rates of flow 122 
4.2.3 Measurement of protein tyrosine phosphorylation  124 
4.2.4  Grb2 association with the LAT-Gads-SLP-76   126
 signalosome 
4.2.5 Spreading of platelets on collagen and other matrix  129
 proteins 
 4.3  Discussion       132 
 
5   Investigation of candidate LAT-like molecules 
 5.1  Introduction       138 
 5.2  Results 
  
  5.2.1 Raising a G6f antibody     141 
  5.2.2 G6f is phosphorylated downstream of GPVI in platelets 143 
  5.2.3 G6f is associated with Grb2 but not Gads   148 
  5.2.4 G6f cannot substitute for LAT in LAT-deficient cells 150 
  5.2.5 G6f is not a novel collagen receptor    152 
  5.2.6 Minimal expression of G6f in mouse platelets  155 
  5.2.7 Studies on LAT-like proteins reveal the presence of  159
   PAG in platelets 
5.2.8 Contribution of LAT-family proteins to GPVI-mediated  161
  platelet activation 
 5.3  Discussion       163 
 
6   General Discussion 
 6.1  Summary of findings     168 
 6.2  The evolution of ITAM receptors and C-type lectins 168 
 6.3  Final thoughts      175 
    
References      176 
 
Appendix I 
 I.1  The LAT-family of adapter proteins    218 
 
 
  
 
 
 
 
 
CHAPTER 1 
GENERAL INTRODUCTION 
  
 
  
Chapter 1 – General Introduction 
Page | 2 
 
1.1 Platelet physiology 
1.1.1 Platelet overview 
Platelets play a major haemostatic role in the body.  They have a discoid shape and 
circulate at a relatively high concentration of 1.5 – 4x108/ml in a quiescent state ready to 
form a haemostatic plug at sites of damage to the vasculature.  Their shape, small size 
(1-3 m) and the physics of laminar flow in blood vessels, whereby red blood cells 
cause the platelets to marginate to the vessel wall, means they are ideally placed to 
detect injury to the vessel wall.  Activation is brought about by exposure to sub-
endothelial matrix proteins, by positive feedback mechanisms from the platelets 
themselves and through the generation of thrombin (Gibbins, 2004).  Pathologic platelet 
activation is found in areas of diseased endothelium and atherosclerotic plaque rupture 
causing thrombotic disorders such as myocardial infarction and stroke, two of the major 
causes of death in the Western world.  Anti-platelet agents (e.g. aspirin and clopidogrel) 
are widely prescribed for individuals at high risk of arterial thrombosis.  The following 
sections give an overview of platelet receptors, activation, and inhibition.  For more 
extensive reviews see (Jackson, 2007; Jackson et al, 2009; Watson and Harrison, 2010).  
 
1.1.2 Platelet genesis 
Platelets have a life-span of approximately ten days (Fritz et al, 1986) before their 
removal by the reticuloendothelial system.  Multipotent haematopoietic stem cells in the 
bone marrow give rise to all circulating blood cells (Figure 1.1).  The cytokine, 
thrombopoietin (TPO), plays a critical role at the early stages of blood cell production 
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and in the maturation of megakaryocytes and subsequently, platelet production.  
Megakaryocytes are large polyploid cells that can grow up to 50 m or more and which 
make up approximately 0.1% of bone marrow cells.  They can each be viewed as 
factories that fragment, releasing 2,000–3,000 platelets into the blood stream (Hartwig 
and Italiano, 2003).  They can also be used as a genetically tractable platelet model with 
the advent of RNA interference and viral expression technologies. 
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Figure 1.1 – Haematopoiesis.  Based on (Kondo et al, 2003). 
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1.1.3 Platelet anatomy 
Platelets are anucleate cells which have the capacity to undergo very limited de novo 
protein synthesis, although the physiological significance of this is unclear.  The 
organelles, proteins and very low levels of mRNA are therefore synthesised in the 
parental megakaryocyte, although the platelet retains the ability to take up some 
proteins from the plasma, most notably fibrinogen.  The plasma membrane is supported 
by an actin cytoskeleton and a ring of microtubules to maintain the resting discoid 
shape.  The membrane contains a large network of invaginations known as the open 
canilicular system (OCS) which greatly increases the surface area of the platelet 
membrane thereby increasing the sites for release of granule content.  The OCS also 
contains the dense tubular system which is a Ca
2+
 store and the site for cyclooxygenase-
1, which is crucial in the production of thromboxane A2 (TxA2), a positive feedback 
platelet agonist.  The plasma membrane contains a wide variety and diversity of 
glycoprotein receptors, many of which are expressed at high level such as integrin IIb3 
(GPIIbIIIa), which facilitate rapid platelet activation at sites of vascular damage.  
Phosphatidylserine (PS) is selectively concentrated on the inner envelope of the 
membrane and is exposed on activation to provide a pro-coagulant surface for thrombin 
generation which both further activates additional platelets and leads to fibrin 
generation as part of the coagulation cascade.  Another clotting factor, Factor XII has 
also recently been shown to be activated by platelet-released polyphosphates (Muller et 
al, 2009). 
 
The cytoplasm contains two distinct secretory vesicles which rapidly release their 
contents upon activation, namely -granules and dense granules.  -granules contain a 
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wide variety of proteins which can be divided according to their function.  These 
include adhesion proteins, such as fibrinogen and von Willebrand Factor (VWF), which 
play a critical role in aggregation and thrombus formation.  They also contain a variety 
of chemokines, such as platelet factor 4 (PF4) and SDF-1 which attract leukocytes and 
stem cells to sites of vessel damage, and growth factors, including PDGF, EGF and 
VEGF which are involved in wound repair and angiogenesis.  They also express a 
number of membrane proteins on their surface that support aggregation, including 
band support binding of leukocytes, namely P-selectin.  Dense granules, so called 
due to their appearance in electron micrographs; contain the major feedback mediators 
adenosine diphosphate (ADP) and adenosine triphosphate (ATP), as well as Ca
2+
, 5-HT 
(serotonin), and polyphosphates (Muller et al, 2009; Watson and Harrison, 2010). 
 
1.1.4 Platelet function in haemostasis 
Platelets circulate in healthy vessels in a quiescent state, continuously sampling the 
endothelium for sites of vascular damage.  Ordinarily, platelets are unable to bind to the 
endothelial cells which release PGI2 (prostacyclin) and nitric oxide and express the 
ectonucleoside triphosphate diphosphohydrolase (CD39/ENTPD1, which hydrolyses 
ATP and ADP to AMP) to prevent platelet activation (Kaczmarek et al, 1996).  Damage 
to the endothelium leads to exposure of sub-endothelial matrix proteins which mediate 
powerful platelet adhesion and activation.  Activated platelets will recruit other platelets 
and provide a surface to catalyse the coagulation cascade leading to formation of a 
thrombus and occlusion of the wound (Gibbins, 2004).  The role of platelets in 
thrombus formation can be described in several stages (Figure 1.2) (Watson and 
Harrison, 2010). 
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(1)  Tethering – Under low shear stress (i.e. venous flow) the collagen binding integrin 
21 can bind to exposed collagen fibres in the sub-endothelial matrix.  This interaction 
has a slow rate of association, which under high shear stress (i.e. arterial flow), is unable 
to tether the platelets.  However, the exposed collagen fibres become coated by soluble 
VWF which undergoes rapid binding to the GPIb-IX-V complex on the platelet surface 
as a result of a fast on-rate of association.  This leads to capture (or tethering) of 
platelets but is unable to mediate stable adhesion due to a fast off-rate of dissociation.  
Thus, on a VWF coated surface, platelets role or slide in the direction of flow. 
 
(2)  Activation and stable adhesion – tethering to VWF brings the low affinity collagen 
receptor GPVI into close proximity with the exposed collagen fibres resulting in its 
activation and the conversion of integrins IIb3 and 21 from an inactive to an active 
conformation.  This in turn leads to stable adhesion through their interactions with VWF 
and collagen, respectively.  The GPIb-IX-V complex also generates intracellular signals 
that, on their own, are insufficient to mediate rapid platelet activation but may act in 
synergy with those from GPVI to induce activation. 
 
(3)  Spreading – Activation-dependent actin polymerisation results in the sequential 
formation of filopodia and lamellipodia thereby increasing the surface area in contact 
with the exposed sub-endothelial matrix and strengthening attachment.  This is in turn 
followed by the formation of actin stress fibres that further reinforce the growing 
aggregate (Calaminus et al, 2007). 
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(4)  Secretion – Activated platelets rapidly synthesis thromboxane A2 and secrete this 
along with the contents of their - and dense granules in response to most activatory 
agonists.  ADP is secreted from dense granules and acts in synergy with thromboxane 
A2 to induce aggregation.  Fibrinogen and VWF, which are stored in -granules, support 
platelet aggregation through cross-linking and capture of circulating platelets, 
respectively (Kulkarni et al, 2000). 
 
(5)  Aggregation and thrombus growth – New, discoid shaped platelets are recruited to 
the growing thrombus by a combination of membrane tethers (Nesbitt et al, 2009) and  
binding to VWF.  They are subsequently activated by ADP and TxA2.  Secretion of the 
adhesion proteins fibrinogen and VWF, and their recruitment from plasma, leads to the 
cross-linking of activated platelets (aggregation) through integrin IIb3.  As mentioned 
above, activated platelets also provide a pro-coagulant surface for the generation of 
thrombin through the coagulation cascade (thrombin is also generated by exposure of 
tissue factor).  Thrombin activates further platelets and mediates conversion of 
fibrinogen to fibrin, resulting in a fibrin mesh which makes up the bulk of the growing 
thrombus and occludes the wound, preventing further blood loss. 
 
(6)  Late stage events in platelet activation – Several other transmembrane glycoprotein 
receptors have been shown to participate during the later stages of aggregation and 
thrombus formation by reinforcing (or consolidating) the growing aggregate, including 
ephrins and eph kinases (Prevost et al, 2005; Brass et al, 2008).  There is also evidence 
that aggregation is further strengthened by sustained Src kinase activity and actin-
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dependent contraction, independent of fibrin formation (Auger and Watson, 2008; Ono 
et al, 2008). 
 
(7)  Clot retraction – Further stabilisation of the thrombus is brought about by the active 
process of clot retraction which is mediated by contraction of the actin cytoskeleton via 
fibrin/fibrinogen-bound IIb3. 
 
Several roles for platelets in processes other than in haemostasis have also been 
described, including inflammatory processes through adhesion to activated endothelium 
and recruitment of leucocytes (Tull et al, 2006; Zarbock et al, 2006), cancer metastasis 
(Jain et al, 2007; Jain et al, 2009), vascular integrity (Aursnes and Pedersen, 1979; 
Kisucka et al, 2006) and recently, in the closure of the ductus arteriousus in newborn 
mice (Echtler et al, 2010).  Other roles for platelets are reviewed by (Smyth et al, 2009). 
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Figure 1.2 – Thrombus formation.  Based on (Jackson et al, 2003; Sachs and 
Nieswandt, 2007; Varga-Szabo et al, 2008). 
 
 
 
Chapter 1 – General Introduction 
Page | 11 
 
1.1.5 Platelet activation and inhibition 
This section is a brief description of some of the major activatory and inhibitory agents 
and receptors, including, GPVI, which is of key importance in this thesis as it is used as 
a comparison to the novel activation receptor, CLEC-2. 
 
Platelet activation – Collagen, a sub-endothelial matrix protein, is a powerful activator 
of platelets through GPVI and integrin 21.  Platelets become tethered to collagen via 
interactions with 21 or GPIb-IX-V (via VWF) allowing for robust signalling through 
GPVI (Nieswandt and Watson, 2003).  This is enhanced through inside-out activation of 
integrin 21 which further facilitates binding to and activation of GPVI.  Limited 
signalling by GPIb-IX-V and integrin 21 has also been described but is of uncertain 
physiological significance (Inoue et al, 2003; Ozaki et al, 2005).  The basement 
membrane protein laminin has also been shown to activate GPVI.  Platelets can become 
tethered to laminin coated surfaces via interactions with 61 or GPIb-IX-V (via VWF) 
(Inoue et al, 2006; Inoue et al, 2008) facilitating activation of GPVI.  GPVI has also 
been shown to be activated by globular adiponectin, although the physiological 
relevance of this is unclear (Riba et al, 2008). 
 
GPVI activates platelets through a tyrosine kinase-linked pathway (described in detail 
later) resulting in the activation of phospholipase C- (PLC) which produces the 
secondary mediators inositol-1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) 
which in turn mediate a cellular increase in both Ca
2+
 and protein kinase C (PKC) 
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activity.  Ca
2+
 release from intracellular stores is mediated by IP3.  This Ca
2+
 release 
stimulates extracellular Ca
2+
 entry through the CRAC (Ca
2+
-release-activated-Ca
2+
) 
channel Orai-1by binding to STIM1which is localised to the intracellular stores (Varga-
Szabo et al, 2009).  PKC has been shown to regulate secretion of both dense and -
granules in mouse platelets (Konopatskaya et al, 2009).  There is also evidence for both 
activatory and inhibitory roles that are specific to other PKC isoforms (Hall et al, 2007; 
Pears et al, 2008).  Additionally, DAG and Ca
2+
 together regulate CALDAG-GEF1, a 
Rap1 (aka Rap1b) GTP exchange factor.  Rap1 plays a role in integrin IIb3 activation 
(Chrzanowska-Wodnicka et al, 2005). 
 
The major platelet integrin IIb3 (making up 15% of surface protein) mediates platelet 
adhesion to VWF and platelet aggregation by cross-linking platelets through soluble 
VWF, fibrinogen and other adhesion proteins, including fibronectin and vitronectin.  It 
is essential for aggregation as demonstrated using specific blocking reagents or platelets 
from patients that lack either subunit of the integrin, a condition known as Glanzmann‟s 
thrombasthaenia.  Outside-in signalling through the integrin leads to further PLC 
activation reinforcing platelet activation, and activation of myosin light chain (MLC) 
which plays a role in shape change, actin stress fibre formation and clot retraction 
(Wonerow et al, 2003; Suzuki-Inoue et al, 2007; Coller and Shattil, 2008). 
 
Activation of platelets is reinforced by release of TxA2, which activates the TP 
thromboxane receptor, and by release of ADP, which signals through the P2Y1 and 
P2Y12 receptors.  P2Y1 and P2Y12 couple to the Gq and Gi classes of G proteins, 
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respectively, while TP couples to Gq and G12/13.  Gq activates PLC, while G12/13 
activates p115Rho, a GTP exchange factor which activates Rho, which activates Rho 
kinase, which regulates Myosin light chain phosphatase, thereby playing a role in shape 
change and stress fibre formation.  Gi inhibits the formation of cAMP through 
adenylyl cyclase (Woulfe et al, 2002; Chrzanowska-Wodnicka et al, 2005) and also 
activates PI3-kinase which phosphorylates inositol-lipids in the membrane to provide 
binding sites for the pleckstrin homology domains of PLC and  isoforms, and various 
other proteins.  The P2Y12 ADP receptor interacts synergistically with Gq and G12/13-
coupled receptors to mediate powerful platelet activation.  This synergy accounts for the 
powerful anti-platelet activation of the P2Y12 antagonist clopidogrel which is used in 
the long term treatment of patients at risk of thrombosis.  Platelets also express an ATP 
receptor, P2X1, which is a Ca
2+
 ion channel.  The physiological significance of P2X1 is 
uncertain due to its low expression level. 
 
The coagulation cascade generates thrombin (Factor IIa) which cleaves fibrinogen 
(Factor Ia) to form fibrin, forming a large part of the bulk of a thrombus.  Thrombin also 
activates platelets through the protease-activated receptor (PAR) family of GPCRs 
which are linked to both Gq and G12/13.  Thrombin cleaves the N-terminus of the 
receptors, exposing a tethered ligand.  Human platelets express PAR-1 and PAR-4 
isoforms of the receptor, while mouse platelets express PAR-4 and the PAR-3 isoform.  
The latter does not directly signal but facilitates the interaction between thrombin and 
PAR-4 (Kahn et al, 1998; Xu et al, 1998; Brass, 2003). 
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Table 1.1 Major platelet activation and adhesion receptors 
Receptor Agonists Receptor 
Type 
Signalling 
Pathway 
GPVI Collagen (physiological) 
Laminin (physiological) 
Globular Adiponectin (pathological?) 
CRP (collagen related peptide) (synthetic) 
Convulxin (snake toxin) 
JAQ1 (antibody) 
 
Ig Tyrosine kinase 
21 Collagen (physiological) Integrin Tyrosine kinase 
(weak) 
61 Laminin (physiological) 
 
Integrin  
GPIb-XI-V VWF (physiological) 
Ristocetin (snake toxin) 
 
Leucine-rich Tyrosine kinase 
IIb3 Fibrinogen (physiological) 
VWF (physiological) 
 
Integrin Tyrosine kinase 
P2Y1 ADP (physiological) 
 
GPCR Gq 
P2Y12 ADP (physiological) 
 
GPCR Gi 
P2X1 ATP (physiological) 
 
Ca
2+
 channel  
TP TxA2 (physiological) 
U46619 (synthetic) 
 
GPCR Gq, G12/13 
PAR1 Thrombin (physiological) 
PAR1 peptide (synthetic) 
 
GPCR Gq, G12/13 
PAR4 Thrombin (physiological) 
PAR4 peptide (synthetic) 
GPCR Gq, G12/13 
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Platelet inhibition – Healthy, intact endothelium has several mechanisms for inhibiting 
platelet activation.  Probably the most powerful mechanism is through nitric oxide (NO) 
generation.  Healthy endothelial cells continuously synthesise NO through nitric oxide 
synthase (NOS) (Jin et al, 2005; Naseem, 2005).  NO is a membrane permeable gas 
with a short half life in the vasculature and so is concentrated close to the endothelial 
cell wall.  NO activates guanylyl cyclase leading to formation of cyclic guanosine 
monophosphate (cGMP) which inhibits platelet activation.  Endothelial cells release 
PGI2 (prostaglandin I2, prostacyclin) which also has short half life (Jin et al, 2005).  
PGI2 acts on the platelet through the G protein-coupled PGI2 receptor (IP) which is 
coupled to Gs.  Activation of this receptor results in an accumulation of cyclic 
adenosine monophosphate (cAMP) and platelet inhibition.  cAMP and cGMP activate 
protein kinase A (PKA) and protein kinase G (PKG) respectively, which phosphorylate 
several common target proteins in platelets,  including Rap1b and vasodilator-
stimulated phosphoprotein (VASP) (Munzel et al, 2003).   In addition, PKG 
phosphorylates the IP3 receptor-associated cGMP kinase substrate (IRAG), which is 
expressed in complex with PKG-1, and the type 1 IP3 receptor (Antl et al, 2007).  
Phosphorylation of IRAG by PKG-1 inhibits IP3-induced Ca
2+
 release.  Another major 
mechanism of endothelial cells inhibiting platelets is by virtue of their expression of 
CD39.  This enzyme will hydrolyse the platelet agonists ATP and ADP to AMP (Jin et 
al, 2005).   
 
Platelets express several ITIM (immunoreceptor tyrosine based inhibitory motif)-
containing receptors namely PECAM-1 (platelet endothelial adhesion molecule 1, 
CD31) (Falati et al, 2006; Dhanjal et al, 2007), CEACAM-1 (carcinoembryonic 
Chapter 1 – General Introduction 
Page | 16 
 
antigen-related cell adhesion molecule 1, CD66a) (Wong et al, 2009), TLT-1 (TREM-
like transcript 1) (Barrow et al, 2004; Washington et al, 2004) and G6b (Newland et al, 
2007; Mori et al, 2008).  ITIMs are binding sites for the inhibitory phosphatases SHP1 
and 2 (SH2 containing tyrosine phosphatase), SHIP1 (SH2 containing inositol-5-
phosphatase) and Csk (c-Src kinase).  The physiological significance of ITIM receptors 
in platelets is unclear, although it is generally accepted that their inhibitory activation is 
relatively weak when compared to that of NO and PGI2 (Dhanjal et al, 2007).  It has 
been speculated that they serve to dampen down constitutive tyrosine kinase signalling 
under basal conditions (Mori et al, 2008). 
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Table 1.2 Major platelet inhibitory mechanisms 
Receptor Agonists Receptor Type Signalling Pathway 
- Nitric oxide  
 
- cGMP 
IP PGI2 
 
GPCR Gs 
CD39 ATP 
ADP 
 
-  
G6b Unknown 
 
Ig SHP1, SHP2, SHIP2 
PECAM-1 PECAM-1 
 
Ig SHP1, SHP2, SHIP2 
CEACAM-1 CEACAM-1 
 
Ig SHP1, SHP2, SHIP2 
TLT-1 Unknown Ig Unknown 
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1.2 Platelet ITAM signalling 
Since the GPVI signalling pathway is a major focus of this thesis, the following section 
describes this signalling pathway in detail and also the major ligands that are used to 
study GPVI function.  The low affinity immune receptor, FcRIIA, which signals via 
the same signalling motif and pathway to that of GPVI, is also described, as is the major 
platelet integrin IIb3, which activates many of the same signalling proteins, although 
the proximal events in its signalling cascade are distinct. 
 
1.2.1 The GPVI-Fc receptor -chain complex 
GPVI is a member of the immunoglobulin (Ig) superfamily of receptors and contains 
two extracellular Ig domains, a single transmembrane domain and a short cytoplasmic 
tail (Clemetson et al, 1999).  Its expression is restricted to platelets and megakaryocytes 
and has been estimated to be expressed on the cell surface at between 4,000 – 6,000 
copies per platelet using a range of antibodies against GPVI (Furihata et al, 2001; Best 
et al, 2003; Samaha et al, 2004; Senis et al, 2009) although there are reports which 
differ from this generally accepted amount (Chen et al, 2002).  It is constitutively 
associated with the FcR chain, which is present as a disulphide-linked homodimer and 
is required for surface expression of GPVI (Nieswandt et al, 2000).   
 
Each FcR chain contains one copy of an immunoreceptor tyrosine-based activatory 
motif (ITAM) which is defined by the consensus Yxx(L/I)x6-12Yxx(L/I), which is 
essential for GPVI signalling.  YxxL is the most frequent sequence, although YxxI does 
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appear in both B-cell receptor ITAMs and also in one of the T cell receptor -chain 
ITAMs.  ITAMs are also found in several of the major immunoreceptor complexes, 
including the T-cell and B-cell receptors and a number of Fc receptors, including FcRI, 
FcRI and FcRIIA where they signal through Src and Syk tyrosine kinases resulting in 
cellular activation (Shaw et al, 1995; Barrow and Trowsdale, 2006; Underhill and 
Goodridge, 2007).  They are also found on a number of virally encoded proteins which 
initiate signalling through the ITAM receptor cascade (Grande et al, 2007). 
 
GPVI is the major signalling receptor for collagen on platelets.  Collagen is comprised 
of three helical peptide chains, which are rich in prolines and hydroxyprolines, and with 
a glycine at every third residue.  GPO (glycine-proline-hydroxyproline) is the specific 
sequence which activates GPVI (Knight et al, 1999).  Several synthetic collagen-related 
peptides (CRP) have been developed based on repeats of the GPO sequence and shown 
to mimic collagen-induced platelet activation (Morton et al, 1995; Asselin et al, 1997).  
Depending on the number of GPO motifs and cross-linking, CRP has the potential to be 
a stronger agonist than collagen due to avidity caused by the repeated GPO sequence.  
Platelets also express a second collagen receptor, integrin 21, which binds sequences 
containing GER but not GPO (Zhang et al, 2003), and which has a greater affinity for 
collagen than GPVI.  Thus, binding to integrin 21 can bring about a net increase in 
activation of GPVI by collagen.  GPVI is also activated by monoclonal antibodies, such 
as JAQ1 (Nieswandt et al, 2000), and by snake venom toxins, such as convulxin 
(Jandrot-Perrus et al, 1997; Polgar et al, 1997).  Convulxin, a snake C-type lectin 
protein produced by the South American rattlesnake (Crotalus durissus terrificus), was 
used in the original purification and cloning of GPVI (Clemetson et al, 1999).  
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Convulxin is a tetrameric protein consisting of - and -subunits and therefore able to 
cluster several GPVI molecules making it a powerful agonist. 
 
Mice engineered to lack GPVI or FcR fail to undergo aggregation to collagen and 
exhibit defects in both adhesion and aggregation under flow (Poole et al, 1997; Best et 
al, 2003; Kato et al, 2003).  FcR-deficient mice also have mildly delayed and 
decreased thrombus formation in vivo following mild but not severe laser injury model 
(Kalia et al, 2008; Senis et al, 2009).   Furthermore, GPVI-immuno-depleted mice (i.e. 
mice treated with an -GPVI antibody to deplete the protein from the platelet 
(Bergmeier et al, 2001)) have reduced thrombus formation in an in vivo ferric chloride 
injury model (Munnix et al, 2005) and or an in vivo laser injury model in response to a 
low but not a high level of laser injury (Hechler et al, 2009).  Deficiency of either GPVI 
or FcR also results in a mild increase in tail bleeding in mice (Kato et al, 2003; Kalia et 
al, 2008) demonstrating that other compensatory mechanisms protect the animal from 
excessive blood loss. 
 
GPVI is constitutively associated with FcR which contains one copy of an ITAM 
sequence which is responsible for the major component of signalling through the 
receptor.  The FcR chain was identified in collagen stimulated platelets through its 
association with the tyrosine kinase Syk (Gibbins et al, 1996).  Subsequently, GPVI in 
complex with FcR was identified as the collagen receptor on platelets via co-
precipitation between GPVI and FcR, and by antibody cross-linking of GPVI to cause 
aggregation (Gibbins et al, 1997).  More recently, definitive proof that GPVI and FcR 
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form a receptor for collagen was achieved through expression in a cell line model using 
a sensitive NFAT-report assay (Tomlinson et al, 2007). Experiments of this nature had 
been attempted previously by transfection of GPVI into the DAMI megakaryocyte cell 
line (Clemetson et al, 1999) and by expression in rat-Rbl cells (Zheng et al, 2001; 
Berlanga et al, 2002).  However, the conclusions from these studies were unclear as 
convulxin was able to flux calcium in non-transfected DAMI cells, thereby 
demonstrating the presence of an endogenous receptor, while the Kahn group, although 
able to confer responsiveness to convulxin, were not able to show responsiveness to 
collagen.  The Kahn group later suggested that this was a consequence of the level of 
receptor expression as they were able to reconstitute signalling in one out of 177 stable 
clones of GPVI expressed in Rbl cells (Chen et al, 2002).  The success of the 
Tomlinson study in reconstituting a robust response to collagen was to use a highly 
sensitive reporter assay that had been previously used to characterise signalling by other 
ITAM receptors (Lin et al, 1999).  Moreover, the Tomlinson study also demonstrated 
that there was no need for a critical level of GPVI to confer signalling to collagen. 
 
1.2.2 The GPVI receptor signalling pathway 
Following ligand binding, the conserved ITAM tyrosine residues are phosphorylated by 
Src family kinases (SFK).  Fyn and Lyn are the major two Src kinases mediating FcR 
phosphorylation as shown using mutant mice and precipitation studies (Ezumi et al, 
1998; Quek et al, 2000), although, significantly, a residual level of activation is seen in 
mice deficient in the two Src kinases indicating involvement of one or more other Src 
kinases (Quek et al, 2000).  Both Fyn and Lyn have been shown to associate via their 
SH3 domains with a poly-proline region of the cytoplasmic tail of GPVI placing them 
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proximal to their substrate.  Further, mutation of this region results in a partial inhibition 
of GPVI mediated signalling (Suzuki-Inoue et al, 2002; Bori-Sanz et al, 2003; Schmaier 
et al, 2009).  The protein tyrosine phosphatase CD148 has also been shown to play a 
role in regulating Fyn and Lyn downstream of GPVI by dephosphorylating an inhibitory 
tyrosine residue which, due to intermolecular binding, holds the SFK in an inactive 
conformation (Senis et al, 2009).  GPVI also contains a calmodulin (CaM) binding site 
which has shown to bind calmodulin in resting cells but which promotes dissociation 
upon activation.  The functional significance of this site in mediating platelet activation 
is unclear (Andrews et al, 2002; Locke et al, 2003). 
 
SFK-mediated phosphorylation of the two ITAM tyrosines provides a docking site for 
the tandem SH2 domains of the Syk family of tyrosine kinases, namely Syk, which is 
widely expressed in haematopoietic cells, and ZAP-70 (-chain associated protein of 70 
kDa), which is localised to T-cells and a sub-population of natural killer cells.  Binding 
of Syk or ZAP-70 to a phosphorylated ITAM leads to activation through a combination 
of molecular re-organisation and phosphorylation by both SFKs and auto-
phosphorylation (Futterer et al, 1998; Brdicka et al, 2005; Arias-Palomo et al, 2007; 
Deindl et al, 2007).  Classically, SH2 domains have micromolar affinity for 
phosphotyrosine groups, but the interaction between the two ITAM tyrosines and the 
tandem SH2 domains of Syk has nanomolar affinity due to cooperativity (Grucza et al, 
1999).  Moreover, mutagenesis studies have shown that both of the conserved ITAM 
tyrosine residues and also both of the Syk SH2 domains are required for signalling 
thereby favouring a model in which Syk kinase binds to the dually phosphorylated 
ITAM (Kurosaki et al, 1995; Fruehling and Longnecker, 1997; Abtahian et al, 2006).  
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Mouse platelets which are deficient in Syk are unresponsive to collagen confirming the 
critical role of the tyrosine kinase in platelet activation by collagen (Poole et al, 1997). 
 
GPVI-mediated activation of Syk has been shown to mediate phosphorylation of a 
number of downstream targets including the membrane scaffolding protein LAT (linker 
for activation of T-cells), which has nine conserved tyrosine residues (Pasquet et al, 
1999; Judd et al, 2002) (Figure 1.3).  When phosphorylated, LAT has been shown to 
bind to a range of SH2 domain-containing proteins thereby forming a „signalosome‟ 
that plays a key role in mediating platelet activation by GPVI.  Among the proteins that 
bind to LAT in platelets are the cytosolic adaptors proteins Grb2 (growth factor receptor 
bound protein 2) and Gads (Grb2 related adaptor protein downstream of Shc), and 
PLC (Asazuma et al, 2000).  The adaptor protein SLP-76 (SH2 domain containing 
leukocyte protein of 76 kDa) is also recruited to the signalosome through binding to 
Gads and PLC (Liu et al, 1999; Yablonski et al, 2001) and is critical for activation of 
PLC (Clements et al, 1999; Gross et al, 1999; Judd et al, 2002).  LAT also binds to PI-
3 kinase (phosphatidylinositol 3-kinase) in platelets (Gibbins et al, 1998).  The product 
of PI 3-kinase, PIP, binds to the pleckstrin homology (PH) domain of PLC2 thereby 
supporting its localisation to the membrane.  The LAT-Gads-SLP-76 signalling triad is 
the focus of the work in Chapter 4 and is discussed in further detail later (see Figure 
1.3). 
 
The recruitment of PLC2 to the signalosome allows it to become activated as a 
consequence of phosphorylation by the Tec family kinases, Btk (Bruton‟s tyrosine 
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kinase) and Tec, which also bind to PIP3 in the membrane (Quek et al, 1998; Atkinson 
et al, 2003), and by binding to SLP-76 (Gross et al, 1999).  A role for both Btk and Tec 
was shown using double-deficient mouse platelets which exhibited a much greater loss 
signalling through GPVI compared to the individual knock-out platelets (Atkinson et al, 
2003).  However, because of the interplay of proteins in the LAT signalosome, it is 
unclear whether additional kinases also mediate phosphorylation of PLC2, including 
Src family kinases.   
 
The Vav family of guanine nucleotide exchange factors (GEF) have also been shown to 
be recruited to the LAT signalosome by binding to SLP-76, Btk/Tec and Syk, and to 
play a critical role in mediating PLC2 activation (Pearce et al, 2002; Pearce et al, 
2004).  In this pathway, Vav is believed to function as an adaptor rather than as a GEF 
for small G proteins, as mutation of the GEF domain does not inhibit TCR signalling 
(Kuhne et al, 2000).  As with the SFKs and Btk/Tec kinases, there is redundancy 
between the Vav family members, as mice deficient in both Vav1 and Vav3 show 
defective GPVI signalling whereas mice deficient in Vav1, Vav2 or Vav3 alone, or a 
combination of both Vav1 and Vav2 show no obvious defect in GPVI signalling (Pearce 
et al, 2002; Pearce et al, 2004). 
 
Activation of PLC2 leads to hydrolysis of its substrate, phosphatidylinositol-4,5-
bisphosphate (PIP2), to form the two second messengers, inositol-1,4,5-trisphosphate 
(IP3) and 1,2-diacylglycerol (DAG), which release Ca
2+
 from intracellular stores and 
activate protein kinase C (PKC), respectively.  PLC2 knock-out mice have a severe 
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blockade in GPVI signalling, although this is not complete as mouse platelets also 
express a small amount of PLC1 (Suzuki-Inoue et al, 2003). 
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Figure 1.3 – The GPVI signalling pathway 
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1.2.3 FcRIIA – A second platelet ITAM receptor 
Human platelets express a second ITAM containing protein, FcRIIA (CD32A), which 
is believed to use the same ITAM signalling pathway as GPVI, but because it is not 
found in the mouse genome (and therefore mouse platelets), the same repertoire of 
studies using mutant platelets have not been performed.  FcRIIA is a low affinity 
member of the Fc (IgG binding) family of Fc receptors and is activated by clustering as 
a result of binding to immune complexes.  It has two extracellular Ig domains, a single 
transmembrane domain and a cytoplasmic tail, although unlike GPVI, this contains its 
own ITAM sequence.  The ITAM sequence can be regarded as atypical in that it is the 
only ITAM in which the tandem YxxL sequences are separated by more than 8 amino 
acids (the number in FcRIIA is 12).  Nevertheless, it has been shown that this length of 
spacer is able to bind to Syk in platelets and B-cells (Chacko et al, 1994; Yanaga et al, 
1995; Chacko et al, 1996).  However, due to its more rigid tertiary structure, it is 
thought that an ITAM of this length would not be able to signal through Zap-70 
(Brdicka et al, 2005; Deindl et al, 2007). 
 
The physiological role of FcRIIA in platelets is unclear, although it has been proposed 
that FcRIIA allows platelets to play a role in the innate immune system by binding to, 
and becoming activated by antibody bound pathogens, thus speeding their clearance.  
FcRIIA is also important in heparin-induced thrombocytopenia, as consequence of 
platelet activation by antibody-mediated clustering.   
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1.2.4 Integrin IIb3 
Integrin IIb3 is a heterodimer of  and  subunits.  It is highly expressed on the 
platelet surface at approximately 80,000 copies per platelet, with an estimated further 
40,000 copies on platelet -granules which become expressed upon platelet activation.  
It is activated by „inside-out‟ signals which induce a conformational change and thereby 
increase its affinity for its endogenous ligands, including fibrinogen and VWF.  In turn, 
ligand-induced clustering generates „outside-in‟ signals which play a role in later stage 
processes such as thrombus stability and clot retraction as discussed above (for review 
see (Coller and Shattil, 2008)).  IIb3 outside-in signalling uses many of the same 
signalling proteins as used by ITAM receptors, thereby fuelling the debate as to whether 
it associates with one or more ITAM-containing proteins.   Indeed, in human platelets, 
the group of Newman and colleagues have proposed FcRIIA as the ITAM that 
facilitates outside-in signalling by the integrin (Boylan et al, 2008).  Nevertheless, the 
absence of this protein from mouse platelets, and studies on transfected cell lines, shows 
that the integrin can signal independent of an ITAM sequence.  Outside-in signalling by 
IIb3 is described in more detail below. 
 
The cytoplasmic tail of the 3 subunit contains an RGD sequence at its C-terminus 
which allows for the constitutive association with SFKs, namely Src, Fyn and Yes 
(Arias-Salgado et al, 2003).  There is also a separate binding site for Fyn (Reddy et al, 
2008).  Csk (C-Src kinase) is also associated with the tail under basal conditions 
(Obergfell et al, 2002).  Csk regulates SFKs by phosphorylating the inhibitory tyrosine 
residue.  Following ligand binding and receptor clustering, Csk dissociates, allowing the 
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SFKs to become active through dephosphorylation of the inhibitory tyrosine by the 
protein tyrosine phosphatases PTP1b (protein tyrosine phosphatase 1b) and CD148, and 
autophosphorylation of an activatory tyrosine residue (Arias-Salgado et al, 2005; Senis 
et al, 2009).  Syk has been shown to associate with the 3 tail, via an interaction 
between the integrin and the Syk N-terminal SH2 domain and inter-domain, which is 
independent of phosphorylation of the integrin (Woodside et al, 2001; Woodside et al, 
2002).  This brings Syk into the proximity of the SFKs and allows it to become 
activated.  Following Syk activation, it can initiate a similar signalling cascade to the 
ITAM pathway with roles shown for SFKs, Syk, SLP-76, PLC2, PI 3-kinase, Tec, 
PKC and Vav family proteins (Judd et al, 2000; Obergfell et al, 2002; Goncalves et al, 
2003; Wonerow et al, 2003; Pearce et al, 2007; Coller and Shattil, 2008).  Interestingly, 
what has been termed late-stage activation of IIb3 results in SFK mediated 
phosphorylation of the 3 tail on two tyrosine residues, Y747 and Y759.  These are not 
in an ITAM sequence and therefore do not allow for binding of Syk.  In fact, their 
phosphorylation destabilises the interaction with Syk, causing dissociation (Woodside et 
al, 2001; Woodside et al, 2002).  Y747 and Y759 have however been shown to bind to 
several other SH2 domain and PTB (phospho-tyrosine binding) domain containing 
proteins and also to myosin II, with evidence for a role in clot retraction (Law et al, 
1999; Suzuki-Inoue et al, 2007). 
 
There is evidence that IIb3 couples to FcRIIA in human platelets as discussed above.  
The Newman group have proposed that FcRIIA is incorporated into IIb3 clusters, 
bringing it into the proximity of active SFKs which then phosphorylate its ITAM 
sequence, providing a docking site for Syk (Boylan et al, 2008; Gao et al, 2009).  The 
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mechanism and stoichiometry of the interaction of FcRIIa and IIb3 is not known.  
However, since FcRIIa is expressed at approximately 5% of the level of IIb3, it 
seems likely that it only associates with a fraction of the integrin.  Interestingly, mouse 
platelets do not express FcRIIa and this may explain why they exhibit much weaker 
signalling compared to human platelets on a fibrinogen coated surface.  
 
1.2.5 The role of GEMs in platelet ITAM signalling  
IIb3 „outside-in‟ signalling and GPVI signalling show distinct requirements on 
glycolipid-enriched microdomains (GEMs) that are also known as lipid rafts.  GPVI 
signalling takes place in lipid rafts, with many of the signalling proteins required for 
GPVI signalling being found in these cholesterol rich membrane domains, including 
LAT which is considered a GEM marker and the Src kinases Fyn and Lyn (Wonerow et 
al, 2002).  IIb3 is found almost exclusively outside of GEMs and signals independent 
of LAT (Wonerow et al, 2002).  The caveat to this is that approximately 2-5% of IIb3 
is found within rafts, which, due to the high expression of the integrin, equates to a level 
of protein comparable that of GPVI or FcRIIA (Dorahy et al, 1996; Miao et al, 2001; 
Wonerow et al, 2002).  Alternatively, this could be due to contamination of the GEM 
preparation.   
 
The SFKs Fyn and Lyn are also able to localise to GEMs by virtue of palmitoylation.  
All SFKs have an N-terminal myristoylation which allows them to associate with the 
inner leaflet of the plasma membrane, however only some of them are palmitoylated.  
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Interestingly, Src lacks the residues for the critical palmitoylation, excluding it from 
GEMs.  This suggests that Src could be the major SFK regulating signalling though the 
integrin (Paige et al, 1993; Koegl et al, 1994; Palacios and Weiss, 2004). 
 
1.2.6 ITAM signalling in other haematopoietic cells 
The signalling pathway downstream of GPVI follows the same pattern as that of other 
ITAM receptors; however, different members of the various protein families substitute 
for each other depending on the cell type.  Thus, the GPVI pathway can be described as 
a hybrid of the T-cell and B-cell ITAM pathways (or vice versa) as shown in Figure 1.4.  
For example, GPVI and the B-cell receptor use Lyn and Syk, whereas the T-cell 
receptor uses Lck (leukocyte-specific kinase) and ZAP-70.  On the other hand, GPVI 
and the T-cell receptor use the adaptors LAT-Gads-SLP-76, while the B-cell receptor 
uses BLNK (B-cell linker, SLP-65).  BLNK is a cytoplasmic adaptor protein from the 
same family as SLP-76 and is capable of fulfilling the same role as the LAT-Gads-SLP-
76 triad (Ishiai et al, 2000).  The major effector protein of the ITAM pathway is PLC.  
The T-cell receptor uses the PLC1 isoform, whereas GPVI and the B-cell receptor use 
PLC2 (although, as mentioned previously, mouse platelets express a small amount of 
PLC1).  The plasticity of these pathways has proved to be a useful tool for studying 
platelet GPVI signalling in the absence of a knock-out mouse model, by transfecting 
platelet receptors into wild type (WT) or mutant B- and T-cells (Tomlinson et al, 2007). 
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Figure 1.4 – Comparison of ITAM pathways.  Platelet ITAM signalling is 
represented by the GPVI/FcR complex for comparison to T-cell receptor and B-cell 
receptor ITAMs.  The integrin is shown using some of the signalling proteins 
independent of an ITAM. 
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1.3 The C-type lectin CLEC-2 in platelets 
Determining the molecular basis of platelet activation by CLEC-2, which signals via a 
single YxxL sequence, is a major focus of this thesis.  The following sections 
summarise the discovery of CLEC-2 and how it is currently known to mediate platelet 
activation.  An endogenous ligand for CLEC-2, podoplanin, was reported in 2008 and 
this too is described along with two other C-type lectin receptors, which are structurally 
related to, and signal in a similar fashion to CLEC-2, namely Dectin-1 and CLEC9A.  
 
1.3.1 CLEC-2 
C-type lectin 2 (CLEC-2) was identified in platelets as a receptor for the snake venom 
toxin rhodocytin as described below (Suzuki-Inoue et al, 2006).  CLEC-2 is a group V 
(non-classical) C-type lectin receptor that is expressed at high level on platelets and at 
low level in mouse but not human neutrophils, and also on rat liver sinusoidal 
endothelial cells (Chaipan et al, 2006; Kerrigan et al, 2009).  mRNA for CLEC-2 (but 
not yet protein) has also been found in several other blood cells, including monocytes, 
dendritic cells and granulocytes (Colonna et al, 2000).  CLEC-2 has an N-terminal 
cytoplasmic tail, a single transmembrane domain, a stalk region and a C-terminal 
carbohydrate-like recognition domain (CRD) that is referred to as a C-type lectin-like 
domain (CTLD) (Weis et al, 1998; Drickamer, 1999).   In CLEC-2, the CTLD lacks the 
key residues for carbohydrate binding which indicates that ligands are likely to bind 
through a protein-protein interaction, as is the case for rhodocytin, which is not 
glycosylated. 
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The cytoplasmic tail of CLEC-2 has a single YxxL motif that is preceded by three 
acidic amino acids, but no other recognised signalling motif (Figure 3.1).  The single 
YxxL sequence distinguishes CLEC-2 from ITAM-containing proteins, which have two 
YxxL sequences separated by 6 – 12 amino acids (Table 1.3).  The CLEC-2 YxxL also 
lacks the conserved upstream amino acids that precede the single YxxL sequences of 
ITIM and ITSM (immunoreceptor tyrosine-based switch motif)-containing proteins that 
have been shown to mediate inhibition of ITAM signalling by recruitment of SH2 
domain containing tyrosine phosphatases (SHP1 or SHP2) or inositol phosphatases 
(SHIP1 or SHIP2) (Table 1.3).  Thus, the YxxL in CLEC-2 is distinct from that in other 
YxxL-containing proteins that are known to regulate intracellular signalling cascades.  
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Table 1.3 YxxL containing proteins 
Type Group Name Sequence 
ITAM 
CONSENSUS  Yxx(L/I)x6-12Yxx(L/I) 
   
Fc receptor FcR-chain SDGVYTGL-----STRNQETYETL 
 FcRRIIA ADGGYMTLNPRAPTDDDKNIYLTL 
   
B-cell receptor CD79a DENLYEGL-----NLDDCSMYEDI 
 CD79b EDHTYEGL-----DIDQTATYEDI 
   
T-cell receptor -chain 1 QNQLYNEL-----NLGRREEYDVL 
 -chain 2 QEGLYNEL----QKDKMAEAYSEI 
 -chain 3 HDGLYQGL-----STARKDTYDAL 
 CD3 NDQLYQPL-----KDREDDQYSHL 
 CD3 NDQVYQPL-----RDRDDAQYSHL 
 CD3 PNPDYEPI-----RKGQRDLYSGL 
   
Intracellular DAP12 TESPYQEL-----QGQRSDVYSDL 
ITIM 
CONSENSUS  (L/I/V)xYxx(L/V) 
   
 PECAM-1 VQYTEV 
   
 CEACAM-1 VTYSTL 
  IIYSEV 
   
 G6b LLYADL 
   
 TLT-1 VTYATV 
ITSM 
CONSENSUS  TxYxx(L/V) 
   
 PECAM-1 TVYSEV 
   
 G6b TIYAVV 
   
 TLT-1 TTYTSL 
ITAM-like 
(hemITAM) 
CONSENSUS  (D/E)E(D/E)xYxxL 
   
C-type lectin CLEC-2 --------MQDEDGYITL 
   
 Dectin-1 MEYHPDLENLDEDGYTQL 
   
 CLEC9A --------MHEEEIYTSL 
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1.3.2 Rhodocytin 
Rhodocytin (also known as aggretin) is a C-type lectin snake venom toxin that was 
purified from the Malayan Pit Viper Calloselasma rhodostoma more than ten years ago 
by two research groups (Huang et al, 1995; Shin and Morita, 1998).  The ability of 
rhodocytin to stimulate powerful platelet activation was initially attributed to binding to 
integrin 2 based on the use of a blocking antibody to the integrin (Huang et al, 1995; 
Suzuki-Inoue et al, 2001).  This hypothesis was later refuted by the demonstration that 
the snake venom toxin was unable to bind to recombinant 2 (Eble et al, 2001).  At 
the same time, however, the Clemetson group reported that platelet activation by 
rhodocytin was inhibited by antibodies to both integrin 2and GPIb(Navdaev et al, 
2001), which was surprising given that a previous finding that cleavage of GPIb had 
no effect on rhodocytin activation (Shin and Morita, 1998).  Moreover, both of these 
receptors, and also the collagen receptor GPVI, were shown to be dispensable for 
platelet activation by rhodocytin snake toxin using mice deficient in the subunit of 
integrin 2which had been depleted of GPIb and GPVI using O-sialoglycoprotein 
endopeptidase and in vivo treatment with GPVI monoclonal antibody, JAQ1, 
respectively (Bergmeier et al, 2001).  Thus, rhodocytin stimulates powerful activation 
of platelets independent of the three receptors (Bergmeier et al, 2001).   
 
The receptor underlying platelet activation by rhodocytin was identified as CLEC-2 
based on a proteomic approach using rhodocytin affinity chromatography and mass 
spectrometry (Suzuki-Inoue et al, 2006).  CLEC-2 was confirmed as a receptor for 
rhodocytin by expression studies in chicken DT40 cells using NFAT activation as a 
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reporter assay (Suzuki-Inoue et al, 2006).  Furthermore, a polyclonal antibody to 
CLEC-2 was shown to mediate powerful activation of human platelets independent of 
the platelet low affinity Fc receptor, FcRIIA, demonstrating that engagement of CLEC-
2 was sufficient to mediate platelet activation (Suzuki-Inoue et al, 2006).  The 
possibility that integrin 2 may facilitate binding of rhodocytin to CLEC-2 was also 
refuted by the demonstration that azide-free preparations of 2-blocking antibodies 
had no effect on platelet activation by the snake toxin (Fuller, 2006).  Thus, these results 
demonstrate that CLEC-2 mediates platelet activation by rhodocytin. 
 
1.3.3 The CLEC-2 signalling pathway  
Rhodocytin stimulates Src kinase-dependent phosphorylation of the only tyrosine in the 
cytoplasmic tail of CLEC-2, located in the conserved YxxL sequence.  Mutation of this 
tyrosine to phenylalanine abolishes NFAT activation in CLEC-2-transfected DT40 cells 
demonstrating the critical role of phosphorylation in mediating activation (Fuller et al, 
2007).  Rhodocytin stimulates a similar pattern of increase in tyrosine phosphorylation 
to that induced by GPVI in platelets, including phosphorylation of the tyrosine kinase 
Syk, thereby suggesting that it signals through an „ITAM-like‟ pathway (Suzuki-Inoue 
et al, 2001; Suzuki-Inoue et al, 2006).  Consistent with this, Syk has been shown to be 
essential for activation of mouse platelets and NFAT induction in transfected DT40 
cells by rhodocytin (Suzuki-Inoue et al., 2006).  In view of this similarity, the single 
YxxL sequence in CLEC-2 has been named a „hemITAM‟ by the group of Reis e Sousa 
(Robinson et al, 2006) although the term „ITAM-like‟ is used in this thesis.   
 
Chapter 1 – General Introduction 
Page | 38 
 
The possible interaction between CLEC-2 and Syk has been further investigated 
through a series of pull-down and immunoprecipitation studies. A direct interaction 
between CLEC-2 and Syk is supported by the observation that Syk can be precipitated 
from platelets by a phosphorylated CLEC-2 peptide and that the tandem SH2 domains 
of Syk precipitate CLEC-2 from rhodocytin-stimulated platelets (Suzuki-Inoue et al, 
2006).  Furthermore, rhodocytin stimulated signalling is blocked in transfected DT40- 
cells by point mutations that disrupt phosphotyrosine binding of the N- and C-terminal 
SH2 domains of Syk (Fuller et al, 2007). On the other hand, neither the N- or C-
terminal SH2 domains of Syk alone are able to precipitate CLEC-2 from rhodocytin-
stimulated platelets suggesting that both SH2 domains are required for a stable 
interaction (Suzuki-Inoue et al, 2006).  These results therefore provide evidence for a 
novel mode of Syk regulation in which two phosphorylated CLEC-2 receptors are 
cross-linked by its N- and C-terminal SH2 domains.   
 
The use of mutant platelets have also highlighted critical roles for LAT, Vav1/3 and 
PLC2 in signalling by CLEC-2 as is the case for signalling by GPVI (Suzuki-Inoue et 
al, 2006).  A role for SLP-76 has also been reported, but unlike GPVI signalling where 
SLP-76 is essential, the requirement for the adapter protein is overcome at high 
concentrations of rhodocytin (Suzuki-Inoue et al, 2006).  Furthermore, the activation of 
platelets by CLEC-2 can also be distinguished from that of GPVI by its dependence 
upon the feedback mediators, ADP and TxA2, and on actin polymerisation, which are 
essential for phosphorylation of the C-type lectin receptor and downstream 
phosphorylation events (Suzuki-Inoue et al, 2001; Pollitt et al, 2010).  The molecular 
explanation for the differential requirement of CLEC-2 and GPVI on the adapter SLP-
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76, secondary mediators and actin polymerisation is not known, but suggests 
fundamental differences in the proximal events underlying platelet activation by the two 
receptors.  The study from Pollitt et al has also provided evidence that CLEC-2 
signalling takes place in GEMs following activation of the receptor, which is not 
surprising given the critical role of LAT and the similarity to ITAM signalling.  CLEC-
2 phosphorylation takes place following translocation to GEMs (Pollitt et al, 2010). 
 
1.3.4 Other platelet C-type lectin receptors 
There are currently four other C-type lectins which are known to be expressed in 
platelets, namely DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-
grabbing non-integrin), P-selectin, CD23 and CD69.  P-selectin (CD62P) has a well 
established role in platelets where it is present on -granules and expressed at the cell 
surface upon platelet activation.  It is widely used as a marker of platelet activation in 
flow cytometry assays.  Its major role is in the recruitment of leukocytes during 
thrombus growth (Falati et al, 2003).  The cytosolic tail of P-selectin does not have any 
recognised signalling motifs. Consistent with this, a study has shown that cross-linking 
P-selectin does not appear to generate regulatory signals in platelets (Sathish et al, 
2004). P-selectin belongs to the selectin group of C-type lectins which are quite 
different to group V C-type lectins.  The extracellular part of the selectins contain, along 
with the N-terminal CTLD, an EGF-like domain and a number of complement 
regulatory domain repeats.  These domains are thought to be important for cellular 
interactions under flow conditions. 
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DC-SIGN (CD209) is highly expressed on dendritic cells where its major role is in the 
binding and internalisation of pathogens.  Activation of DC-SIGN in dendritic cells has 
been shown to result in ERK and PI-3 kinase activation, PLC2 phosphorylation and 
Ca
2+
 mobilisation.  It has also been shown to be associated with Lyn and Syk (Caparros 
et al, 2006) and to be linked to Raf-1 and possibly Ras, both part of the MAP (mitogen 
activated protein) kinase signalling pathway (Gringhuis et al, 2007; Gringhuis et al, 
2010), although the role of MAP kinases in platelets is currently controversial as 
platelets do not have a nucleus and only limited functional roles have been described in 
platelets (Adam et al, 2008). 
 
The cytoplasmic tail of DC-SIGN contains a YxxL sequence, however this is not 
preceded by the acidic DEDG sequence that is found in ITAM-like receptors (the DC-
SIGN sequence is QTRGYKSL).  Furthermore, mutation of this YxxL sequence does 
not affect the ability of DC-SIGN to generate a weak signal upon cross-linking as 
measured using a NFAT reporter assay in DT40 cells (Fuller et al, 2007) .  DC-SIGN is 
expressed at low levels on platelets where it has been shown to facilitate binding and 
internalisation of pathogens, in particular, viral particles (Boukour et al, 2006).  DC-
SIGN binds to several different viruses, including HIV (human immuno-deficiency 
virus), HCV (hepatitis C virus) and HPV (human papillomavirus) (Geijtenbeek et al, 
2000; Pohlmann et al, 2003; Garcia-Pineres et al, 2006).  The uptake of viral particles 
by platelets has been proposed to result in their degradation in the open canilicular 
system (Boukour et al, 2006). In some cases, however, the viruses remain infectious and 
the platelet can act as a means of viral dispersal throughout the body (Chaipan et al, 
2006). 
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CD69 and CD23 are only expressed at low level on platelets and no function has, as yet, 
been attributed to their presence on platelets.  CD69 does not contain any recognised 
signalling motifs in its cytoplasmic tail.  There is however a single report that antibody 
cross-linking of CD69 on platelets promotes aggregation.  This study was flawed 
however as FcRIIA was not blocked thereby leaving the possibility that the Fc receptor 
mediated the aggregation response (Testi et al, 1990).  CD23 is a low affinity IgE 
receptor and it has been shown to play an inhibitory role on IgE synthesis in B-cells 
through an unknown mechanism (Yu et al, 1994).  A functional role for CD23 in 
platelets however has not been established.  The cytoplasmic tail of CD23 contains a 
YxxI motif although there are no reports of its phosphorylation.  Further, this sequence 
is preceded by EEGQ which does not correspond to the „ITAM-like sequence‟ that is 
present in CLEC-2 and Dectin-1.  
 
1.3.5 Endogenous CLEC-2 ligands 
The first evidence for an endogenous ligand for CLEC-2 was shown in a study 
investigating binding of platelets to HIV-1 viral particles (Chaipan et al, 2006).  This 
study reported that platelets could bind to and internalise the viral particles by a 
mechanism dependent on CLEC-2 and DC-SIGN (Chaipan et al, 2006).  DC-SIGN was 
shown to be the major contributor through binding to the viral envelope protein Env via 
bound mannose sugars (Geijtenbeek et al, 2000).  Interestingly, CLEC-2 binding to the 
viral particles was not dependant on the Env protein suggesting that it recognised a host 
protein derived from the cell used to make the virus.  Blockade of both CLEC-2 and 
DC-SIGN severely inhibited binding to the viral particles suggesting that these two 
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proteins interacted together to aid the dissemination of the virus throughout the infected 
patient (Chaipan et al, 2006). 
 
As the viral particles were grown in HEK-293T cells (human embryonic kidney), it was 
proposed that these cells expressed an endogenous ligand for CLEC-2.  Consistent with 
this, addition of HEK-293T cells to platelets was shown to mediate aggregation, which 
was blocked by PD173952, an inhibitor of Src family kinases, and to stimulate NFAT 
production in DT40 cells transfected with CLEC-2 (Christou et al, 2008).  At the time 
that the studies were performed, however, the nature of the activating ligand was not 
known.  
 
Podoplanin was identified as a CLEC-2 ligand by Katsue Suzuki-Inoue, who had 
performed the original affinity purification studies that led to the identification of 
CLEC-2 (Suzuki-Inoue et al, 2007).  Podoplanin is expressed on the leading edge of 
many tumour cells and underlies tumour cell-mediated platelet aggregation (Kato et al, 
2003).  It has been proposed that activation of platelets by tumour cells facilitates cancer 
metastasis by release of growth factors and metalloproteinases which facilitate tumour 
cell growth and invasion, respectively (Nash et al, 2002; Gupta and Massague, 2004).  
Activation of platelets by tumour cells occurs after a characteristic lag phase that is 
reminiscent of rhodocytin induced platelet aggregation (Kaneko et al, 2004; Kaneko et 
al, 2007).    In view of this similarity, Suzuki-Inoue et al sought to identify the platelet 
receptor which was mediating platelet activation by podoplanin on tumour cells, 
hypothesising that CLEC-2 was the candidate.   
Chapter 1 – General Introduction 
Page | 43 
 
Suzuki-Inoue et al demonstrated an interaction between the two proteins by flow 
cytometry using recombinant CLEC-2 binding to podoplanin expressing Chinese 
hamster ovary cells (CHO).  This association was shown to be dependent on podoplanin 
glycosylation as it was lost when podoplanin was expressed in mutant CHO cells which 
lacked a sialic acid transporter and therefore are unable to fully glycosylate surface 
proteins (Suzuki-Inoue et al, 2007).  Furthermore, the podoplanin transfected CHO cells 
were able to mediate platelet aggregation, whereas the mutant CHO cells could not.  
They confirmed that platelet aggregation was induced by podoplanin expressing tumour 
cells and showed that lymphatic endothelial cells (LECs), which endogenously express 
podoplanin at high level, could also mediate platelet aggregation.  Furthermore, 
aggregation by podoplanin-expressing tumour cells or LECs was blocked by 
recombinant CLEC-2, and was dependent on SFKs (Suzuki-Inoue et al, 2007).  
Together, these data provided definitive evidence for podoplanin as a CLEC-2 ligand. 
 
The above discovery enabled the demonstration that the ligand on HEK-293T cell was 
also podoplanin, a finding that was performed through a collaboration between the 
Birmingham Platelet Group and Chris O‟Callaghan in Oxford (Christou et al, 2008).  
The association was confirmed using several methods, including flow cytometry using 
recombinant CLEC-2 and HEK-293T cells, and by precipitation studies from cell 
lysates, which pulled out a band of 36 kDa that was identified as podoplanin.  Further, 
recombinant podoplanin and HEK-293T cells stimulated NFAT activity in CLEC-2 
transfected DT40 cells and this was blocked with an -podoplanin antibody (NZ-1).  
The affinity (KD) of the interaction between the two proteins was calculated to be 24 
M using surface plasmon resonance (Christou et al, 2008).   
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Podoplanin (also known as aggrus, T1, GP36, GP38) is a type I transmembrane 
sialoglycoprotein with a relatively large (206 amino acids), heavily glycosylated, 
extracellular domain, a single transmembrane domain and a short (9 amino acids) 
cytoplasmic tail (sequence – RKMSGRYSP).  The tail contains two serine residues that 
are present in putative PKA and PKC phosphorylation sites and a single tyrosine 
residue, although there are no reports of a functional role for phosphorylation of any of 
these three residues.  On the other hand, podoplanin has been proposed to interact with 
ERM (ezrin, radixin, moesin) family of proteins, with a direct interaction with ezrin and 
moesin being mediated by the three basic amino acids in the cytoplasmic tail (Martin-
Villar et al, 2006).  Expression of podoplanin in Madin-Darby canine kidney (MDCK) 
cells, an epithelial cell line, resulted in an up-regulation of RhoA and epithelial-
mesenchymal transition (EMT). The EMT transition results in cells acquiring migratory 
features, a process required for many responses including tissue remodelling during 
development, as well as wound healing, inflammation and tumour invasion and 
metastasis (Bissell and Radisky, 2001; Thiery, 2002).  Mutations based around the R/K 
group showed that the association of podoplanin with ERM family proteins was 
required for the increase in RhoA activity in the MDCK cells (Martin-Villar et al, 
2006).  These observations suggest that, in addition to being a ligand for CLEC-2, 
podoplanin may be a functional receptor in its own right. 
 
Podoplanin has a wide expression profile and is expressed at particularly high levels on 
kidney podocytes (hence its name), type I alveolar cells, lymphatic endothelial cells and 
metastatic tumour cells.  Two different podoplanin knock-out mice have been described 
as summarised in Table 1.4 (Ramirez et al, 2003; Schacht et al, 2003; Fu et al, 2008; 
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Mahtab et al, 2008; Uhrin et al, 2010).  The two mice were made by deletion  of the 
promoter and exon 1 (Mahtab et al, 2008) or by deletion of exons 2-5 (Ramirez et al, 
2003) through insertion of a neomycin cassette, with neither mouse expressing 
podoplanin protein.  Cardiac developmental problems were observed on a proportion of 
the first of these two knockouts, which is attributed to defective epithelial-mesenchymal 
transition (Mahtab et al, 2008).  This knock-out shows 40% prenatal lethality.  Of the 
null mice which survive to birth, 50% die within the first weeks after birth (the fate of 
the remaining 50% is not stated).  Backcrossing from a 129 Sv x Swiss background to a 
C57Bl/6 background resulted in survival of approximately 20% of the null mice to 
adulthood and are fertile, but no prenatal lethality is described (Uhrin et al, 2010).  
Cardiac defects were not described for the second knockout, which was bred on a 129 
Sv Ev background.   The birth rate for this knockout was 75% of that expected from 
Mendelian genetics, although the authors stated that this figure was statistically 
insignificant and they did not report prenatal lethality (Ramirez et al, 2003).  All of the 
mice died however within minutes to hours after birth due to defective lung 
development resulting in lungs that were unable to expand to perform gas exchange 
(Ramirez et al, 2003). 
 
Both of the knock-out models show defective lymphatic separation during development, 
resulting in blood filled, dilated lymphatics and lymphoedema (Schacht et al, 2003; Fu 
et al, 2008; Uhrin et al, 2010).  The most recent of these studies monitored development 
of the lymphatics and observed platelet aggregates in the separation zone between the 
cardinal vein and the newly forming lymph sacs in the wild type but not the knockout 
mice (Uhrin et al, 2010).  This raises the possibility that platelets play a crucial role in 
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the separation of lymphatics through the interaction of CLEC-2 and podoplanin.  
Antibody blockade of podoplanin in utero resulted in the same phenotype as the knock-
out (Uhrin et al, 2010). 
 
A similar defect in lymphatic separation from the vasculature is seen in knock-out mice 
lacking Syk, SLP-76 or PLC2 (Abtahian et al, 2003; Sebzda et al, 2006; Ichise et al, 
2009).  The defect does not appear to be as severe, however, particularly in mice 
deficient in PLC2 which may be attributed to a low level of PLC1 (Suzuki-Inoue et al, 
2003).  Since these three proteins are required for CLEC-2 signalling, the results 
provide further evidence for a role for podoplanin-mediated CLEC-2 activation of 
platelets in development of the lymphatics.  There are several explanations for the 
overlapping but distinct phenotypes of these three mice relative to those lacking 
podoplanin, including the possibility that podoplanin functions as a signalling receptor 
with CLEC-2 serving as a ligand. 
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Table 1.4 Podoplanin
-/-
 summary 
Reference Defects 
 
MOUSE USED – Generated by deletion of exons 2-5 by insertion of Neo cassette 
 
(Ramirez et al, 
2003) 
Mice born at close to Mendelian ratios.  Die 3-10 min after birth due to 
respiratory failure.  A few mice survived up to 4 hours.  Lung 
morphology affected.  Fewer and attenuated type I alveolar cells.  
Smaller airspaces with abundant surfactant.  Lung defects attributed to 
disrupted epithelial-mesenchymal signalling. 
(Schacht et al, 2003) 
Defective lymphatic but not blood vessel pattern formation.  Diminished 
lymphatic transport, congenital lymphoedema and dilated lymphatic 
vessels.  Normal epidermal differentiation despite podoplanin expression 
in basal epidermis. 
(Fu et al, 2008) 
Blood-filled lymphatics.  Similar phenotype seen in EHC T-Syn
-/- 
(endothelial and haematopoietic
 
specific knock-out of T-synthase) mice 
which have significantly reduced podoplanin due to loss of 
glycosylation.  EHC T-Syn
-/- 
mice survive and develop fatty liver disease 
due to misconnected lymphatics. 
 
MOUSE USED – Generated by deletion of promoter and exon 1 by insertion of Neo cassette 
 
(Mahtab et al, 2008) 
Increased embryonic and foetal lethality by 40%.  50% of neonates die 
within the first weeks of life.  Cause of death unknown, but possibly 
cardiac in origin.  Impaired cardiac development based on defective 
epicardial-myocardial interaction and reduced epithelial-mesenchymal 
transformation. 
(Uhrin et al, 2010) 
Mice were backcrossed onto a C57Bl/6 background.  55% of neonates 
die during the first week and are smaller than wild types.  Some show 
petechia.  20% survive to adulthood achieving normal weights, life spans 
and are fertile.  Blood filled, non-separated lymphatics.  The lymph sacs 
bud off from the cardinal vein in development.  This separation zone is 
podoplanin positive and platelet aggregates are found here.  The 
knockout lacks platelet aggregates on lymphatic endothelium. 
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A recent publication has provided evidence for a further endogenous CLEC-2 ligand 
and for a critical role of CLEC-2 in haemostasis (May et al, 2009).  In this study mice 
were treated with a CLEC-2 antibody which resulted in thrombocytopenia.  Following 
recovery from this thrombocytopenia, the platelets were shown to be depleted of surface 
CLEC-2 for several days suggesting that the antibody had inhibited CLEC-2 expression 
on newly formed platelets.  These CLEC-2-deficient platelets were unable to aggregate 
or express P-selectin in response to rhodocytin whereas the response to collagen, 
convulxin, thrombin, ADP, and U46619 was not altered (although only single doses of 
these agonists were tested therefore leaving the possibility that a dose-response curve 
may have highlighted a smaller defect).  This result demonstrates that, in the low shear 
environment of an aggregation assay, CLEC-2 is only required for platelet activation by 
rhodocytin.  However, when the CLEC-2-depleteted platelets were flowed in whole 
blood through collagen-coated capillaries at intermediate (1000 s
-1
) and high (1700 s
-1
) 
shear rates, there was a marked decrease in platelet aggregate formation.  The initial 
attachment of the platelets was unaffected but the recruitment of further platelets and 
aggregate growth was inhibited in the absence of CLEC-2.  In blood that was not anti-
coagulated, and therefore thrombin generation allowed to occur, this defect was 
overcome.  This suggests that CLEC-2 is playing a vital role in thrombus formation at 
arterial rates of shear.  Moreover, using an in vivo ferric chloride injury model, the 
CLEC-2-depleted mice failed to fully occlude their vessels.  Thrombi still formed at the 
injury site with similar kinetics to the control but due to increased embolisation and 
release of single platelets, the thrombi did not become occlusive.  The CLEC-2 deficient 
mice also exhibited an increased bleeding time (by approximately 50%) as measured by 
a tail bleeding assay.  As podoplanin expression is not found in blood cells, including 
platelets, this study suggests that CLEC-2 has another ligand which is either found in 
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plasma or is expressed by/secreted by platelets and which contributes to thrombus 
formation.  It also highlights the potential of CLEC-2 as a drug target for anti-platelet 
therapy. 
 
1.3.6 Dectin-1 and CLEC9A  
CLEC-2 is a member of the group V family of C-type lectins which is closely related to 
the group II family having a single extracellular C-type lectin domain, a stalk region, a 
single transmembrane domain and a short cytoplasmic tail.  Group II C-type lectins are 
considered the „classical‟ C-type lectins, requiring Ca2+ for ligand binding, while group 
V are „non-classical‟ C-type lectins as they do not require Ca2+ for binding (Drickamer, 
1993).  Many of the cytoplasmic tails of the group II and group V families of C-type 
lectins either contain recognised signalling motifs or associate with proteins with 
signalling motifs.  Some examples are summarised in Table 1.5. 
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Table 1.5 Other C-type lectin signalling motifs 
C-type 
lectin 
Other names References Motif 
CLEC12A MICL (myeloid inhibitory C-
type lectin) 
(Marshall et al, 2004; Pyz 
et al, 2008) 
 ITIM 
CLEC12B  (Hoffmann et al, 2007) 
 
CLEC5A MDL-1 (myeloid DAP12 
associating lectin) 
(Bakker et al, 1999) ITAM – 
associated with 
DAP12 
CLEC6A Dectin-2 (Sato et al, 2006) 
 
ITAM – 
associated with 
FcR 
CLEC4A CD303, BDCA2 (blood 
dendritic cell antigen 2) 
 
(Cao et al, 2007; Rock et 
al, 2007) 
 
CLEC4E Mincle (macrophage-inducible 
C-type lectin) 
(Wells et al, 2008; 
Yamasaki et al, 2008; 
Yamasaki et al, 2009) 
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CLEC-2, Dectin-1 (CLEC7A) and CLEC9A appear to be unique within the group V 
family of C-type lectin receptors in that they have a single YxxL in their cytoplasmic 
tails which is preceded by three negatively charged amino acids and a glycine or 
isoleucine residue (Table 1.3).  All three signal through sequential activation of Src and 
Syk tyrosine kinases downstream of phosphorylation of the conserved tyrosine in the 
YxxL sequence in their cytoplasmic tail (Fuller et al, 2007; Huysamen et al, 2008).  The 
significance of the three acidic amino acid residues and glycine in the regulation of Syk 
by CLEC-2 has been investigated by expression of receptor mutants in DT40 cells 
(Fuller et al, 2007).   Mutation of D3 and E4 to alanine had little effect on receptor 
signalling, while mutation of G6 to alanine abolished the response possibly due to steric 
hindrance.  The significance of D5 could not be assessed as mutation to alanine 
prevented surface expression of CLEC-2.   Thus, the overall significance of the acidic 
acid region in signalling by CLEC-2 is uncertain. 
 
CLEC-2 and Dectin-1 share the same acidic amino acid sequence upstream of the single 
cytoplasmic YxxL motif, namely DEDG.  In CLEC9A, this upstream sequence is EEEI, 
although the functional significance of this difference, if any, is not known.  Unlike 
CLEC-2 and Dectin-1, CLEC9A is expressed as covalently-linked dimer on the cell 
surface.  This dimerisation suggests a possible mechanism of regulation of Syk through 
binding of the two individual SH2 domains in the tyrosine kinase to separate, 
phosphorylated YxxLs in two molecules of CLEC9A, as illustrated in Figure 3.10.  
Moreover, a similar mechanism of regulation of Syk may also apply to CLEC-2 as 
activation is lost upon mutation of the phosphotyrosine binding motif in either of the 
Syk SH2 domains (Fuller et al, 2007).  Because of the similarity in sequence, structure 
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and mode of signalling by Dectin-1 and CLEC9A to that for CLEC-2, these two C-type 
lectins are described in further detail below. 
 
Dectin-1 – Dectin-1 is a group V C-type lectin receptor for -glucan found primarily on 
dendritic cells (Brown et al, 2003), macrophages, monocytes, polymorphonuclear 
(PMN) cells but also on B-cells, eosinophils and mast cells (Willment et al, 2001; 
Olynych et al, 2006).  -glucans are immunostimulatory carbohydrate polymers found 
on in the cell wall of fungal, some plant and some bacterial cells (Brown and Gordon, 
2001; Brown and Gordon, 2003).  Dectin-1 also has a role in homeostasis as a currently 
unidentified endogenous ligand has been shown to be on T-cells (Ariizumi et al, 2000; 
Willment et al, 2001; Grunebach et al, 2002) and Dectin-1 has also been shown to be 
activated by apoptotic cells, again by an unidentified ligand (Weck et al, 2008).  
Activation of Dectin-1 results in dendritic cell maturation, phagocytosis, endocytosis 
and production and release of a variety of cytokines and chemokines (Brown, 2006; 
Reid et al, 2009) 
 
Dectin-1 has two tyrosine motifs in its cytoplasmic tail, namely the ITAM-like motif, 
DEDGYxxL, which is described above, and a separate motif with the sequence YxxxL 
and YxxxI in human and mouse, respectively.  The YxxxL sequence is dispensable for 
signalling by the C-type lectin receptor, whereas the ITAM-like sequence is essential 
for activation (Brown et al, 2003; Gantner et al, 2003; Herre et al, 2004; Rogers et al, 
2005; Underhill et al, 2005; Fuller et al, 2007).  Signalling by Dectin-1, as is the case 
for CLEC-2, is dependent on SFKs and Syk, as shown using selective inhibitors and 
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mutant mouse bone marrow-derived cells (Underhill et al, 2005).  In addition, there is 
evidence that Dectin-1 can signal independently of Syk, again through the DEDGYxxL 
sequence, although the physiological relevance of this and the underlying mechanism is 
unknown (Herre et al, 2004; Rogers et al, 2005; Brown, 2006; Gringhuis et al, 2009). 
 
CLEC9A – CLEC9A (DNGR-1 (DC, NK lectin group receptor-1)) is a group V C-type 
lectin receptor.  It has been found in brain, thymus and spleen (Huysamen et al, 2008).  
CLEC9A is also expressed in subsets of haematopoietic cells, namely B cells, BDCA3
+
 
(thrombomodulin) dendritic cells (a rare subset of dendritic cells), CD14
+
CD16
-
 
monocytes and CD14
-
CD11b
-
CD64
+
 cells (Caminschi et al, 2008; Huysamen et al, 
2008; Sancho et al, 2008). 
 
The only functional role ascribed to CLEC9A to date is as a receptor for necrotic cells 
(Sancho et al, 2009).  Sancho et al demonstrated that necrotic cells express a ligand for 
CLEC9A that becomes externalised during necrosis.  However, they show that the 
functional role for CLEC9A is for efficient antigen-presentation by the dendritic cell, 
rather than for antigen uptake.  Interestingly, the related C-type lectin receptor, Mincle, 
is also activated by cells undergoing apoptosis (Yamasaki et al, 2008). 
 
It appears therefore that the major roles described for both Dectin-1 and CLEC9A are in 
the innate immune system and homeostasis through the activation of dendritic cells.  
These cells are the link between the innate and the adaptive immune system, expressing 
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a host of Toll-like receptors and C-type lectins which bind to and internalise invading 
pathogens (innate immunity).  The internalised pathogens are processed, and fragments 
are attached to the major histocompatibility complex (MHC class II) which is in turn 
presented at the cell surface.  The MHC and attached antigen is therefore presented for 
the activation of helper T-cells and killer T-cells (adaptive immunity).  Because of this 
function, dendritic cells and macrophages are often referred to as antigen presenting 
cells (APC).  B-cells can also perform this function but rather than binding to a 
pathogen directly, they bind to antibodies which have already recognised the pathogen, 
and subsequently internalise the complex. 
 
Despite the similarities between the structure, sequence and signalling of CLEC-2, 
Dectin-1 and CLEC9A it is apparent that they play different roles and have different 
ligands.  Dectin-1 has a well characterised exogenous ligand and is involved in the 
immune response to pathogens which express it.  It also has unidentified endogenous 
ligands on T-cells and apoptotic cells.  CLEC-2 has two or more endogenous ligands 
and appears to play roles in haemostasis and possibly development of the lymphatics 
and lungs.  Whether it is possible that CLEC-2 can recognise further exogenous ligands 
(other than rhodocytin) and also plays a role in pattern recognition, or whether Dectin-1 
has any role in development remain to be seen.  CLEC9A also recognises an 
endogenous ligand on apoptotic cells with no other ligands as yet identified.  It remains 
to be seen if CLEC9A has further endogenous or exogenous ligands and roles outside of 
the immune system. 
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1.4 Aims of the thesis 
The proximal events underlying ITAM receptor signalling are reasonably well 
understood whereas, at the time that this work was begun, the mode of regulation of Syk 
by CLEC-2 and the related „ITAM-like‟ receptors was uncertain.  The aim of the work 
undertaken in this thesis was; 
 
1. To investigate the mechanism of regulation of Syk by CLEC-2, with special 
focus on the hypothesis that activation is achieved through receptor 
dimerisation. 
 
2. To compare the functional roles of the adapters Gads and LAT in platelet 
activation by GPVI and CLEC-2 given their differential requirement for SLP-76. 
 
3. To investigate whether the LAT-independent component of platelet activation 
platelet by GPVI and CLEC-2 is due to the presence of one or more further 
LAT-like molecules in platelets.  These studies were limited to platelet 
activation by GPVI in view of the similarity in the functional role of LAT in 
supporting platelet activation by the collagen receptor and CLEC-2. 
  
  
 

 
 
 
CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Antibodies and reagents 
The agonists and antagonists used in the course of this thesis are listed in Table 2.1 and 
2.2 respectively.  Table 2.3 lists the antibodies used.  If unstated, materials used are 
from Sigma (Poole, UK) or from previously described sources (Atkinson et al, 2003; 
Bori-Sanz et al, 2003; Pearce et al, 2004) 
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Table 2.1 Agonists 
Agonist Target Source 
Collagen (HORM) GPVI 
21 
Nycomed (Munich, Germany) 
CRP (YGKO(GPO)10GKOG) GPVI Dr RW Farndale (Cambridge 
University, UK) 
Rhodocytin CLEC2 Dr JA Eble (University of 
Frankfurt, Germany) (Eble et al, 
2001) 
Thrombin PAR-1 
PAR-3 
PAR-4 
Sigma (Poole, UK) 
VWF GPIb Dr MC Berndt (Monash 
University, Australia) 
Fibrinogen IIb3  Enzyme Research Laboratories 
(Swansea, UK) 
ADP P2Y1 
P2Y12 
Sigma (Poole, UK) 
Phorbol Myristate Acetate 
(PMA) 
PKC Sigma (Poole, UK) 
Ionomycin Ca
2+
 Sigma (Poole, UK) 
 
 
Table 2.2 Antagonists 
Inhibitors Target Source 
Indomethacin Cycloxygenase Sigma (Poole, UK) 
Apyrase ADP Sigma (Poole, UK) 
EGTA Ca
2+
 Sigma (Poole, UK) 
Lotrafiban IIb3  GlaxoSmithKline (USA) 
Pervanadate Tyrosine phosphatases Sigma (Poole, UK) 
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Table 2.3 Antibodies 
Antibody Host 
species 
Use* Source 
PRIMARY    
CLEC-2 (human) Goat IP:  2 g/ml 
WB:  1 g/ml 
R+D Systems (Abingdon, UK) 
G6f (human) Rabbit IP:  5 l 
WB:  1/200 
Invitrogen (UK) 
G6f (mouse) Rabbit IP:  5 l 
WB:  1/200 
Invitrogen (UK) 
Gads Rabbit IP:  2 g/ml 
WB:  2 g/ml 
Millipore (Bucks, UK) 
Goat IgG - - R+D Systems (Abingdon, UK) 
Grb2 Rabbit IP:  2 g/ml 
WB:  1/500 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
LAT Rabbit IP:  5 g/ml 
WB:  1/500 
Millipore (Bucks, UK) 
Mouse IgG - - R+D Systems (Abingdon, UK) 
Myc (9B11) Mouse FC:  10 g/ml 
WB:  1/1000 
Cell Signalling Technology 
(Herts, UK) 
Phosphotyrosine (4G10) Mouse IP:  2 g/ml 
WB:  1/1000 
Millipore (Bucks, UK) 
PLC2 Rabbit IP:  1/500 
WB:  1/1000 
Dr MG Tomlinson (Birmingham, 
UK) 
P-Selectin FITC-
conjugate (mouse) 
Rat FC:  1/100 BD Bioscience (Oxford, UK) 
Rabbit IgG - - Millipore (Bucks, UK) 
Sheep IgG - - Millipore (Bucks, UK) 
SLP-76 Sheep IP:  4 g/ml 
WB:  1/500 
Millipore (Bucks, UK) 
Syk Rabbit IP:  1/500 
WB:  1/1000 
Dr MG Tomlinson (Birmingham, 
UK) 
SECONDARY    
Goat IgG HRP-conjugate Chicken WB:  1/10000 R+D Systems (Abingdon, UK) 
Mouse IgG FITC-
conjugate 
Sheep FC:  1/100 Sigma (Poole, UK) 
Mouse IgG HRP-
conjugate 
Sheep WB:  1/10000 Amersham Bioscience (Bucks, 
UK) 
Rabbit IgG HRP-
conjugate 
Donkey WB:  1/10000 Amersham Bioscience (Bucks, 
UK) 
Sheep IgG HRP-
conjugate 
Donkey WB:  1/20000 R+D Systems (Abingdon, UK) 
    
*IP:  Immunoprecipitation, WB:  Western Blot, FC:  Flow cytometry 
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21.2  Plasmids and constructs 
Human CLEC-2 sub-cloned into pEF6 vector with a C-terminal Myc tag (Invitrogen).  
A point mutation of tyrosine 7 to phenylalanine (Y7F) was generated and sub-cloned 
into pEF6 vector with an N-terminal FLAG tag.  These were provided by Dr Gemma 
Fuller and Dr Andrew Pearce (University of Birmingham, UK).  The CLEC-2 mutations 
shown in Table 2.4 were generated by a two-step PCR method (Higuchi et al, 1988) 
using the vector primers 5147 and 4150 in pEF6 with a C-terminal Myc tag using the 
restriction enzymes Kpn I (5‟) and Not I (3‟) (New England Biolabs, Herts, UK).  Pfu 
Turbo DNA polymerase (Stratagene), Rapid ligation kit (Roche, East Sussex, UK), 
DH5 chemically competent E.coli, mini-prep and maxi-prep kits (Sigma, Poole, UK) 
were used for cloning according to manufacturers protocols.  All cloning was verified 
by Plasmid to Profile sequencing.  Human GPVI in pcDNA3 with a C-terminal Myc tag 
(Invitrogen) and untagged human FcR in pEF6 were provided by Dr Mike Tomlinson 
(University of Birmingham, UK).  FcR with an N-terminal Myc tag was provided by 
Dr Jun Mori (University of Birmingham, UK) (Mori et al, 2008).  The FcR mutations 
shown in Table 2.4 were generated by a one-step PCR method using a Quikchange II 
XL site-directed mutagenesis kit (Stratagene) into pEF6 with an N-terminal Myc tag.  
Human G6f was cloned into pEF6 vector with a C-terminal Myc tag (Invitrogen) using 
a two-stage, nested PCR approach, from K562 cDNA (human erythroleukaemic cell 
line) using the restriction enzymes Bgl II (5‟) and Eco RI (3‟) (New England Biolabs, 
Herts, UK).  Mouse G6f was cloned into pEF6 vector with a C-terminal Myc tag 
(Invitrogen) using PCR from primary mouse megakaryocyte cDNA using the restriction 
enzymes Kpn I (5‟) and Eco RI (3‟) (New England Biolabs, Herts, UK).  The nuclear 
factor of activated T-cells (NFAT)-luciferase reporter containing three copies of the 
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distal NFAT site from the IL-2 promoter (Shapiro et al, 1997) was provided by Prof 
Arthur Weiss (UCSF School of Medicine, USA).  The pEF6-lacZ reporter was from 
Invitrogen.  GST-fusion proteins of Syk N-SH2, C-SH2 and tSH2 domains were 
provided by Dr C Law (University of Washington, USA) (Law et al, 1996).  A GST-
fusion protein of the Syk tSH2 domains was also provided by Klaus Fütterer (University 
of Birmingham) (Futterer et al, 1998). 
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Table 2.4 Constructs 
Construct Primers 
T9A CLEC-2 FWD:  5‟-CAT GCA GGA TGA AGA TGG ATA CAT CGC CTT 
AAA TAT TAA AAC TCG-3‟ 
REV:  5‟-CGA GTT TTA ATA TTT AAG GCG ATG TAT CCA 
TCT TCA TCC TGC ATG-3‟ 
21-28 CLEC-2 FWD:  5‟-TAA AAC TCG GAA ACC AGC TCT CAT CTG GTG 
GCG TGT GAT GGC TTT GAT TC-3‟ 
REV:  5‟-GAA TCA AAG CCA TCA CAC GCC ACC AGA TGA 
GAG CTG GTT TCC GAG TTT TA-3‟ 
S21/27A CLEC-2 FWD:  5‟-GAA ACC AGC TCT CAT CGC CGT TGG CTC TGC 
ATC CGC CTC CTG GTG GC-3‟ 
REV:  5‟-GCC ACC AGG AGG CGG ATG CAG AGC CAA 
CGG CGA TGA GAG CTG GTT TC-3‟ 
Y66F FcR  FWD:  5‟- CAG ATG GTG TTT TCA CGG GCC TGA G-3‟ 
REV:  5‟- CTC AGG CCC GTG AAA ACA CCA TCT G-3‟ 
Y77F FcR  FWD:  5‟- GGA ACC AGG AGA CTT TCG AGA CTC TGA 
AGC-3‟ 
REV:  5‟- GCT TCA GAG TCT CGA AAG TCT CCT GGT TCC-
3‟ 
Human G6f (1
st
 
round) 
FWD:  5‟-TGG GGG AGA TCT ACC ATG GCA GTC TTA TTC 
CTC C-3‟ 
REV:  5‟-TTT TTC ACC TGG GCT TGT GGG CA-3‟ 
Human G6f (2
nd
 
round) 
FWD:  5‟-TGG GGG AGA TCT ACC ATG GCA GTC TTA TTC 
CTC CTC CTG-3‟ 
REV:  5‟-TAG TAG GAA TTC CCT GGG CTT GTG GGC AGG 
TG-3‟ 
Mouse G6f FWD:  5‟-TAG TAG GGT ACC ACC ATG GCA GTT GTA GTA 
TTC CTC CTG-3‟ 
REV:  5‟-TAG TAG GAA TTC CCT GGT CTT GTG GTT AGG 
TGG G-3‟ 
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2.1.3 Mice 
Gads deficient and LAT deficient mice were generated as previously described 
(Samelson et al, 1999; Zhang et al, 1999; Yoder et al, 2001).  LAT mice were kindly 
provided by Dr Lawrence Samelson.  Gads mice were kindly provided by Dr Jane 
McGlade (Hospital for Sick Children, Toronto, Canada).  Mice were bred as 
heterozygotes allowing the use of litter matched wild-type control mice.  LAT mice 
were provided on a C57Bl/6 background, Gads mice on a Balb-c background.  Gads 
mice were subsequently back-crossed for nine generations onto a C57Bl/6 background.  
Housing and husbandry was in accordance with Home Office regulations under the 
Animals (Scientific Procedures) Act 1986.  The mice used in chapter 5, deficient in 
PAG, LIME, NTAL, LAT, LAX, and the compound knock-out mice, NTAL/LAT 
deficient, NTAL/LAT/LAX deficient and PAG/LIME deficient were all provided by Dr 
Burkhart Schraven and were used in his labs in the Institute for Molecular and Clinical 
Immunology (Medical Faculty, Otto-Von-Guericke University, Magdeburg, Germany).  
These mice, and control mice, were all provided on a C57Bl/6 background. 
 
2.2 Platelet preparation 
2.2.1 Human washed platelet preparation 
Blood was taken by venipuncture from healthy, drug free volunteers on the day of 
experiments into 10% sodium citrate.  The blood was further anti-coagulated by 
addition of 10% acid citrate dextrose (ACD: 120 mM sodium citrate, 110 mM glucose, 
80 mM citric acid).  Platelet rich plasma (PRP) was retained following centrifugation 
for 20 minutes at 200 g.  Prostacyclin (10 g/ml) was added to inhibit platelet activation 
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prior to centrifugation for 10 minutes at 1000 g.  The plasma was discarded and the 
platelet pellet washed in 25 ml modified Tyrode‟s-HEPES buffer (134 mM NaCl, 0.34 
mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM 
MgCl2; pH 7.3) and 3 ml ACD.  Prostacyclin (10 g/ml) was added prior to final 
centrifugation for 10 minutes at 1000 g.  The platelet pellet was resuspended in 
Tyrode‟s-HEPES buffer at a concentration of 2 x 107/ml for static adhesion and 
spreading assays, 2 x 10
8
/ml for aggregation assays and 5 x 10
8
-1 x 10
9
/ml for protein 
biochemistry.  The platelets were allowed to rest for at least 30 minutes prior to 
experimentation. 
 
2.2.2 Mouse washed platelet preparation 
Mice were terminally CO2-narcosed following isofluorane anaesthesia.  A laparotomy 
was then performed and blood was taken from the descending aorta into 10% ACD.  
The blood was diluted further with addition of 200 l of Tyrode‟s-HEPES buffer and 
centrifuged in a microcentrifuge at 2000 rpm for 5 minutes.  The PRP and top third of 
erythrocytes were retained and centrifuged at 200 g for 6 minutes.  PRP was retained 
and to maximise platelet recovery, a further 200 l of Tyrode‟s-HEPES buffer was 
added to the remaining erythrocytes, mixed, and centrifuged again at 200 g for 6 
minutes.  The second collection of PRP was pooled with the first and following addition 
of 10 g/ml prostacyclin, centrifuged at 1000 g for 6 minutes.  The platelet pellet was 
resuspended in Tyrode‟s-HEPES buffer at a concentration of 2 x 107/ml for static 
adhesion and spreading assays, 2 x 10
8
/ml for aggregation and ATP secretion assays 
and 5 x 10
8
/ml for protein biochemistry.  The platelets were allowed to rest for at least 
30 minutes prior to experimentation. 
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2.3 Platelet functional studies 
2.3.1 Aggregation and stimulation for biochemistry 
Aggregation/stimulation was performed in a dual channel Born lumi-aggregometer 
(model 460VS; Chronolog, Labmedics, Manchester, UK) at 37˚C with stirring at 1200 
rpm.  The optical density of the platelet suspension was measured against a blank 
reading from Tyrode‟s-HEPES buffer and recorded in real time on a chart recorder 
(Chronolog, Labmedics, Manchester, UK). 
 
Aggregation/stimulation experiments were carried out in silconised glass test tubes.  
The platelets were pre-incubated with stated inhibitors for 10 minutes before the 
experiment.  Platelets were pre-incubated with EGTA (1 mM), indomethacin (10 M) 
and apyrase (2 U/ml) to block aggregation, thromboxane A2 (TxA2) and ADP 
respectively.  Platelets were then warmed to 37˚C for 1 minute followed by 1 minute 
with stirring followed by addition of the agonist.  Aggregation was monitored for 5-10 
minutes.  Stimulations were allowed to proceed for the stated times and then the 
platelets were lysed by the addition of an equal volume of 2 x lysis buffer plus protease 
inhibitors (300 mM NaCl, 20 mM Tris, 2 mM EGTA, 2 mM EDTA, 2% NP-40; pH 7.4 
plus 2.5 mM Na3VO4, 100 g/ml AEBSF, 5 g/ml leupeptin, 5 g/ml aprotinin, 0.5 
g/ml pepstatin). 
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2.3.2 ATP secretion 
Secretion assays were carried out in the same way as aggregation studies.  Platelets 
were pre-incubated for 2 minutes with Chrono-lume, a luciferin/luciferase reagent 
(Chronolog, Labmedics, Manchester, UK).  After addition of agonist, light emission 
from the luciferase reaction, catalysed by secreted ATP was recorded on a chart 
recorder in real time. 
 
2.3.3 Static adhesion and spreading 
Glass coverslips were coated using either 100 g/ml fibrinogen, 100 g/ml collagen or 
10 g/ml VWF at 4˚C overnight followed by washing with three changes of PBS.  The 
coverslips were then blocked with 5 mg/ml heat denatured BSA for 1 hour at room 
temperature followed by washing with three changes of PBS.  VWF coated coverslips 
were then treated with 2 g/ml botrocetin for 10 min at room at room temperature 
followed by washing with three changes of PBS.  Washed platelets were then added to 
the coverslips and allowed to adhere and spread for 45 mins at 37˚C in the presence of 2 
U/ml apyrase and 10 M indomethacin.  Non-adherent platelets were washed away with 
three changes of PBS.  Adherent platelets were then fixed with 3.7% paraformaldehyde 
for 10 minutes at room temperature.  The coverslips were then mounted onto glass 
slides using Hydromount (National Diagnostics, Atlanta, USA) and imaged by 
differential interference contrast (DIC) microscopy using a Zeiss Axiovert 200 M 
microscope.  Platelet surface area was then analysed using ImageJ software (NIH, 
Bethesda, USA). 
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2.3.4 P-Selectin exposure 
Washed mouse platelets were stimulated with stated agonists for 10 minutes at 37˚C in 
a volume of 50 l in the presence of 1 mM EGTA to prevent aggregation.  The platelets 
were stained with 100 g/ml FITC-conjugated -mouse P-selectin antibody for a 
further 10 minutes at 37˚C in the dark.  The platelets were diluted by addition of 200 l 
Tyrode‟s-HEPES buffer and analysed with a FACScalibur (BD Biosciences) and 
CellQuest software. 
 
2.3.5 In vitro flow adhesion 
Mouse blood was drawn as above, into sodium heparin (5 U/ml) and PPACK (40 M).  
Glass capillary tubes (1 x 0.1 mm; Camlab, Cambridge, UK) were coated with 100 
g/ml Horm collagen for 1h at room temperature whilst rotating slowly.  The capillaries 
were washed with PBS and blocked with 5 mg/ml heat-inactivated BSA for 1h at room 
temperature before being mounted on the stage of an inverted fluorescent microscope 
(DM IRB; Leica Microsystems Ltd, Milton Keynes, UK) equipped with a digital 
camera (CoolSnap ES, Photometrics, Huntington Beach, CA, USA).  Anticoagulated 
whole blood was pre-incubated with 2 M DiOC6 for 15 minutes at 37˚C to 
fluorescently label the cells.  The blood was then perfused through the capillary for 4 
minutes at a wall shear rate of 1000 s
-1
 at 37˚C followed by washing for 3 minutes at the 
same shear rate with Tyrode‟s-HEPES buffer.  Fluorescent images were recorded at 
approximately 2 second intervals for 2 minutes and the images linked to create a movie.  
Adherent cells were then fixed with 3.7% paraformaldehyde for 30 minutes and imaged 
using DIC microscopy on a Zeiss Axiovert 200 M microscope. 
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2.4 Cell culture 
2.4.1 Cell culture 
DT40 chicken B-cells were grown in RPMI supplemented with 10% foetal bovine 
serum (FBS), 1% chicken serum, 100 U/ml penicillin, 100 g/ml streptomycin, 50 M 
-mercaptoethanol and 20 mM GlutaMAX.  Human endothelial kidney (HEK) 293T 
cells were grown in DMEM supplemented with 10% FBS 100 U/ml penicillin, 100 
g/ml streptomycin, and 20 mM GlutaMAX.  Jcam2 human Jurkat T-cells were grown 
in RPMI supplemented with 10% foetal bovine serum (FBS), 100 U/ml penicillin, 100 
g/ml streptomycin, and 20 mM GlutaMAX. 
 
2.4.2 Transfection 
DT40 cells and Jcam2 cells were transfected in a volume of 400 l cytomix (120 mM 
KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM K2HPO4, 10 mM KH2PO4, 
25 mM HEPES, 0.04 mM ATP, 5 mM glutathione; pH 7.6) by electroporation using a 
GenePulser II (Biorad) set at 350 V and 500 F.  Cells were grown for 20 hours before 
use in experiments.  HEK 293T cells were transfected by a calcium phosphate method:  
DNA was diluted in 500 l water containing 252 mM CaCl2 followed by drop wise 
addition of 500 l of 2 x HEPES buffered saline (280 mM NaCl, 10 mM KCl, 1.5 mM 
Na2HPO4, 50 mM HEPES, 12 mM dextrose; pH 7.5).  This was allowed to precipitate at 
room temperature for 10 minutes then added to cells and incubated for 24 hours after 
which time, the media was removed and replaced with fresh media for a further 24 
hours after which time the cells were used for experiments. 
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2.5 Cell line reporter assay 
2.5.1 NFAT-luciferase assay 
DT40 cells or Jcam2 cells were transfected with stated amounts of stated receptors in 
addition to 20 g of the luciferase reporter construct and also, 2 g of pEF6-lacZ as a 
control for transfection efficiency.  Twenty hours after transfection cells were counted 
in the presence of Trypan blue to exclude dead cells and the live cells were split for the 
luciferase assay, -galactosidase assay for transfection efficiency and flow cytometry to 
assay surface expression of the receptor of interest.  Stimulations were performed in 
triplicate in a 96-well plate using 10
5
 cells per well in a final volume of 100 l for 6 
hours at 37˚C with stated agonists.  PMA (50 ng/ml) with ionomycin (1 M) were used 
as a positive control to show all cells were responsive.  Following the 6 hour 
stimulation, cells were lysed with the addition of 11 l harvest buffer (0.2 M potassium 
phosphate buffer; pH 7.8, 10% Triton X-100 and 1 mM DTT) for 5 minutes at room 
temperature.  The lysate (100 l) was added to an equal volume of assay buffer (0.2 M 
potassium phosphate buffer; pH 7.8, 20 mM MgCl2, 10 mM ATP).  Luciferase activity 
was measured with a Centro LB 960 microplate luminometer (Berthold Technologies, 
Germany) by addition of 50 l of 1 mM luciferin (MP Biomedicals, UK).  Data from 
the triplicates were averaged and normalised to -galactosidase activity, then expressed 
as fold increase over basal. 
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2.5.2 -galactosidase assay 
From each transfection, live cells (10
5
) were assayed in triplicate using the Galacto-
Light chemiluminescent reporter assay, according to the manufacturer‟s instructions 
(Applied Biosystems, Bedford, Mass, USA).  -galactosidase activity was measured 
with a Centro LB 960 microplate luminometer. 
 
2.5.3 Flow cytometry 
From each transfection, live cells (10
5
) were used to confirm surface expression of the 
receptor where possible.  Cells were stained with primary antibody in a volume of 50 l 
of PBS for 20 minutes on ice.  Cells were then washed in 1 ml of PBS and stained with 
FITC- conjugated secondary antibody in a volume of 50 l of PBS for 20 minutes on 
ice in the dark.  Stained cells were then analysed with a FACScalibur (BD Biosciences) 
and CellQuest software.  
 
2.6 Protein biochemistry 
2.6.1 Immunoprecipitation and pull-downs 
Lysates made as described above were pre-cleared with either protein A sepharose 
(PAS), or protein G sepharose (PGS) for immunoprecipitation (IP), or streptavidin-
agarose for pull-downs.  Lysates were pre-cleared for 60 minutes at 4˚C and then 
insoluble debris and the beads were pelleted by centrifugation at 18000 g in a 
microcentrifuge at 4˚C.  Cleared lysates were transferred to a new tube and 50 l was 
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removed and added to an equal volume of 2 x Laemmli sample buffer (Reducing: 20% 
glycerol, 10% -mercaptoethanol, 4% SDS, 50 mM tris, trace Brilliant Blue R; Non-
reducing: 20% glycerol, 4% SDS, 50 mM tris, trace Brilliant Blue R) for whole cell 
protein studies.  For IP experiments, the remaining cleared lysate was incubated with 
stated antibody and PAS (rabbit antibodies) or PGS (mouse, sheep and goat antibodies) 
for 90 minutes at 4˚C.  For pull-down experiments, the remaining cleared lysate was 
incubated with a biotinylated peptide and streptavidin-agarose for 90 minutes at 4˚C.  
The agarose or sepharose beads were subsequently washed with three changes of lysis 
buffer and associated proteins were eluted into 2 x Laemmli sample buffer and boiled 
for 5 minutes at 100˚C. 
 
2.6.2 SDS-PAGE and Western Blotting 
Denatured proteins were separated by electrophoresis through sodium dodecyl sulphate 
polyacrylamide gels (10% unless otherwise stated).  Prestained molecular weight 
markers (Bio-Rad, Hemel Hempsted, UK) were run alongside samples.  Separated 
proteins were then electro-transferred onto polyvinylidene difluoride (PVDF) 
membranes using a wet transfer method at 30 V for 90 minutes.  Membranes were then 
blocked with blocking buffer (5% (w/v) bovine serum albumin (BSA) and 0.1% (w/v) 
sodium azide in TBS-T (Tris-buffered saline (200 mM Tris, 1.37 M NaCl; pH 7.6 
containing 0.1% Tween-100)) for 1 hour prior to Western Blotting. 
 
The blocked membranes were then incubated with primary antibodies in blocking buffer 
for 1 hour followed by washing for 5 minutes at a time, with three changes of TBS-T.  
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The membranes were then incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies in TBS-T for 1 hour followed by washing for 5 minutes at a time, 
with three changes of TBS-T.  The membranes were then incubated with enhanced 
chemiluminescence (ECL, Amersham Bioscience, Buck, UK) reagent for 1 minute and 
then developed by exposure to autoradiographs.  In the cases where the membranes 
were required for a second blotting the antibodies were removed by stripping.  The 
membranes were incubated with stripping buffer (TBST-T containing 2% SDS) 
supplemented with 1% -mercaptoethanol for 20 minutes at 80˚C followed by 
incubation with stripping buffer for a further 20 minutes at 80˚C.  The membranes were 
then washed in several changes of TBS-T and blocked again in blocking buffer.  The 
blotting process was then repeated. 
 
2.6.3 Platelet surface protein cross-linking 
Following platelet stimulation, Sulfo-EGS at a final concentration of 0.15 mM or 1.5 
mM was added and allowed to incubate at room temperature for 30 minutes.  The 
reaction was then quenched with the addition of Tris-HCl (pH 7.5) at a final 
concentration of 25 mM, and allowed to incubate for a further 20 minutes at room 
temperature.  The platelets were then lysed with the addition of an equal volume of 2x 
ice cold NP-40 lysis buffer. 
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2.6.4 GST-fusion proteins 
2.6.4.1  Expression 
Constructs for the GST-tagged N-SH2, C-SH2 and tSH2 domains of Syk were 
transformed into DH5 E.coli cells and grown as a 100 ml overnight culture in Luria-
Bertani broth (LB; 10 g tryptone, 5 g yeast extract, 10 g NaCl per litre) plus ampicillin 
(100 g/ml) at 37˚C with shaking.  This was then split to inoculate four flasks of LB 
broth (1 litre) plus ampicillin (100 g/ml) and grown at 37˚C with shaking until the 
optical density at 600 nm (OD600) was approximately 0.75.  The cultures were then 
allowed to cool to room temperature and induced to express the fusion proteins with the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.1 mM).  These were then 
incubated overnight with shaking at room temperature. 
 
2.6.4.2  Purification 
The cultures were centrifuged for 30 min at 4500 rpm (JLA 8.1000 rotor, BD) and 4˚C.  
The bacterial pellet was then resuspended in 200 ml of lysis buffer (PBS containing 1% 
Triton-X100, 1% aprotinin, 5 g/ml leupeptin, 1 mM PMSF, 1 mM EDTA and 1 mM 
DTT) and sonicated on ice extensively.  Cellular debris was then removed by 
centrifugation for 20 min at 15000 rpm (JA 25.50 rotor, BD) and 4˚C.  The cleared 
lysate was then passed through a 10 ml column of glutathione-agarose and recycled five 
times.  The column was then washed extensively with 500 ml PBS, then 300 ml Tris (10 
mM Tris, 0.5 M NaCl and 1% NP40; pH 7) followed by 300 ml PBS.  The bound GST-
fusion proteins were then eluted from the column with 25 ml PBS containing 10 mM 
glutathione (pH7).  For surface plasmon resonance studies the protein was used in this 
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form with the GST-tag still attached.  Aggregated protein was removed using size-
exclusion chromatography (HiLoad 16/60 Superdex-200 120 ml column, GE 
Healthcare, UK).  For ITC and fluorescence titration experiments, the GST-tag was 
removed with the addition of 40 U of thrombin and incubated at room temperature for 6 
hours.  A further 40 U were added and left to incubate overnight at room temperature 
followed by a final addition of 25 U and incubated for 9 hours at room temperature.  
The free glutathione was then removed by extensive dialysis (three changes of buffer 
for 8 hrs at a time).  The cleaved proteins were then passed through the regenerated 
glutathione-agarose column to deplete the free GST; recycling 10 times.  Aggregated 
protein and remaining GST was removed using size-exclusion chromatography (HiLoad 
16/60 Superdex-200 120 ml column, GE Healthcare, UK). 
 
2.7  Surface Plasmon Resonance (SPR) 
SPR experiments were performed using a Biacore 3000 machine (Biacore, GE 
Healthcare, UK).  Biotin tagged CLEC-2 and FcR peptides were attached to CM5 
research grade sensor chips (Biacore AB) following attachment of streptavidin to the 
chip using amine coupling.  All experiments were performed at 25˚C in HBS-EP buffer 
(150 mM NaCl, 1 mM MgCl2, 10 mM HEPES, 0.005% Surfactant P-20; pH 7.4).  
Different concentrations of N-SH2, C-SH2 and tSH2 domains were injected over all 
peptide surfaces to determine equilibrium dissociation constants (KD).  All injections 
were compared to a negative control flow cell containing no peptide. 
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2.8 Isothermal Titration Calorimetry (ITC) 
ITC measurements were made in a VP-ITC isothermal titration calorimeter (MicroCal, 
GE Healthcare, UK).  Both Syk tSH2 domains and CLEC-2 peptides were extensively 
dialysed into experimental buffer (50 mM HEPES, 150 mM NaCl, 150 mM glycine, 1 
mM EDTA and 5 mM -mercaptoethanol; pH 7.5) prior to experimentation.  Protein 
and peptide concentrations were determined by spectrophotometry using a ND-1000 
spectrophotometer (Nanodrop, Thermo Scientific, UK).  The tSH2of Syk (8 M) were 
loaded into the calorimeter cell (V = 1.42 ml) and the CLEC-2 peptide (2 mM) was 
loaded into the injection syringe.  Titrations were computer controlled and performed at 
25˚C.  Negative control injections of peptide into buffer were performed under the same 
conditions. 
 
2.9 Tryptophan fluorescence titration 
Fluorescence measurements were performed in a PTI spectrofluorimeter (Photon 
Technology International Ltd. UK).  Both Syk SH2 domains and CLEC-2 peptides were 
extensively dialysed into experimental buffer (50 mM HEPES, 150 mM NaCl, 150 mM 
glycine, 1 mM EDTA and 5 mM -mercaptoethanol; pH 7.5) prior to experimentation.  
Protein and peptide concentrations were determined by spectrophotometry using a ND-
1000 spectrophotometer (Nanodrop, Thermo Scientific, UK).  The SH2 domains of Syk 
(3 ml of 250 nM) were loaded into a quartz cuvette and placed into the cell turret with 
constant stirring.  The CLEC-2 peptide (2 mM) was titrated in and allowed to mix for 2 
min before scanning.  An excitation wavelength of 295 nm was used and emission 
spectra were collected over the range of 300-420 nm in 2.5 nm steps.  Slit widths of 
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0.75 mm were used for both excitation and emission.  The peak fluorescence of 340 nm 
was monitored for binding constant calculation. 
 
2.10 Analysis of data 
Data is shown from a single experiment which is representative of 3-5 experiments.  
Where data is expressed in chart form, results are shown as arithmetic mean ± standard 
error unless otherwise stated.  NFAT-luciferase data is expressed as geometric mean ± 
standard error.  Statistical analysis was carried out using unpaired Student‟s t-test.  
Significance was taken for P < 0.05.  Where differences reached statistical significance, 
this is stated (with p values) on the corresponding figure and legend.  Where statistical 
significance is not explicitly stated, any differences were not statistically significant. 
 
  
 
 
 
 
 
CHAPTER 3 
A CLEC-2 DIMER IS CAPABLE OF ITAM-LIKE 
SIGNALLING THROUGH SYK TYROSINE KINASE 
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3.1 Introduction 
CLEC-2 has been shown to activate platelets using a signalling pathway that is similar 
to that which is used by GPVI, an ITAM receptor, despite having a single YxxL in its 
cytosolic tail (Suzuki-Inoue et al, 2006; Fuller et al, 2007).  Critically, point mutations 
in the conserved tyrosine within the YxxL sequence in CLEC-2 or in either of the Syk 
SH2 domains, which destroying their phosphotyrosine binding capacity, cause complete 
ablation of CLEC-2 signalling (Fuller et al, 2007).  Further, only a fusion protein 
encoding both Syk SH2 domains is able to precipitate CLEC-2 from rhodocytin-
stimulated platelet lysates (Suzuki-Inoue et al, 2006; Fuller et al, 2007).  These results 
demonstrate that both SH2 domains and the CLEC-2 YxxL sequence are critically 
required for signalling by the C-type lectin receptor. 
 
Two models can be put forward to explain these results: (i) the presence of a second 
binding site in the CLEC-2 cytoplasmic tail that is required for binding, either directly 
or indirectly, to one of the Syk SH2 domains, or (ii) that CLEC-2 regulates Syk through 
dimerisation, thereby providing two YxxL sequences.  The recent publication on 
CLEC9A, which is a covalent dimer, lends circumstantial evidence for this second 
model (Huysamen et al, 2008).  Further, a CLEC-2 specific F(ab‟)2 fragment, but not a 
F(ab) fragment, is able to mediate activation of mouse platelets providing further 
supporting this second model (May et al, 2009). 
 
In regard to the first model, we hypothesised that a second binding site would be 
conserved between species and most likely with Dectin-1 and CLEC9A which are the 
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only other two known proteins that signal through a single YxxL motif.  Sequence 
alignment of CLEC-2 from 9 species using ClustalW (www.ebi.ac.uk/clustalw/) 
highlighted the complete conservation of the MQDEDGYxxL sequence, and two serine 
residues at positions 21 and 27 (number from human CLEC-2).  Several positively 
charged amino acids and a WR sequence at the juxtamembrane position were also 
conserved (Figure 3.1 a).  Sequence alignment of Dectin-1 from 9 species also 
highlighted conservation of the DEDGYxxL sequence and of two serine residues in 
equivalent positions, but not the other conserved amino acids in CLEC-2 apart from the 
membrane WR sequence (Figure 3.1 b).  The same relationship did not hold for the 
recently discovered third member of this family, CLEC9A (Figure 3.1c).  The 
conserved DEDG sequence was replaced by the similarly charged EEEI sequence and 
just one of the serines was conserved. 
 
Sequence alignment also highlighted the presence of a threonine residue at position 9 in 
CLEC-2, the Y+2 position in the YxxL.  Dectin-1 had a conserved threonine at Y+1 of 
its YxxL and this was also seen in CLEC9A.  Previous studies using mast cells or 
mouse platelets have shown that the presence of a threonine in position Y+1 in the FcR 
ITAM can be a target of PKC ( or ) phosphorylation, and that this phosphorylation 
allows for a tighter interaction with the Syk SH2 domains and maximal activation of 
Syk (Germano et al, 1994; Swann et al, 1999; Pears et al, 2008).  
 
The aims of this chapter are to investigate the mechanism of regulation of Syk by 
CLEC-2 in order to distinguish between the two models proposed above.  This will be 
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achieved by investigation of whether CLEC-2 signals as a monomer or as a 
dimer/oligomer; by mutation of the two conserved serine and threonine residues; and by 
co-expression of wild type and the Y7F mutant of CLEC-2 to investigate whether the 
latter inhibits signalling, as predicted by the dimerisation model.  The presence of the 
conserved serine and threonine residues is of particular interest compared to other 
conserved sequences in CLEC-2 given their potential for phosphorylation.  Alongside 
this, direct measurement of binding of the SH2 domains of Syk to peptides based on the 
cytosolic sequence of CLEC-2 using a variety of protein chemistry and biophysical 
techniques was performed. 
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Figure 3.1 – Sequence alignment of CLEC-2 family proteins.  a) 9 species of CLEC-
2 were aligned using ClustalW web-based software, highlighting the conserved 
MQDEGDYxTL motif and serines 21 and 27.  b) 9 species of Dectin-1 were aligned, 
highlighting the conserved DEDGYTxL motif and serine residues.  c) Human CLEC-2, 
Dectin-1 and CLEC9A were aligned, highlighting the partially conserved DEDGYxxL 
motifs and serine residues.  
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3.2 Results 
3.2.1 Structure-function relationships of the CLEC-2 cytoplasmic tail and Syk 
tandem SH2 domains 
To investigate a potential role of conserved residues in the CLEC-2 tail, we used a 
combination of peptide pull-down studies, to ascertain if a CLEC-2 model peptide could 
associate with Syk from a platelet lysate, and a DT40 cell line assay using mutant forms 
of CLEC-2.  Expression of WT CLEC-2 along with a NFAT-luciferase reporter gene 
can be used to monitor activation by rhodocytin in a DT40 cell line.  This cell line has 
been used as a model system for GPVI-FcR and CLEC-2 signalling previously (Fuller 
et al, 2007; Tomlinson et al, 2007).  In this model, CLEC-2 and GPVI-FcR use the 
ITAM signalling machinery of the B-cell receptor to activate PLC2, resulting in NFAT 
activation and subsequent expression of luciferase.  In confirmation of the previously 
published result (Fuller et al, 2007) rhodocytin stimulated luciferase activity in DT40 
cells transfected WT CLEC-2 but not Y7F mutant, in which the tyrosine of the single 
YxxL motif was mutated to phenylalanine (Figure 3.2 a).  This confirms the critical role 
of the conserved tyrosine in signalling by CLEC-2. 
 
In line with the above, Syk was precipitated from platelet lysates using a 
phosphorylated but not a non-phosphorylated peptide encoding the first 13 amino acids 
(aa) of the CLEC-2 tail (Figure 3.2 b).  This region includes the conserved DEDGYxxL 
sequence.  Furthermore, there was no observable increase in the amount of Syk pulled 
out when a tyrosine phosphorylated peptide encoding the full 31aa cytoplasmic tail of 
CLEC-2 was used (Figure 3.2 c) suggesting that the first 13aa, and therefore the YxxL 
Chapter 3 – A CLEC-2 dimer is capable of ITAM-like signalling through Syk tyrosine kinase 
Page | 83 
 
sequence, is sufficient for Syk association.  It is important to note however that the 
interaction between the peptide and Syk in this experiment could be mediated through 
binding of two separate phosphorylated peptides to individual SH2 domains in Syk, 
bearing in mind that multiple phosphorylated peptides are attached to the beads used for 
precipitation.  These observations therefore do not rule out a possible direct or indirect 
interaction between the Syk tandem SH2 domains and a second site in the CLEC-2 
cytosolic tail which may take place in an intact cell. 
 
Using a similar approach, the contribution of the two conserved serine residues was also 
investigated.  Mutation of the serines to alanines, or deletion of the serine rich region 
21-28, had no significant effect on the ability of the mutant CLEC-2 to induce NFAT 
activation relative to the WT receptor in transiently transfected DT40 cells (Figure 3.3 
a).  Likewise, a tyrosine phosphorylated 31aa peptide in which both S21 and S27 were 
replaced by alanine was able to associate with Syk to the same degree as the WT 
peptide (Figure 3.3 b).  These results provide evidence against a functional role of the 
serine residues in mediating the association with Syk or signalling to PLC2 and 
subsequent NFAT activation. 
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Figure 3.2 – YxxL is essential for Syk association and signalling through CLEC-2.  
a)  DT40 cells were transfected with 10 g/ml of the stated CLEC-2 construct and a 
NFAT-luciferase reporter plasmid.  Transfected cells were stimulated with 50 nM 
rhodocytin for 6 hrs at 37˚C and then the luciferase activity was measured as a readout 
of signalling.  Results were normalised for transfection efficiency and plotted as a 
percentage of the WT response.  Error bars represent the geometric mean ± standard 
error of three to six separate experiments.  b) Washed platelets (5 x 10
8
/ml) were lysed 
with 2x NP40 lysis buffer, pre-cleared and interacting proteins precipitated with the 
addition of 10 g of the relevant biotinylated CLEC-2 peptide.  Precipitated proteins 
were separated by SDS-PAGE and western blotted for the presence of Syk.  
Densitometry is shown in the histograms.  Result is representative of three experiments. 
Chapter 3 – A CLEC-2 dimer is capable of ITAM-like signalling through Syk tyrosine kinase 
Page | 85 
 
 
Figure 3.3 – Serines-21 and 27 are dispensable for Syk association and signalling 
through CLEC-2.  a)  DT40 cells were transfected with 10 g/ml of the stated CLEC-2 
construct and a NFAT-luciferase reporter plasmid.  Transfected cells were stimulated 
with 50 nM rhodocytin for 6 hrs at 37˚C and then the luciferase activity was measured 
as a readout of signalling.  Results were normalised for transfection efficiency and 
plotted as a percentage of the WT response.  Error bars represent the geometric mean ± 
standard error of three to six separate experiments.  b) Washed platelets (5 x 10
8
/ml) 
were lysed with 2x NP40 lysis buffer, pre-cleared and interacting proteins precipitated 
with the addition of 10 g of the relevant biotinylated CLEC-2 peptide.  Precipitated 
proteins were separated by SDS-PAGE and western blotted for the presence of Syk.  
Densitometry is shown in the histograms.  Result is representative of three experiments.  
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The same approach was also used to investigate the role of the conserved threonine in 
the Y+2 position in the CLEC-2 YxxL sequence.  Mutation of the threonine to alanine 
had no significant effect on the ability of rhodocytin to stimulate NFAT activity in 
DT40 cells (Figure 3.4 a).  Further, a 13aa peptide containing phosphotyrosine and 
phosphothreonine residues at position 7 and 9 was able to precipitate a similar level of 
Syk from a platelet lysate (Figure 3.4 b).  This provides evidence against a functional 
role of the conserved threonine at position 9 in signalling by CLEC-2. 
 
These results confirm a critical role for the phosphorylated YxxL sequence in binding to 
Syk and mediating signalling by CLEC-2, but demonstrate that the two conserved 
serines at positions 21 and 27 and the partially conserved threonine at position 9 are 
dispensable for these events.  The functional role of the two conserved serines and 
threonine residues remains to be determined.  The present results have therefore failed 
to provide evidence for a second binding site in the CLEC-2 tail that supports binding 
and activation of Syk and thereby indirectly favour a model in which Syk cross-links 
two molecules of CLEC-2 via its tandem SH2 domains, both of which are known to be 
essential for CLEC-2 signalling (Fuller et al, 2007). 
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Figure 3.4 – Threonine-9 is dispensable for Syk association and signalling through 
CLEC-2.  a)  DT40 cells were transfected with 10 g/ml of the stated CLEC-2 
construct and a NFAT-luciferase reporter plasmid.  Transfected cells were stimulated 
with 50 nM rhodocytin for 6 hrs at 37˚C and then the luciferase activity was measured 
as a readout of signalling.  Results were normalised for transfection efficiency and 
plotted as a percentage of the WT response.  Error bars represent the geometric mean ± 
standard error of three to six separate experiments.  b) Washed platelets (5 x 10
8
/ml) 
were lysed with 2x NP40 lysis buffer, pre-cleared and interacting proteins precipitated 
with the addition of 10 g of the relevant biotinylated CLEC-2 peptide.  Precipitated 
proteins were separated by SDS-PAGE and western blotted for the presence of Syk.  
Densitometry is shown in the histograms.  Result is representative of three experiments.  
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3.2.2 Dominant negative effect of Y7F CLEC-2 on signalling by WT CLEC-2 
In order to further investigate the mechanism of regulation of Syk by CLEC-2, I co-
expressed wild type CLEC-2 with varying levels of the Y7F mutant of CLEC-2.  The 
rationale for this experiment is that the Y7F mutant should have an inhibitory effect if 
the cross-linking/dimerisation model is correct whereas it will have no effect if Syk is 
activated by a single CLEC-2 receptor.  The alternative possibility that the Y7F mutant 
is able to inhibit activation of Syk by a single CLEC-2 receptor seems unlikely.  When 
expressed at a ratio of 3:1, Y7F to WT, NFAT activity was inhibited to approximately 
25% that of the WT receptor.  This response increases to approximately 40% when the 
ratio is decreased to 1:1 and is restored to approximately normal levels when the 
amount of Y7F CLEC-2 is titrated down below a ratio of 0.05:1 (Figure 3.5 a).  Surface 
expression of WT CLEC-2 was measured by flow cytometry using an -Myc antibody 
which only detected the WT CLEC-2 due to the presence of a Myc tag.  The surface 
expression of WT CLEC-2 was not significantly affected by expression of the Y7F 
mutant (Figure 3.5 b).  In contrast, the weak constitutive (agonist-independent) signal 
induced by expression of CLEC-2 that has been previously described (Mori et al, 2008) 
was not inhibited in the presence of the Y7F mutant suggesting that it may be mediated 
through a CLEC-2 monomer.  These data provide evidence that ligand-activated CLEC-
2 is unable to signal as a monomer in response to activation by rhodocytin and that 
expression of the Y7F inactive mutant has a „dominant negative‟ effect as a result of 
forming dimeric or higher order structures with wild type receptors that are unable to 
signal. 
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Figure 3.5 – The Y7F CLEC-2 mutant inhibits signalling by the wild type receptor.  
a) DT40 cells were transfected with 10 g/ml of WT CLEC-2 (black text) and/or 
varying amounts of Y7F CLEC-2 (grey text) shown as a ratio, and a NFAT-luciferase 
reporter gene.  Transfected cells were stimulated with 50 nM rhodocytin for 6 hrs at 
37˚C after which time, the amount of luciferase activity was measured as a readout of 
signalling.  Results were normalised for transfection efficiency and plotted as a 
percentage of the WT response.  Error bars represent the geometric mean ± standard 
error of three to eight separate experiments.  b) Transfected cells were analysed by flow 
cytometry for surface expression of Myc-tagged WT CLEC-2.  The selected gate was 
drawn to exclude ~99% of mock transfected cells.  No WT expression is seen in the 
Y7F transfection alone, and WT expression is similar when co-transfected with varying 
amounts of Y7F. 
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3.2.3 CLEC-2 oligomers are present on the platelet surface 
The above results favour a dimerisation/oligomerisation model of signalling by CLEC-
2.  To further investigate this, we used the cross-linker Sulfo-EGS, which is known to 
cross-link surface proteins that lie within a distance of 16.1 Å (12 atoms) of each other 
(Browning and Ribolini, 1989; Dihazi and Sinz, 2003; Sinz, 2003).  In non-stimulated 
or rhodocytin-stimulated platelets, CLEC-2 migrates on SDS-PAGE as a characteristic 
doublet due to differential glycosylation (Suzuki-Inoue et al, 2006; Watson et al, 2007).  
The molecular weights of the differentially glycosylated forms of CLEC-2 (30 and 40 
kDa) suggest that both are present as a monomer and is consistent with the fact that they 
are reduced to a single band of just less than 30 kDa upon deglycosylation (Suzuki-
Inoue et al, 2006).  Following addition of a low or high concentration of the cross-linker 
Sulfo-EGS, the presence of several higher molecular weight bands of CLEC-2 can be 
seen together with a corresponding reduction in intensity of the 30 and 40 kDa bands 
(Figure 3.6 a).  In the absence of stimulation, a new, broad band is observed at between 
60 – 80 kDa which corresponds approximately to a doubling of the molecular weight of 
monomeric CLEC-2.  With the higher concentration of cross-linker, there is the 
suggestion of higher order structures in non-stimulated platelets, with a corresponding 
reduction in both the monomeric and predicted dimeric forms of the receptor.  In the 
presence of rhodocytin, Sulfo-EGS induces formation of the predicted CLEC-2 dimer 
along with higher order structures, most notably at the higher of the two concentrations, 
where there is almost no detectable monomeric CLEC-2.  The broad nature and 
smearing of the bands could reflect a combination of higher oligomeric forms of CLEC-
2 and possibly cross-linking to other proteins.  Interestingly, western blotting studies 
failed to detect the presence of rhodocytin in the higher order structures suggesting that 
direct cross-linking to the toxin had not occurred (not shown). 
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A similar overall pattern of change in CLEC-2 dimerisation/oligomerisation was seen in 
whole cell lysates prepared from basal (not shown) and rhodocytin-activated platelets, 
as demonstrated by western blotting for CLEC-2 (Figure 3.7 b).  In marked contrast, 
there was no apparent dimerisation/oligomerisation of the low affinity immune receptor, 
FcRIIA, or the membrane-associated protein Src in the presence of the intermediate 
and high concentration of Sulfo-EGS in basal (not shown) or rhodocytin-activated 
platelets (Figure 3.7 b) as shown by the similar levels of the monomeric forms of both 
proteins and no higher molecular weight forms present as revealed by western blotting 
(Figure 3.7 b).  This result demonstrates that the oligomerisation of CLEC-2 is not 
simply the result of a non-specific effect of cross-linking of platelet surface proteins. 
 
Together, these results provide evidence for the presence of monomeric, dimeric and 
oligomeric forms of CLEC-2 on the platelet surface, although it should be noted that 
these structures may also be due to binding to one or more additional proteins.  
Nevertheless, the loss of the monomeric and the corresponding increase in the 60 – 80 
kDa band is consistent with the proposal that CLEC-2 forms a dimer thereby providing 
adjacent binding sites for Syk through its phosphorylated YxxL domains. 
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Figure 3.6 – CLEC-2 oligomers are present on the platelet surface.  Washed 
platelets (5 x 10
8
/ml) under basal or rhodocytin stimulated (100 nM) conditions had 
their surface proteins cross-linked with the addition of 0.15 mM or 1.5 mM Sulfo-EGS 
cross-linking reagent, with a linker length of 16 Å.  The cross-linking reaction was 
subsequently blocked and then the platelets were lysed with 2x NP40 lysis buffer.  a)  
The lysates were then pre-cleared with protein G Sepharose, then immunoprecipitated 
with -CLEC-2 antibody and PGS.  Precipitated proteins were separated by SDS-PAGE 
and western blotted for CLEC-2.  b) Lysates were separated by reducing SDS-PAGE 
and western blotted for CLEC-2, FcRIIA and Src.  The results are representative of 
three experiments 
a) 
b) 
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3.2.4 Affinity measurements of Syk SH2 domains for CLEC-2 
The above results support a model in which the tandem SH2 domains in Syk bind to the 
phosphorylated YxxL sequence in separate CLEC-2 monomers.  This is consistent with 
our previous report that point mutants that disrupt binding of the individual SH2 
domains to phosphotyrosine abrogate signalling by CLEC-2 (Fuller et al, 2007). 
 
For this model to be correct, both SH2 domains of Syk must be able to bind to the 
phosphorylated YxxL sequence.  This was investigated using surface plasmon 
resonance (SPR) to measure the equilibrium dissociation constants (KD) of binding of 
the N-SH2, C-SH2 and the tandem SH2 (tSH2) domains of Syk to surfaces coated with 
the phosphorylated or non-phosphorylated 13aa CLEC-2 peptide (Figure 3.7 a).  These 
proteins were expressed as GST-fusion proteins in DH5 E.coli cells and affinity 
purified on a glutathione-agarose column (Figure 3.7 b).  No detectable binding was 
observed for any of the SH2 domains when flowed over the non-phosphorylated CLEC-
2 peptide (not shown), confirming the requirement for phosphorylation of the conserved 
tyrosine residue.  There was also no detectable binding observed for GST alone or in a 
reference flow cell (not shown).  Specific binding was observed when the peptides were 
flowed over a tyrosine phosphorylated CLEC-2 peptide.  From the resulting curves, we 
calculated a KD of 10.5 M (±2 M) for the N-SH2 domain alone and 2.35 M (±0.54 
M) for the C-SH2 domain alone demonstrating the ability of both SH2 domains to 
bind to phosphorylated CLEC-2 YxxL with similar affinity.  Moreover, when the tSH2 
domain protein was flowed over the tyrosine phosphorylated CLEC-2 peptide, a KD of 
256 nM (±59.9 nM) was calculated thereby demonstrating cooperativity in binding of 
the two SH2 domains, i.e. the divalent nature of the tSH2 domain protein binding to the 
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peptide surface under flow results in an increased affinity as a function of the affinities 
of the two SH2 domains and avidity of the surface.  As a comparison, the individuals 
and tandem Syk SH2 domains were flowed over a dually phosphorylated peptide based 
on the FcR ITAM sequence.  Cooperativity was again observed when the tSH2 
domains were flowed over the peptide with a calculated KD of 19.7 nM (±1.79 nM) 
compared to the individual KDs of 19.7 M (±1.1 M) and 1.71 M (±0.36 M), 
respectively, for the N- and C-SH2 terminal domains alone.  These data therefore 
confirm that the Syk tandem SH2 domain protein binds with higher affinity than the 
single Syk SH2 domains to a surface containing multiple copies of a single or tandem 
phosphorylated YxxL-containing peptides.  This has important implications for the 
binding of Syk to a dually phosphorylated ITAM protein or to the phosphorylated 
CLEC-2 tail when presented as a dimer.  Consistent with this data, quantitative western 
blotting was used to show that twice the amount of a CLEC-2 peptide was able to 
associate with the tSH2 domains of Syk compared with the single SH2 domains alone 
providing further evidence of an interaction with a 2:1 stoichiometry of CLEC-2 to Syk 
(Figure 3.7 c). 
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Figure 3.7 – Surface plasmon resonance measurements of the CLEC-2-Syk SH2 
interaction.  a) Biotinylated CLEC-2 and FcR peptides were bound to streptavidin-
coated biosensor chips surfaces.  The N-SH2 (ai), C-SH2 (aii) or the tSH2 (aiii) 
domains of Syk were flowed over the chip at a range of concentrations.  Non-linear 
regression was used to analyse the data and calculate KD values.  The results are 
representative of three experiments.  b)  GST-fusion proteins were inducibly over-
expressed in DH5 cells, and purified on a glutathione-agarose column.  20 l samples 
were ran on SDS-PAGE and proteins visualised with Coomassie stain.  c)  GST-tagged 
Syk SH2 domain proteins were incubated with a 50-fold excess of biotinylated 
phospho-CLEC-2 peptide and precipitated with glutathione-agarose beads.  The 
precipitated proteins were dot-blotted and the amount of associated CLEC-2 was 
measured using HRP-streptavidin and densitometric analysis.  The result is 
representative of four experiments 
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The results from the SPR were particularly encouraging as the results for binding to the 
CLEC-2 peptide followed the same pattern of cooperativity as binding to the FcR 
ITAM peptide.  However, to have greater confidence we wanted to use another 
technique to try to confirm the measured affinities.  Firstly we chose to use isothermal 
titration calorimetry (ITC) due to its sensitivity, and because it is also possible to 
directly determine the stoichiometry of an interaction.  ITC requires high concentrations 
of pure protein without any GST-tags attached.  We therefore scaled up the production 
of the tSH2 protein, cleaved off the GST-tag with thrombin, and performed several 
purification steps with glutathione-agarose columns and size-exclusion chromatography 
(Figure 3.8 a).  Titration of the phosphorylated CLEC-2 peptide caused a small heat 
exchange which was titratable down to only the heat exchanged due to the heat of 
dilution of buffer, thereby demonstrating an interaction (Figure 3.8 b).  However, under 
the conditions required for this experiment (i.e. stirring conditions at room temperature 
for 3-4 hours), the tSH2 protein did not remain stable for long enough to collect high 
quality data.  Without the GST-tag, the protein came out of solution after extended 
periods of time above 4˚C but these experiments could not be performed in the presence 
of the GST-tag due to the possibility of GST forming dimers and non-specific 
interactions with the peptide.  Therefore, the data was insufficient to directly measure 
the stoichiometry of the interaction.  However, it was possible to fit the collected data to 
a two-site but not to a single-site binding curve, consistent with the model in which the 
tandem Syk SH2 domains bind to two phosphorylated CLEC-2 peptides.  The two 
calculated KDs from this fitting were 28 M and 2.07 mM.  These values do not 
correspond with the above results, most likely due to the instability of the proteins under 
the experimental conditions, thereby making the data unreliable.  It may be possible to 
repeat these experiments in the future at 4ºC to bypass the instability of the SH2 
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domains however, the decreased temperature would mean that many of the measured 
thermodynamic parameters would not be comparable to those measured in assays at 
room temperature although the stoichiometry would presumably still be possible to 
calculated at the lower temperature. 
 
Due to the failure of the ITC, we used a third approach to investigate binding of the 
tSH2 domains of Syk to a CLEC-2 peptide, namely tryptophan fluorescence titration.  
This technique is based on the principle that binding to the peptide causes a change in 
fluorescence of one or more tryptophan groups in the tandem Syk SH2 domains (Grucza 
et al, 1999; Kim et al, 2000).  The N-terminal 13aa CLEC-2 peptide was used for these 
studies as this supports a similar level of binding of Syk to that of the 31aa 
phosphorylated peptide and does not contain any tryptophan residues.  Addition of the 
peptide resulted in a saturatable decrease in peak tryptophan fluorescence of the tandem 
Syk SH2 domains at 340 nm, indicative of ligand binding (Figure 3.8 c).  The resulting 
dissociation constant (KD) of 5.72 M (±2.14 M) for the Syk tSH2:CLEC-2 interaction 
was of a similar order to the SPR derived KD of the CLEC-2 peptide associating with 
either the N- or C-terminal Syk SH2 domains alone.  In contrast, the fluorescence data 
recorded a 20-fold weaker binding to the tSH2 domains than was observed by SPR.  
This discrepancy may reflect the influence of avidity in the binding between the Syk 
tSH2 domains and a surface-immobilised peptide whereas the tryptophan fluorescence 
measurements were made in solution.  In contrast, we were unable to detect binding of 
the CLEC-2 peptide to the single C-terminal SH2 domain of Syk over the same 
concentration range (not shown).  The equivalent experiment was not valid for the N-
terminal SH2 domain as this does not contain a tryptophan residue.  It should also be 
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noted that there is also a single tryptophan residue in the SH2 linker region which is 
present only in the tSH2 domain protein.  It is therefore possible that ligand binding is 
causing only the linker region tryptophan to change its fluorescence and this could 
explain the lack of fluorescence change with the C-terminal SH2 domain. 
 
Chapter 3 – A CLEC-2 dimer is capable of ITAM-like signalling through Syk tyrosine kinase 
Page | 99 
 
 
Figure 3.8 – SPR and tryptophan fluorescence measurements.  a) GST-fusion tSH2 
domain protein was inducibly over-expressed in DH5 cells, and purified on a 
glutathione-agarose column.  Eluted fractions were treated with thrombin to cleave off 
the GST-tag.  Samples were run on SDS-PAGE and proteins visualised with Coomassie 
stain (ai).  Free GST was depleted using a glutathione agarose column.  Samples were 
run on SDS-PAGE and proteins visualised with Coomassie stain (aii).  Size exclusion 
chromatography was used to further purify the tSH2 domain protein (aiii).  The blue 
line represents absorbance at 280 nm, the red line represents absorbance at 254 nm.  
Samples from CV (void column volume), and the two major peaks were run on SDS-
PAGE and proteins visualised with Coomassie stain.  The second peak contains pure 
tSH2 domain protein and was eluted off the column with a predicted MW of 29.65 kDa.  
Chapter 3 – A CLEC-2 dimer is capable of ITAM-like signalling through Syk tyrosine kinase 
Page | 100 
 
 
Figure 3.8 – continued.  b) The purified tSH2 domains of Syk were loaded into the cell 
of an ITC instrument (MicroCal) and allowed to equilibrate to 25˚C.  Computer 
controlled injections of a CLEC-2 peptide were performed and the power required for a 
reference cell to match the temperature in the experimental cell was plotted (upper 
panel), and integrated to calculated power per mole of peptide (lower panel).  Origin 
Lab ITC software was used to fit the data to various binding models.  The graph is 
representative of 2 experiments.  c) The purified tSH2 domains of Syk were placed into 
a quartz cuvette in a PTI (Photon Technology International) spectrofluorimeter.  
Following excitation at 295 nm, emission at 340 nm was plotted during titration of a 
CLEC-2 peptide.  Non-linear regression was used to analyse the data and calculate KD 
values.  The graph is representative of 3 experiments. 
Chapter 3 – A CLEC-2 dimer is capable of ITAM-like signalling through Syk tyrosine kinase 
Page | 101 
 
3.2.5 GPVI requires both FcR YxxL sequences to signal 
The above observations that CLEC-2 is able to signal with only a single YxxL by 
forming a dimer, raises the question as to whether an ITAM receptor, containing tandem 
YxxL sequences, is able to activate Syk through cross-linking adjacent phosphorylated 
YxxLs or if binding to a doubly phosphorylated ITAM is essential for activation.  This 
question was addressed through the generation of single and double point mutations (Y-
F) of the conserved ITAM tyrosines in FcR which associates with GPVI.  This work 
was performed in collaboration with Dr. Jun Mori.  An N-terminal Myc-tagged version 
of FcR, which supports a similar level of signalling to that of the wild type protein 
(Mori et al, 2008), was used in these studies to enable measurement of the level of 
surface expression.  As shown in Figure 3.9 a, mutation of the C-terminal ITAM 
tyrosine, or mutation of both ITAM tyrosines, abolished NFAT activation by collagen 
in DT40 cells transfected with GPVI and mutant FcR, whereas mutation of the N-
terminal ITAM tyrosine alone suppressed the response by more than 95%.  Expression 
of the various FcR mutants did not significantly affect the surface expression of GPVI 
as determined by flow cytometry using an -GPVI antibody (Figure 3.9 b).  Thus, these 
results demonstrate that both ITAM tyrosines are required for robust signalling by the 
GPVI-FcR complex and that FcR is unable to function efficiently through 
phosphorylation of a single YxxL. 
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Figure 3.9 – GPVI signalling requires both ITAM tyrosines.  a) DT40 cells were 
transfected with 2 g/ml of stated FcR construct, 2 g/ml of GPVI, along with a 
NFAT-luciferase reporter gene.  Transfected cells were then stimulated with 10 g/ml 
collagen for 6 hrs at 37˚C after which time, the amount of luciferase activity was 
measured as a readout of signalling.  Results were normalised for transfection efficiency 
and plotted as a percentage of the WT response.  Error bars represent the geometric 
mean ± standard error of three separate experiments.  b) Transfected cells were analysed 
by flow cytometry for surface expression of GPVI.  The selected gate was drawn to 
exclude ~99% of mock transfected cells.  GPVI expression is similar when co-
transfected with the various FcR point mutants. 
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3.3 Discussion 
In this chapter I have considered two models for regulation of Syk by CLEC-2 via a 
single YxxL sequence, bearing in mind that it has previously been reported that 
activation requires the phosphotyrosine binding activity of both of the Syk SH2 
domains (Fuller et al, 2007).  The first model proposes the presence of a second (either 
direct or indirect) binding site for one of the Syk SH2 domains in the cytoplasmic tail of 
CLEC-2.  This possibility was tested by mutational analysis of conserved residues using 
peptide pull-down assays and cell line reporter assays.  Sequence alignment of multiple 
species of CLEC-2, and of the related family member Dectin-1, highlighted 
conservation of serines at position 21 and 27 (numbering from human CLEC-2).  
However, mutational analysis of these two residues failed to provide evidence for a 
functional role in mediating the association with Syk or for activation of NFAT activity 
in DT40 cells, which is critically dependent on engagement of Syk and PLC2 (Fuller et 
al, 2007).  Likewise, the partially conserved threonine at the Y+2 position in the CLEC-
2 YxxL sequence was shown to be dispensable for Syk association and NFAT 
activation.  In fact, a short 13aa peptide was found to be sufficient to mediate the 
association with Syk.  However, it may be possible that these residues are conserved 
throughout the family for some other function that is not required for the signalling 
pathway involving Syk. 
 
The second model is through dimerisation, with CLEC-2 interacting with the tandem 
SH2 domains of Syk via phosphotyrosines found in adjacent CLEC-2 molecules (Figure 
3.10).  In support of this model, co-expression of functionally inactive Y7F CLEC-2 
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with the wild type receptor was found to inhibit signalling, with the response being 
restored by titrating down the amount of the Y7F mutant.  Importantly, this effect of the 
Y7F mutant was not due to altered surface expression of the wild type receptor.  This 
suggests that WT CLEC-2 is unable to signal when present as a complex with the Y7F 
mutant.  This, taken with the dependence of both SH2 domains of Syk and the 
conserved tyrosine in the single YxxL of CLEC-2 (Fuller et al, 2007), suggests that the 
minimum signalling unit is a CLEC-2 dimer, recruiting a single molecule of Syk. 
 
It is also interesting to consider that for Syk to be able to cross-link two CLEC-2 
molecules, the linker region between the tandem SH2 domains would require a degree 
of flexibility.  Various structural studies have shown that this linker region (interdomain 
A) interacts with the kinase domain helping to regulate its activity and that in Syk it is 
more flexible than in Zap-70 (Futterer et al, 1998; Zeitlmann et al, 1998; Grucza et al, 
1999; Brdicka et al, 2005; Deindl et al, 2007).  Therefore we can hypothesise that 
CLEC-2 signalling would be much less efficient through Zap-70 as it would be less 
likely to cross-link two CLEC-2 molecules and interact with the kinase domain 
correctly. 
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Figure 3.10 – Proposed model for Syk cross-linking a CLEC-2 dimer. 
  
Chapter 3 – A CLEC-2 dimer is capable of ITAM-like signalling through Syk tyrosine kinase 
Page | 106 
 
In further support of this model, cross-linking studies revealed the presence of dimeric 
and higher ordered complexes of CLEC-2.  Moreover, the presence of these structures 
under basal conditions suggests that ligand binding is not required for the formation of 
CLEC-2 clusters.  However, following rhodocytin stimulation, there was a shift towards 
higher molecular weight structures and a further lowering of the level of the monomeric 
form, suggesting that binding to rhodocytin induces or stabilises the formation of these 
higher, oligomeric forms.  This is not surprising given the observation that rhodocytin is 
tetrameric and therefore potentially able to cluster up to eight molecules of CLEC-2 
(Watson et al, 2008). 
 
Using both SPR and tryptophan fluorescence we were able to measure the affinity of the 
interaction between the SH2 domains and CLEC-2 peptides.  SPR showed an increase 
in affinity for the tSH2 domains compared to the single SH2 domains, thereby 
suggesting cooperative binding under the flow conditions of the assay.  A similar result 
was found with an FcR peptide which is a known binding partner for the Syk tandem 
SH2 domains.  This result was backed up with quantitative western blotting which 
showed that twice the amount of a CLEC-2 peptide was able to associate with the tSH2 
protein compared to the single SH2 domains, giving further evidence that both of the 
SH2 domains are able to bind to a single CLEC-2 peptide.  Tryptophan fluorescence 
was used to obtain a second measurement of the affinity of the interaction with the 
tandem SH2 domain peptide.  The approximate one order of magnitude lower affinity is 
consistent with the affinity measured using SPR for binding to the individual Syk SH2 
domains, reflecting the absence of cooperativity as the study was performed in solution 
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rather than on a monolayer.  ITC measurements were unable to provide suitable data to 
directly measure the stoichiometry of the interaction. 
 
This family of proteins may present a novel modification of ITAM signalling, which 
uses phosphorylation of the two conserved tyrosines in an ITAM sequence for optimal 
signalling.  Given the dimerisation model, it is of interest to consider why FcR does 
not function in this way as shown in the NFAT studies by the abolition/dramatic 
inhibition of response following mutation of the individual FcR YxxL sequences.  One 
possible explanation is that FcR, which is a covalent dimer, is expressed in a 
conformation that does not favour cross-linking of YxxL groups on separate chains, 
possibly to dampen or prevent signalling in the absence of agonist binding.  It is also 
possible that it is a difference in agonists as rhodocytin is potentially able to cluster up 
to eight CLEC-2 molecules whereas, although collagen is able to cluster GPVI 
molecules, due to the spacing of the GPO repeats it may not bring the molecules into 
close enough proximity for the FcR molecules to be cross-linked by Syk.  It may be 
that CRP would be able to induce a signal in the single point mutant of FcR by 
inducing tighter clustering of the receptor and being sufficient to initiate signalling 
through Syk. 
 
On the other hand, the presence of two YxxL groups on the same chain facilitates 
binding to proteins with tandem SH2 domains without a need for receptor 
dimerisation/oligomerisation.  This is illustrated by comparison of the KDs derived for 
binding of single and tandem SH2 domains of Syk to immobilised tyrosine 
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phosphorylated peptides in the surface plasmon resonance experiments described above.  
Dual YxxL groups that form an ITAM are found in separate exons 
(http://www.ensembl.org) suggesting that ITAM-like receptors preceded ITAM 
receptors and that the latter arose through gene duplication.  The greater number of 
ITAM receptors over ITAM-like receptors may reflect an evolutionary advantage in 
having two YxxL groups on the same protein, although this may also reflect the fact 
that the majority of ITAM receptors are composed of multiple chains which may 
hamper dimerisation/oligomerisation. 
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4.1 Introduction 
Although there are many parallels between the CLEC-2 and GPVI signalling pathways, 
one of the distinguishing features is in regard to the role of the adaptor protein, SLP-76, 
in the activation of PLC2.  GPVI has been shown to have an absolute requirement for 
SLP-76 in platelet activation (Clements et al, 1999; Gross et al, 1999; Judd et al, 2000), 
whereas the response to low but not to high concentrations of rhodocytin are inhibited 
in the absence of the adapter (Suzuki-Inoue et al, 2006).  Furthermore, this differential 
requirement is also seen between CLEC-2 and GPVI in DT40 cells using an NFAT 
reporter assay that is driven by activation of PLC2 (Fuller et al, 2007).  SLP-76 has 
also been shown to play an essential role in signalling by other ITAM receptors, 
including the T-cell antigen receptor (Fang et al, 1996; Motto et al, 1996; Wardenburg 
et al, 1996) thereby indicating that the partial role in signalling by CLEC-2 may be a 
distinguishing feature between ITAM and ITAM-like receptors.  It is therefore 
important to consider whether other proteins that regulate SLP-76 have a differential 
role in signalling by these two classes of receptor. 
 
SLP-76 has been shown to be constitutively associated with the adaptor protein Gads 
(Grb2 adaptor downstream of Shc, also known as Mona/Grap2/GrpL/Grf40) and to 
form a complex with the membrane adapter LAT in activated platelets and T-cells (Liu 
et al, 1999).  Gads has a central SH3 domain, flanked by two SH2 domains.  The 
constitutive association with SLP-76 is by virtue of an atypical interaction between the 
SH3 domain of Gads and an RxxK motif on SLP-76 which is of very high affinity (~3 
nM) relative to other SH3 interactions which fall within the micromolar range (Liu et al, 
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2003; Seet et al, 2007).  Phosphorylation of the membrane bound adaptor protein LAT 
at position 191 (and to a lesser extent 171) (Zhang et al, 2000; Paz et al, 2001; Perez-
Villar et al, 2002) by a Syk family kinase, leads to recruitment of Gads via an SH2-
phosphotyrosine interaction, thereby recruiting SLP-76 to the membrane.  The complex 
of LAT-Gads-SLP-76 recruits PLC2 and several other proteins to the membrane, 
including Vav and Tec family kinases, forming a LAT signalosome that is integral for 
activation of PLC 
 
Gads is a member of the Grb2 (Growth factor receptor bound protein) adaptor family 
which comprises Gads, Grb2 and Grap (Grb2 related adaptor protein).  All three have 
the same domain organisation and moreover Grb2 has also been shown to bind to both 
LAT, via tyrosines Y171, Y191 and Y226 (Zhang et al, 2000; Paz et al, 2001; Perez-
Villar et al, 2002), and to SLP-76, through a classical PxxP-SH3 interaction with a 
lower affinity (~3 M) relative to the interaction between Gads and SLP-76 (Seet et al, 
2007).  Significantly, Grb2 has been shown to substitute for Gads in reconstitution of B-
cell receptor signalling in chicken DT40 cells (Ishiai et al, 2000).  This is a very 
artificial system, however, in which the B-cell equivalent of SLP-76 (BLNK/SLP-65) is 
removed by homologous recombination and cells transfected with various mutated 
forms of LAT and SLP-76 along with Gads or Grb2.  Thus it is unclear whether Grb2 is 
able to substitute for Gads in more physiological systems. 
 
As mentioned above, the ITAM containing T-cell receptor (TCR, and therefore the pre-
TCR) also uses the LAT-Gads-SLP-76 signalosome for activation of PLC1.  Mice 
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deficient in SLP-76 do not express any mature T-cells due to a blockade of signalling 
through the pre-TCR, which is analogous to blockade of GPVI signalling (Clements et 
al, 1998; Pivniouk et al, 1998; Clements et al, 1999).  Mice deficient in LAT also do 
not express mature T-cells, again due to a block in pre-TCR signalling (Zhang et al, 
1999), whereas GPVI signalling is able to bypass the requirement to LAT at high 
agonist concentrations (Pasquet et al, 1999).  Similarly there is a loss of PLC1 
activation by the TCR in either SLP-76 or LAT deficient Jurkat cells, which is a 
commonly used immortalised T lymphocyte cell line (Finco et al, 1998; Yablonski et al, 
1998).  Interestingly, mice deficient in Gads do have a limited degree of pre-TCR 
signalling which results in the production of mature T-cells, albeit in reduced numbers 
(Yoder et al, 2001).  Consistent with this, disruption of the Gads-SLP-76 interaction 
impairs TCR signalling in Jurkat cells by approximately 50% (Yablonski et al, 2001; 
Jordan et al, 2007), confirming that Gads plays a partial role in TCR signalling. 
 
The role of Gads in platelets has not been studied in detail.  It has been shown to 
associate with SLP-76 (Liu et al, 1999; Asazuma et al, 2000) and, more recently, to 
undergo tyrosine phosphorylation downstream of GPVI, although the significance of 
this is unclear (Garcia et al, 2006).  The only functional study using Gads-deficient 
mice reported that Gads was not required for platelet -granule secretion following 
stimulation with a single, high concentration (20-30 nM) of the GPVI specific snake 
toxin, convulxin, whereas LAT was essential for activation by these concentrations of 
the toxin (Judd et al, 2002).  Further,  mutation of the Gads binding site on SLP-76 has 
been shown to impair platelet -granule secretion by more than 50% in response to a 
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low dose (5 nM) of convulxin (Abtahian et al, 2006). The role of Gads in signalling by 
CLEC-2 is unclear. 
 
The adapter SLP-76 has also been shown to shown to play a critical role in the 
regulation of PLC2 by integrin IIb3 and the GPIb-IX-V complex (Judd et al, 2000; 
Judd et al, 2002; Liu et al, 2005), whereas the role of Gads in signalling by these two 
receptors is not established.  In contrast, the membrane adapter LAT has been reported 
to have a differential role in signalling by integrin IIb3 and the GPIb-IX-V.  The 
membrane adaptor is localised to lipids rafts on the platelet surface, which are enriched 
in many signalling proteins including several Src family kinases.  The integrin IIb3 is 
excluded from these domains and, consistent with this, has been shown to regulate 
PLC2 independent of LAT (Wonerow and Watson, 2001; Wonerow et al, 2002).  In 
contrast, the membrane adapter has been shown to play a partial role in the regulation of 
PLC2 by GPIb-IX-V, which has been shown to be recruited to rafts in activated 
platelets (Wu et al, 2001; Jin et al, 2007). 
 
The aim of this chapter is to compare the role of Gads and LAT in platelet activation by 
the major membrane glycoprotein receptors using mutant mice, with special emphasis 
on activation by GPVI and CLEC-2 given their differential dependence on SLP-76. 
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4.2 Results 
4.2.1 Comparison of the role of Gads and LAT in platelet aggregation and 
secretion 
The role of Gads and LAT in supporting platelet aggregation by the GPVI-specific 
agonist CRP was compared using mice deficient in the two proteins.  Platelet 
aggregation was monitored in a Born-lumi aggregometer which measures light 
transmission through the platelet suspension: as the platelets become activated and form 
larger but less numerous aggregates, the amount of light transmission increases.  WT 
platelets responded to a range of CRP concentrations (0.3-10 g/ml) with a 
characteristic shape change response (as reflected an initial decrease in light 
transmission) followed by full aggregation (increase in light transmission) (Figure 4.1).  
All of these concentrations of CRP were able to elicit a full aggregation response; 
however, the lower ones had a more pronounced shape change because of increase in 
the time to onset of aggregation. 
 
In the absence of LAT, the dose-response curve for platelet aggregation to CRP was 
shifted such that a supra-maximal concentration of CRP (10 g/ml) in washed platelets 
only induced a sub-maximal aggregation response.  In contrast, full aggregation was 
achieved a concentration of 1 g/ml in litter matched WT controls.  Further, the onset of 
aggregation was also delayed in response to 10 g/ml of CRP, whereas there was a 
much greater delay and reduction in aggregation with 3 g/ml of CRP, while 1 g/ml 
was unable to induce aggregation (Figure 4.1 a).  In contrast, the dose-response curve 
was only slightly shifted in the absence of Gads.  A CRP concentration of 1 g/ml 
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which was ineffective with LAT-deficient platelets was able to induce full aggregation 
in the absence of Gads, although there was a notable delay in the onset of aggregation 
(Figure 4.1 a).  Further, Gads-deficient platelets responded very weakly to 0.3 g/ml 
CRP and with a large delay in onset.  On the other hand, aggregation induced by a low 
concentration of the GPCR agonist thrombin (0.03 U/ml), was not altered in the absence 
of either LAT or Gads (Figure 4.1 b). 
 
The aggregation response to rhodocytin in WT platelets is distinct from that of GPVI in 
that it has a characteristic delay which decreases with increasing concentration over the 
range 3-30 nM.  At a threefold lower concentration of 1 nM prolonged shape change is 
seen which is eventually followed by weak aggregation.  In the absence of LAT, there 
was a loss of aggregation to 3 nM rhodocytin which could be overcome by increasing 
the concentration to 30 nM, thereby restoring the response to the same level as WT 
platelets (Figure 4.1 c).  This result is in agreement with previously published work 
(Suzuki-Inoue et al, 2006).  In contrast, in the absence of Gads the response to 3 nM 
rhodocytin was comparable to the WT response.  At the lower concentration of 1 nM, 
shape change was further prolonged relative to litter matched controls and aggregation 
was not seen (Figure 4.1 c). 
 
These results demonstrate that the aggregation defect in the absence of Gads is very 
minor in comparison to the defect seen in the absence of LAT.  However, the two mice 
were on different strain backgrounds thereby raising the possibility that this could 
account for the difference.  To investigate this, the Gads
-/-
 mice were backcrossed for 
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nine generations from the Balb-c background on which they were supplied onto a 
C57Bl/6 background to match the LAT
-/-
 mice.  With the Gads
-/-
 mice on the equivalent 
background to the LAT
-/-
 mice we were able to assess the possible effect of the 
background on the extent of the Gads
-/-
 defect.  Using the same concentrations of both 
CRP and Rhodocytin as used above, we found no apparent difference in the severity of 
the defect in the absence of Gads (Figure 4.1 d).  There was again, slightly delayed but 
full aggregation to 1 g/ml CRP and a partial response to 0.3 g/ml CRP.  The response 
to 3 nM rhodocytin was comparable to the WT response, while the lower concentration 
of 1 nM was unable to induce aggregation.  However, the WT response is slightly 
delayed compared to the response in the Balb-c mice.  This small difference may be due 
to agonist batch differences, as these experiments were performed several months after 
the initial Balb-c background experiments. 
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Figure 4.1 – Aggregation responses in Gads-/- and LAT-/- platelets. 
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Figure 4.1 – continued.  Washed platelets (2 x 108/ml) were stimulated in an 
aggregometer with CRP (a), thrombin (b) or rhodocytin (c) and allowed to aggregate.  
Percentage light transmission was calculated.  (d) Washed platelets (2 x 10
8
/ml) from 
Balb-c or backcrossed C57Bl/6 mice were stimulated in an aggregometer with CRP or 
rhodocytin and allowed to aggregate.  Results are representative of between three and 
eight experiments. 
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Figure 4.1 – continued 
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Dense granule secretion was monitored in real-time along with aggregation in a Born-
lumi aggregometer.  Secreted ATP was detected by virtue of its catalysis of a luciferin-
luciferase light reaction.  After the experiment was completed, the addition of a known 
amount of ATP enabled quantification.  Both CRP and rhodocytin stimulate secretion of 
ATP in wild type platelets in an agonist-dependent manner.  In both cases, there is a 
delay in secretion which coincides with the end of the shape change response (Figure 
4.2). 
 
Similar to aggregation, secretion was abolished in the absence of LAT in response to 1 
g/ml CRP but was partially restored at the higher concentration of 3 g/ml.  In 
comparison there was a marked delay and decrease in the rate of secretion in the 
absence of Gads in response to 1 g/ml CRP.  A lower concentration of 0.3 g/ml 
shows a more pronounced defect in secretion (Figure 4.2 a).  The overall pattern of the 
decrease in the Gads deficient mice is similar to that for aggregation although it appears 
to be more substantial. 
 
There was also a reduction and delay in secretion induced by 1 nM rhodocytin in the 
absence of Gads, although there near full recovery at 3 nM.  In comparison, the 
response to 3 nM rhodocytin was reduced by more than 90% in the absence of LAT, 
with partial recovery observed in response to 30 nM (Figure 4.2 b).  These results 
therefore correspond to those for aggregation.  In comparison, secretion to a low dose of 
thrombin was not altered in the absence of Gads or LAT (Figure 4.2 c).  Secretion 
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experiments were performed on both backgrounds of Gads
-/-
 mice but as with 
aggregation, not significant differences were seen (not shown). 
 
These results demonstrate the relatively minor role of Gads in mediating platelet 
activation through both GPVI and CLEC-2, in contrast to the greater, yet dispensable 
role of LAT.  Neither protein plays a significant role in platelet activation by thrombin. 
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Figure 4.2 – ATP secretion in Gads-/- and LAT-/- platelets.  Washed platelets (2 x 
10
8
/ml) were stimulated in an aggregometer with CRP (a), rhodocytin (b) or thrombin 
(c) and allowed to aggregate.  ATP secretion was measured using light emission from 
luciferin/luciferase.  Results are representative of between three and eight experiments. 
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Figure 4.2 – continued 
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4.2.2 Platelet aggregation on collagen at arteriolar rates of flow 
Platelet aggregometry takes place in a low shear environment in contrast to the high 
shear forces that exist within arterioles.  Thus, it is possible that Gads and LAT may 
have a more significant role under flow conditions, where the speed of platelet integrin 
activation may be rate limiting in mediating platelet stable adhesion and aggregate 
growth.  To address this, I monitored aggregate formation in heparinised whole blood 
over a collagen-coated surface at an intermediate arteriolar flow rate of 1000 s
-1
.  This 
assay allows monitoring of aggregate formation in real time using a monolayer of 
collagen which has been described as a highly thrombogenic component of the 
extracellular matrix. 
 
When blood from WT mice was flowed at 1000 s
-1
 over the collagen surface, there was 
a rapid formation of a platelet monolayer followed by aggregate formation due to the 
capture and activation of further platelets.  Fluorescent and DIC endpoint images show 
these large, elongated 3-dimensional aggregates present in abundance at 4 min (Figure 
4.3).  There was no detectable difference in the initial stages of adhesion and platelet 
aggregate growth using blood from Gads
-/-
 mice compared to the WT (Figure 4.3 and 
not shown).  In comparison, LAT
-/-
 platelets were only able to form a monolayer on the 
collagen surface (Figure 4.3).  This strongly suggests that the level of signalling through 
GPVI following adherence to collagen is sufficient to bypass the small defect caused by 
the absence of Gads but not the larger defect caused by the absence of LAT.  
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Figure 4.3 – Adhesion of Gads-/- and LAT-/- platelets on collagen under flow 
conditions.  Heparinised whole mouse blood was fluorescently labelled with DiOC6 
and passed through collagen-coated glass capillaries at an intermediate shear rate of 
1000 s
-1
.  Platelets were imaged with a fluorescent microscope (lower) and subsequently 
fixed and imaged by differential interference contrast (DIC) microscopy (upper).  
Results are representative of five experiments. 
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4.2.3 Measurement of protein tyrosine phosphorylation 
The above results suggest a critical role for LAT in platelet function downstream of 
GPVI and CLEC-2 in contrast to the much more minor role of Gads.  To investigate the 
molecular basis of this, we measured tyrosine phosphorylation of key signalling 
proteins in the two receptor cascades, Syk, SLP-76, and PLC2.  Several concentrations 
of both CRP (0-3 g/ml) and rhodocytin (0-300 nM) were used to stimulate platelets for 
up to one and two minutes respectively, before lysis.  The tyrosine phosphorylation of 
these proteins was measured following immunoprecipitation and western blotting.  Both 
agonists stimulated a dose-dependent increase in tyrosine phosphorylation of all three 
proteins (Figure 4.4).  In the absence of Gads there was a small but consistent reduction 
in CRP-induced tyrosine phosphorylation of Syk, SLP-76 and PLC2 in comparison to 
wild type platelets (Figure 4.4 a), consistent with a supporting role for Gads in 
mediating activation of PLC2 through the LAT signalosome.  There was also a minor 
reduction in phosphorylation of SLP-76 and PLC2 in Gads-/- platelets in response to 
low concentrations of rhodocytin, whereas Syk phosphorylation appeared unaltered 
(Figure 4.4 b).  In comparison, there was a marked inhibition of phosphorylation of all 
three proteins in the absence of LAT in response to both CRP and rhodocytin, as 
previously reported (Pasquet et al, 1999; Suzuki-Inoue et al, 2006).  The reduction in 
Syk phosphorylation in platelets deficient in LAT and, in the case of GPVI, Gads, 
indicates a role for the LAT signalosome in maintaining Syk phosphorylation.  These 
results correspond to those for aggregation and secretion, with minor and major roles 
for Gads and LAT, respectively, in regulating tyrosine phosphorylation of PLC2 
downstream of GPVI and CLEC-2. 
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Figure 4.4 – Measurement of tyrosine phosphorylation in Gads-/- and LAT-/- 
platelets.  Washed platelets (5x 10
8
/ml) were stimulated with CRP for 60 sec (a) or 
rhodocytin for 120 sec (b) and subsequently lysed with NP-40 detergent.  PLC2, SLP-
76 and Syk were immunoprecipitated and samples were analysed by SDS-PAGE and 
western blotting for phosphotyrosine (4G10) and reprobed for PLC2, SLP-76 and Syk.  
Results are representative of between four and six experiments. 
 
 
 
Chapter 4 – Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2 
Page | 128 
 
4.2.4 Grb2 association with the LAT-Gads-SLP-76 signalosome 
The relatively minor role of Gads in mediating platelet activation by both CRP and 
rhodocytin raises the issue of whether there is a Gads-related protein that supports 
platelet activation downstream of GPVI and CLEC-2 through binding to LAT.  Gads 
belongs to a family of three adaptors, of which only Gads and Grb2 are expressed in 
platelets.  Grb2 has been shown to associate with both LAT and SLP-76 in T-cells and 
therefore has the potential to have a redundant role with Gads in platelets downstream 
of GPVI or CLEC-2.  The data so far has shown no apparent difference in the 
contribution of Gads in signalling by GPVI and CLEC-2, with the adapter playing a 
very minor role in either pathway.  Therefore, studies designed to compare the role of 
Gads and Grb2 focussed only on platelet activation by GPVI. 
 
Gads and Grb2 were immunoprecipitated from basal and CRP (10 g/ml) stimulated 
platelets and samples analysed for protein tyrosine phosphorylation (Figure 4.5).  
Tyrosine phosphorylated bands of 38 and 76 kDa, which co-migrate with LAT and 
SLP-76, respectively, were observed to immunoprecipitate with Gads, along with a 
band of 45 kDa that was detected after 90 seconds which co-migrates with a band that 
has previously been identified as Gads (Garcia et al, 2006).  Two further unidentified 
tyrosine phosphorylated bands of 60 and 150 kDa were also present.  In comparison, a 
major tyrosine phosphorylated band of 38 kDa that co-migrates with LAT is observed in 
the Grb2 immunoprecipitates, along with a weakly tyrosine phosphorylated band of 76 
kDa that co-migrates with SLP-76.  There is also a prominent tyrosine phosphorylated 
band of 125 kDa that has not been identified.  Confirmation that the 38 and 76 kDa 
bands correspond to LAT and SLP-76 was achieved by immunoprecipitation of both 
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proteins and Western blotting (not shown), although it is possible that these bands 
contain additional proteins.  These results indicate that Gads efficiently precipitates 
LAT and SLP-76 from platelets, which are presumably present as a complex.  In 
comparison, Grb2 binds to other protein complexes, although the presence of a small 
amount of SLP-76 and a high level of LAT indicates that it may also form a complex 
with the two adapters. 
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Figure 4.5 – Gads and Grb2 associate with LAT and SLP-76 in platelets.  Washed 
platelets (5x 10
8
/ml) were stimulated with 10 g/ml CRP for 30 and 90 sec and 
subsequently lysed with NP-40 detergent.  Gads and Grb2 were immunoprecipitated 
and samples were analysed by SDS-PAGE and western blotting for phosphotyrosine 
(4G10) and reprobed for Gads and Grb2.  Results are representative of five experiments. 
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4.2.5 Spreading of platelets on collagen and other matrix proteins 
As there is also a role for SLP-76 in signalling through IIb3 and GPIb-IX-V, I also 
investigated a potential role for Gads and LAT in spreading of platelets on surfaces 
coated with fibrinogen which binds IIb3 or VWF which can bind to both IIb3 and 
GPIb-IX-V under the right conditions.  Platelets were also spread on collagen coated 
surfaces as a comparison.  As the assay is under static conditions, immobilised VWF 
was pre-treated with botrocetin to activate it.  This pre-treatment confers specific 
binding to GPIb-IX-V but not to integrin IIb3 which requires pre-treatment with 
ristocetin for specific binding (McCarty et al, 2006).  Both botrocetin and ristocetin are 
snake venom toxins which act upon VWF causing conformational changes allowing 
binding to the above receptors.  These changes are physiologically induced by the shear 
forces under flow.  WT platelets adhere to the surface coated proteins and undergo 
spreading.  Spreading occurs in stages, firstly with the formation of actin-rich finger-
like protrusions (filopodia) followed by formation of actin-rich sheet-like structures 
(lamellipodia) which form between the filopodia.  This is then followed by formation of 
stress fibres.  This is referred to as full spreading, examples of which can be readily seen 
on collagen (Figure 4.6 a).  In contrast to results for human platelets, WT mouse 
platelets generate only filopodia and limited lamellipodia on fibrinogen or VWF-
botrocetin as illustrated in Figure 4.6 a and shown by others (Pearce et al, 2007; 
Calaminus et al, 2008). 
 
In the absence of Gads or LAT there was no significant difference in the surface area or 
morphology of platelets spread on either fibrinogen or VWF-botrocetin compared to 
WT platelets after 45 minutes of spreading (Figure 4.6).  This indicates that although 
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SLP-76 has been shown to be important in signalling downstream of IIb3 and GPIb-
IX-V, this role is independent of the LAT-Gads-SLP-76 signalosome.  Surprisingly, 
there was no significant difference in the spreading of LAT
-/-
 platelets on collagen 
compared to WT platelets, whereas there was a small but significant decrease in surface 
area in the absence of Gads (Figure 4.6 b).  While this is consistent with a minor role for 
Gads in signalling by GPVI, the lack of effect in the absence of LAT argues against this 
interpretation.  It is therefore possible that this reflects an unknown role for LAT in 
platelet development or in signalling by another receptor which contributes to platelet 
spreading. 
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Figure 4.6 – Spreading of Gads-/- and LAT-/- platelets on matrix proteins.  Washed 
platelets (2 x 10
7
/ml) were allowed to spread on collagen, fibrinogen or botrocetin-
treated VWF coated cover-slips for 45 min at 37˚C.  Non-adherent platelets were 
subsequently washed away and adherent platelets were fixed and imaged by differential 
interference contrast (DIC) microscopy (a).  Surface area of adherent platelets was 
calculated using ImageJ software (b).  The results are representative of five fields of 
view from three mice ± 95% confidence interval.  Statistical significance was calculated 
using a Student‟s t-test. 
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4.3 Discussion 
The primary aim of the work in this Chapter was to compare the roles of Gads and LAT 
in the regulation of PLC2 by GPVI and CLEC-2 signalling in view of the differential 
role of SLP-76, which forms a signalosome with LAT and Gads, between the two 
receptors.  SLP-76
-/-
 mice have previously been shown to have a complete blockade of 
GPVI signalling and also lack any mature T-cells (Yablonski et al, 1998; Clements et 
al, 1999; Gross et al, 1999; Judd et al, 2000) whereas CLEC-2 signalling was able to 
overcome SLP-76-deficiency with sufficiently high agonist concentrations (Suzuki-
Inoue et al, 2006).  In agreement with previous studies, LAT was shown to have major 
role in GPVI-mediated aggregation and secretion, although high concentrations of CRP 
were able to induce aggregation and secretion in the absence of LAT.  Furthermore, 
LAT
-/- 
platelets formed a monolayer but were unable to support aggregation when 
flowed over collagen at an arteriolar rate of flow.  This can be explained by the limited 
degree of platelet activation that occurs in the absence of LAT which is sufficient to 
support stable adhesion through integrins 21 and IIb3, which bind to collagen and 
VWF, respectively, but being insufficient to mediate the robust secretion that is 
essential for capture of flowing platelets and aggregate growth (Auger et al, 2005; 
Sarratt et al, 2005).  LAT also plays a critical role in aggregation and secretion induced 
by rhodocytin, although, as was the case for CRP, higher concentrations of rhodocytin 
are able to induce aggregation and secretion in the absence of LAT.  In contrast, LAT 
was not required for adhesion or spreading induced by integrin IIb3, GPIb-IX-V or 
collagen, which binds to both GPVI and integrin 21.  The lack of effect on collagen 
was surprising and suggests that LAT is either not essential or is not rate-limiting in the 
events that underlie aggregation and secretion.  Because of the absence of a role in 
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signalling by collagen in this assay, it is not possible to draw conclusions surrounding 
the role of LAT in signalling by integrin IIb3 and GPIb-IX-V. 
 
In comparison, Gads was found to have a minor role in mediating platelet activation by 
both GPVI and CLEC-2, as illustrated by a slight delay in onset and reduction in the 
magnitude of aggregation and secretion to low but not intermediate or high 
concentrations of both CRP and rhodocytin.  This minor effect did not translate into a 
defect in aggregate formation under flow on collagen suggesting that this effect has 
minor if any physiological significance.  Gads is also not required for spreading induced 
by integrin IIb3 or GPIb-IX-V although it was found to play a minor role in mediating 
spreading on collagen, although the molecular basis of this is unclear as no defect was 
observed in the absence of LAT as discussed above.  We attribute the minor role of 
Gads in platelet activation by GPVI and CLEC-2 to supporting the recruitment of SLP-
76 to the LAT signalosome, bearing in mind that it is able to efficiently precipitate both 
proteins in stimulated platelets.  However, the relatively minor phenotype of the Gads-
deficient platelets compared to that of platelets deficient in LAT or SLP-76 suggests the 
presence of one or more, more prominent pathways of regulation of SLP-76 by LAT.  
Furthermore, there must also be a LAT-independent pathway of regulation of SLP-76 in 
view of the fact that platelets deficient in this adapter protein have a more marked 
phenotype than those deficient in LAT, at least following activation by GPVI. 
 
This minor role for Gads in supporting both GPVI and CLEC-2 signalling in platelets is 
in line with its more limited role in TCR signalling relative to that of LAT and SLP-76.  
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For example, mice deficient in Gads have a marked reduction in mature T-cells (Yoder 
et al, 2001) as a consequence of inhibited pre-TCR signalling, whereas mice deficient in 
LAT and SLP-76 have a blockade of pre-TCR signalling, resulting in no circulating T-
cells.  Further, mutation of the site of interaction of Gads with LAT reduces signalling 
through the T-cell receptor by approximately 50% (Zhang et al, 2000) in contrast to the 
full inhibition of T-cell signalling that is observed in the absence of LAT and SLP-76 
(Finco et al, 1998; Yablonski et al, 1998).    Thus, the relatively minor role of Gads in 
TCR, CLEC-2 and GPVI signalling in comparison with those of LAT and SLP-76, may 
be to facilitate the interaction of the two adapter proteins in response to threshold levels 
of receptor stimulation. 
 
Platelets express the Gads-related adapter, Grb2, which also binds to LAT and SLP-76.  
This raises the possibility that a role for Gads could be masked by the presence of Grb2, 
especially in light of studies in a DT40 cell model reporting that Gads and Grb2 are 
both able to couple LAT and SLP-76, albeit Gads does this more efficiently (Ishiai et al, 
2000).  Indeed, this is in line with the present result which demonstrates that Grb2 
associates strongly with LAT but only weakly with SLP-76, whereas Gads is 
constitutively associated with SLP-76 (not shown).  The strong binding of Grb2 to LAT 
is explained by the presence of three sites for association of Grb2 with LAT at 
phosphotyrosines Y171, Y191 and Y226 (Zhang et al, 2000; Paz et al, 2001; Perez-
Villar et al, 2002), compared with a single, major site for Gads at phosphotyrosine 
Y191, and to a lesser extent Y171 (Zhang et al, 2000; Paz et al, 2001; Perez-Villar et al, 
2002).  On the other hand, the increased binding of Gads to SLP-76 is explained by the 
very high affinity of the association between the C-terminal SH3 domain of Gads and a 
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RxxK motif on SLP-76 of 3 nM (Liu et al, 1999; Seet et al, 2007).  This is an atypical 
interaction, as the majority of SH3 domains bind to proline rich sequences with 
micromolar affinity, including the C-terminal SH3 domain of Grb2 which binds to a 
proline rich region in SLP-76 with an affinity of 3 M (Seet et al, 2007).  Grb2 knock-
out mice are embryonically lethal due to its ubiquitous expression.  For future work it 
would be interesting if a platelet specific Grb2 knock-out could be generated as this 
could be studied in regards to GPVI and CLEC-2 signalling and also crossed with the 
Gads
-/-
 mouse to make platelets deficient in both proteins.  This would make it possible 
to address the possible redundancy of these two proteins. 
 
Overall, these observations, along with previously published data, emphasise that SLP-
76 and LAT are the key adapters in bringing PLC2 to the membrane, with SLP-76 
being essential for tyrosine phosphorylation and activation of PLC2.  In the absence of 
LAT, a limited degree of tyrosine phosphorylation of PLC2 occurs which is sufficient 
to enable recovery of aggregation to high concentrations of CRP in the absence of shear.  
On the other hand, platelet aggregation on collagen at arteriolar shear is abolished in the 
absence of LAT resulting in increased tail-bleeding and impaired thrombus formation in 
vivo (Kalia et al, 2008).  Interestingly, a reduction in tyrosine phosphorylation of Syk 
was also observed in the absence of LAT in platelets stimulated by CRP and rhodocytin.  
This reduction is possibly due to increased accessibility of tyrosine residues in Syk to 
protein tyrosine phosphatases in the absence of LAT, or due to the lack of signals that 
recruit Src kinases to the signalosome. 
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In comparison to LAT and SLP-76, Gads has a relatively minor role in recruiting SLP-
76 to LAT and activation of PLC2, and does not contribute to platelet aggregation at 
arteriolar shear.  Indeed, it may be that the evolution of a role for Gads in mediating the 
interaction between LAT and SLP-76 has occurred because of its role in facilitating 
weak signalling by the pre-TCR to ensure an optimal number of mature T-cells in the 
circulation rather than to facilitate TCR or platelet activation at higher agonist 
concentrations.  Consistent with this theory, Gads can be bypassed in a LAT 
signalosome as PLC can be recruited to LAT through a direct interaction between LAT 
Y132 and its N-terminal SH2 domain (Zhang et al, 1998; Aguado et al, 2002; Sommers 
et al, 2002). 
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5.1 Introduction 
The previous chapter investigated the requirement for Gads in GPVI and CLEC-2 
signalling using mice deficient in Gads, an adaptor protein which couples SLP-76 to 
LAT.  SLP-76 is essential for activation of phospholipase C by GPVI whereas, in 
contrast, CLEC-2 is able to bypass the requirement for the adapter at high agonist 
concentrations.  The membrane adapter LAT also plays a key role in platelet activation 
by GPVI and CLEC-2, although in both instances, high agonist concentrations bypass 
the requirement for the membrane adapter. 
 
LAT belongs to a family of transmembrane adaptor proteins as described in detail in 
Appendix I.  The partial requirement for LAT in GPVI and CLEC-2 signalling raises 
the possibility that one or more LAT-like molecules are present in platelets and exhibit 
redundancy with LAT.  Furthermore, this could also explain why SLP-76 but not LAT 
is required in IIb3-mediated outside-in signalling, especially given that a mutation in 
SLP-76 which destroys its ability to bind to LAT inhibits spreading on fibrinogen 
(Abtahian et al, 2006).  Signalling by GPVI and CLEC-2 takes place in lipid rafts (also 
known as glycosphingolipid-enriched microdomains or GEMs), where LAT is localised, 
whereas IIb3 signalling takes place outside of these domains (Wonerow et al, 2002; 
Pollitt et al, 2010).  This may therefore explain why LAT does not play a role in 
signalling by the integrin.   
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Although structurally unrelated to the LAT family of adapter proteins, several candidate 
membrane adapter proteins/novel cell surface receptors have been identified which 
contain one or more cytoplasmic tyrosines that undergo tyrosine phosphorylation and 
mediate binding to SH2 domain-containing proteins.  It is therefore possible that one or 
more of these could also explain the partial or lack of role of LAT in mediating 
activation of platelets by surface glycoprotein receptors.  One such candidate is G6f 
which is found in the multi-histocompatibility complex class III gene region along with 
several other proteins that are expressed in platelets including the novel ITIM receptor, 
G6b-B (Ribas et al, 2001).  G6f has a predicted molecular weight of 36 kDa, similar to 
that of LAT, and consists of a glycosylated extracellular Ig domain, a transmembrane 
domain and a cytoplasmic tail containing a single tyrosine residue at position 281 in the 
human sequence.  Expression of wild type G6f but not the Y281F mutant in K562 cells 
and treatment with the tyrosine phosphatase inhibitor vanadate leads to association with 
Grb2 and Grb7, therefore establishing tyrosine 281 as a docking site for SH2 domain-
containing proteins (De Vet et al, 2003).  Furthermore, cross-linking G6f through an N-
terminal T7 tag using a T7 antibody resulted in Erk phosphorylation in K562 cells, 
presumably as a result of recruitment of Grb2 and activation of Ras (De Vet et al, 
2003).  Importantly, we have identified the presence of G6f in platelets by analysing 
tyrosine phosphorylated proteins in CRP-stimulated human platelets (Garcia et al, 
2006).  Potentially, therefore, tyrosine phosphorylation of G6f in platelets could account 
for some of the redundancy with LAT bearing in mind that both proteins bind to the 
adapter Grb2. 
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The aim of this chapter is to investigate the presence of the various LAT family proteins 
and G6f in platelets and to investigate whether they are phosphorylated downstream of 
GPVI and CLEC-2.  Furthermore, through collaboration with Dr Burkhart Schraven in 
Magdeburg, Germany, the functional roles of the LAT-like proteins have been 
investigated using mice deficient in one or more of the transmembrane family of 
adapters.  
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5.2 Results 
5.2.1 Raising a G6f antibody 
To confirm whether G6f is expressed in platelets, a rabbit polyclonal antibody was 
raised against a peptide based on the cytoplasmic tail (amino acids 259-274) of human 
G6f (Figure 5.1 a).  The antibody was raised in rabbits using a commercial company, 
Invitrogen, and the bleeds tested against human G6f expressed in 293T HEK (human 
kidney epithelial) cells alongside mock transfected cells.  To achieve this, I cloned 
human G6f into a pEF6 expression vector (Invitrogen) with a C-terminal Myc tag 
attached using a two-round, or „nested‟ PCR approach.  The cDNA was obtained from 
K562 cells, which were used in the original cloning of G6f (De Vet et al, 2003).   
 
G6f was transfected into 293T HEK cells and the expressed protein immunoprecipitated 
using an antibody against the Myc tag.  The immunoprecipitate was then used for 
testing of serum from two rabbits immunised against G6f.  This work revealed the 
presence of a clear band of approximately 45 kDa with the serum from all three bleeds 
of both rabbits (not shown)  The final bleed from the second rabbit had the strongest 
response as shown in Figure 5.1 b.  Importantly, this band was not present in the mock 
transfected control cell lysates or in the pre-immune rabbit serum (not shown).  This 
band was successfully reprobed for the presence of Myc, confirming that the antibody 
recognises G6f (Figure 5.1 b).  There was also a minor band of approximately 85 kDa 
which was not visible when reprobed with the Myc antibody (not shown) indicating that 
it is not a dimer of G6f. 
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Figure 5.1 – A new antibody recognises transfected G6f.  a) Human and mouse G6f 
were aligned using ClustalW web-based software highlighting the conserved YxN motif 
in bold, and the regions used as antigen are shown in red.  b) 293T cells were 
transfected with G6f or an empty vector control and subsequently lysed with NP-40 
detergent.  Myc-tagged proteins were immunoprecipitated and samples were analysed 
by SDS-PAGE and western blotting with the third bleed test serum and reprobed for 
Myc.  Results are representative of three experiments.  Similar results were seen with 
both first and second bleed serum samples, whereas the pre-immune serum was 
negative. 
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5.2.2 G6f is phosphorylated downstream of GPVI in platelets 
G6f was identified by Dr Ángel García through analysis of tyrosine phosphorylated 
proteins in CRP-stimulated human platelets (Garcia et al, 2006).  This approach 
identified several proteins that undergo tyrosine phosphorylation upon stimulation by 
CRP, including G6f.  Confirmation of tyrosine phosphorylation of G6f was achieved 
using the novel antibody to the membrane adapter described above.  Platelets were 
stimulated with CRP (10 g/ml) for 30–300 sec and tyrosine phosphorylated proteins 
were immunoprecipitated using the monoclonal -phosphotyrosine antibody, clone 
4G10 and western blotted for G6f (Figure 5.2 a).  A clear band for G6f was seen in the 
whole cell lysate lane, whereas there was a minor band in the immunoprecipitate from 
non-stimulated platelets.  Following CRP stimulation, a marked increase in the amount 
of G6f was detected which peaked at 90 sec.  These results confirm that G6f is present 
in platelets and strongly suggest that it undergoes tyrosine phosphorylation upon 
activation of GPVI.  Interestingly, G6f runs as a smaller sized protein (~40 kDa) 
compared to over-expressed G6f in the HEK 293T cells, most likely due to differential 
glycosylation.  Interestingly, a second band of approximately 70 kDa was also identified 
by western blotting using the novel antibody to G6f.  This could represent a covalent 
dimer of the transmembrane protein or a non-specific band. 
 
The G6f antibody was tested for its ability to immunoprecipitate G6f from platelets 
stimulated with CRP (10 g/ml) in order to directly confirm that it undergoes tyrosine 
phosphorylation upon activation of the collagen receptor (Figure 5.2 b).  Western 
blotting with the anti-phosphotyrosine antibody 4G10 revealed the presence of a major 
band of 40 kDa in CRP-stimulated platelets.  Re-probing with the G6f serum identified 
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the same band thereby demonstrating that it is G6f.  Several weakly phosphorylated 
bands were also observed on the 4G10 western blot, most notably at 50, 70 and 85 kDa, 
which are likely to represent co-precipitating proteins.  In addition, G6f may interact 
with non-tyrosine phosphorylated proteins although these would not be seen using this 
experimental design.   
 
The novel antibody was used to investigate the ability of other agonists to stimulate 
phosphorylation of G6f.  These studies were performed in the absence or combined 
presence of apyrase and indomethacin in order to block the feedback effects of ADP and 
thromboxane A2 and thereby establish whether phosphorylation was direct.  Apyrase 
hydrolyses ATP and ADP to AMP and will therefore remove any ADP secreted by the 
activated platelets and indomethacin is a cycloxygenase (COX) 1 and 2 inhibitor which 
inhibits the production of thromboxanes from arachidonic acid in the platelet.  CRP (10 
g/ml) stimulated robust phosphorylation of G6f which was not altered in the presence 
of apyrase and indomethacin (Figure 5.2 c).  Collagen (10 g/ml) also stimulated 
marked phosphorylation of G6f.  In contrast, a high concentration of rhodocytin (300 
nM) stimulated weak tyrosine phosphorylation of G6f which was completely blocked in 
the presence of apyrase and indomethacin suggesting that stimulation through CLEC-2 
is critically dependent on the secondary mediators ADP and TxA2.  The G protein-
coupled receptor agonist thrombin (1 U/ml) but not ADP (100 M) also stimulated 
weak tyrosine phosphorylation of G6f.  In addition, thrombin and rhodocytin stimulated 
weak tyrosine phosphorylation of a doublet of approximately 70 kDa which may be the 
same band as observed in CRP-stimulated platelets.  A small increase in G6f 
phosphorylation was also seen when platelets were spread on a fibrinogen-coated 
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surface whereas there was no such increase on a BSA-coated surface (Figure 5.2 d).  
Reprobing the gel revealed the presence of a much higher amount of G6f in the 
fibrinogen-stimulated platelets.  Despite this difference, the complete absence of a co-
migrating tyrosine phosphorylated band in non-stimulated platelets supports the idea 
that integrin IIb3 is able to induce weak phosphorylation of G6f.
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Figure 5.2 – G6f is undergoes tyrosine phosphorylation downstream of GPVI in 
platelets. 
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Figure 5.2 – continued.  a) Washed platelets (5x 108/ml) were stimulated with 10 
g/ml CRP for up to 300 sec and subsequently lysed with NP-40 detergent.  Tyrosine 
phosphorylated proteins were immunoprecipitated using 4G10.  WCL = whole cell 
lysate.  b) Washed platelets (5x 10
8
/ml) were stimulated with 10 g/ml CRP for up to 90 
sec and subsequently lysed with NP-40 detergent.  c)  Washed platelets (5x 10
8
/ml) 
were stimulated with 10 g/ml CRP for 90 sec, 10 g/ml collagen for 90 sec, 1 U/ml 
thrombin for 60 sec, 300 nM rhodocytin for 300 sec or 100 M ADP for 60 sec, and 
subsequently lysed with NP-40 detergent.  Apy = apyrase, Indo = indomethacin.  d) 
Washed platelets (5x 10
8
/ml) were spread on surfaces coated with 100 g/ml fibrinogen 
or 5 mg/ml BSA for 45 mins at 37˚C.  Adherent cells were lysed with NP-40 detergent.  
In b, c and d, G6f was immunoprecipitated using the newly raised antibody.  Samples 
were all analysed by SDS-PAGE and western blotting for phosphotyrosine (4G10) and 
G6f.  Results are representative of three experiments. 
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5.2.3 G6f is associated with Grb2 but not Gads 
Grb2 was shown to associate with G6f in a phosphorylation dependent manner in K562 
cells (De Vet et al, 2003).  Co-immunoprecipitation studies where therefore performed 
to investigate whether Grb2 and the closely related adapter protein Gads associate with 
G6f in platelets.  Platelets were stimulated with CRP (10 g/ml) for 30 and 90 sec and 
lysed.  Gads, Grb2 and G6f were immunoprecipitated from the lysates and the samples 
subjected to SDS-PAGE before western blotting for the presence of all three proteins 
(Figure 5.3).  There was no detectable association between Gads with either Grb2 or 
G6f.  Similarly, Grb2 was not detected following immunoprecipitation of G6f.  On the 
other hand, G6f could be weakly detected in the Grb2 immunoprecipitate at 30 sec and 
robustly at 90 sec, confirming the phosphorylation-dependent association seen 
previously (De Vet et al, 2003).  The absence of Grb2 in the G6f immunoprecipitate 
may be due to a steric effect as the peptide that was chosen for immunisation is only 
four amino acids upstream of Y281 (Figure 5.1 a). 
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Figure 5.3 – G6f associates with Grb2 in a phosphorylation dependant manner.  
Washed platelets (5x 10
8
/ml) were stimulated with 10 g/ml CRP for up to 90 sec and 
subsequently lysed with NP-40 detergent.  G6f, Gads and Grb2 were 
immunoprecipitated and samples were analysed by SDS-PAGE and western blotting for 
Gads, Grb2 and G6f.  Results are representative of three experiments. 
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5.2.4 G6f cannot substitute for LAT in LAT-deficient cells 
LAT-deficient Jurkat T-cells (Jcam2) were used to investigate whether G6f can act as a 
LAT-replacement molecule in the GPVI signalling pathway.  The Jcam2 cells were 
generated by Dr Arthur Weiss (San Francisco) using a mutagenesis strategy and 
screening for the absence of LAT (Finco et al, 1998).  The reintroduction of LAT into 
the cells served as a control to show that LAT is sufficient to restore activation bearing 
in mind that the mutagenesis strategy may have introduced other mutations.  The Jcam2 
cells were transfected with both GPVI and FcR and either LAT or G6f.  Receptor 
activation was monitored using a NFAT-luciferase reporter construct as described in 
Chapter 3.  Jcam2 cells transfected with GPVI and FcR were unresponsive to collagen 
unless co-transfected with LAT (Figure 5.4).  Although it was noticeable that the 
response was weak compared to that in DT40 cells it was comparable to previous 
experiments in Jurkat cells (Fuller et al, 2007).  In contrast, co-transfection of G6f was 
unable to restore the response to collagen suggesting that it is unable to mimic the loss 
of LAT in this cell line model. 
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Figure 5.4 – G6f cannot substitute for LAT.  Jcam2 cells were transfected with 2 
g/ml each of GPVI, FcR, G6f and LAT as specified, and a NFAT-luciferase reporter 
plasmid.  Transfected cells were stimulated with 10 M collagen for 6 hrs at 37˚C and 
then the luciferase activity was measured as a readout of signalling.  Results were 
normalised for transfection efficiency and plotted as fold increase over basal.  Result is 
representative of three experiments. 
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5.2.5 G6f is not a novel collagen receptor 
G6f was identified in a proteomic analysis of CRP-stimulated platelets raising the 
possibility that it is a receptor for CRP or collagen and that it is able to confer activation 
of PLC2.  To test this possibility, we monitored phosphorylation of G6f and NFAT 
activation in transfected DT40 cells stimulated by CRP or collagen.  Cells transfected 
with GPVI/FcR exhibited a robust NFAT response to collagen and a smaller response 
to CRP (Figure 5.5 a).  The difference between the two agonists in this model has been 
previously described and is attributed to weak but sustained signalling over the 6 hour 
incubation with collagen compared to powerful but short lived activation with CRP 
(Tomlinson et al, 2007).  Transfection of G6f alone was unable to confer a response to 
collagen or CRP.  Furthermore, the response to collagen or CRP in cells that had been 
co-transfected with G6f and GPVI/FcR was not significantly different to that in cells 
transfected with GPVI/FcR thereby demonstrating that G6f does not contribute to the 
activation of PLC2 in this cell line model. 
 
As a second, indirect test, of whether G6f is a collagen receptor, I monitored tyrosine 
phosphorylation of the membrane adapter in G6f-transfected cells stimulated by CRP.  
The synthetic collagen was used in these studies since G6f was first identified as a 
tyrosine phosphorylated protein in CRP-stimulated platelets (Garcia et al, 2006).  G6f is 
weakly tyrosine phosphorylated in basal, serum-starved DT40 cells with no significant 
increase in phosphorylation upon stimulation by CRP.  In contrast, the tyrosine 
phosphatase inhibitor, pervanadate, induced a marked increase in tyrosine 
phosphorylation of G6f (Figure 5.5 b).  The disparity between the level of tyrosine 
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phosphorylation of G6f in CRP and pervanadate treatment strongly suggests that G6f is 
not a receptor for CRP. 
 
Higher agonist concentrations were not tested suggesting the possibility that G6f could 
show a signalling response or phosphorylation if stimulated with higher concentrations.  
However, these concentrations are considered to be maximal with regards to platelet 
stimulation and the DT40 NFAT assay and therefore it seems unlikely that any potential 
signalling to supra-high agonist concentrations would have any physiological relevance. 
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Figure 5.5 – G6f is not a CRP receptor.  a) DT40 cells were transfected with 2 g/ml 
of GPVI and FcR, G6f or a combination of both, and a NFAT-luciferase reporter 
plasmid.  Transfected cells were stimulated with 10 g/ml collagen or 10 g/ml CRP 
for 6 hrs at 37˚C and then the luciferase activity was measured as a readout of 
signalling.  Results were normalised for transfection efficiency and plotted as a 
percentage of the GPVI-collagen response.  Error bars represent the geometric mean ± 
standard error of three experiments.  b) DT40 cells were transfected with G6f.  
Following serum starvation, cells were stimulated with 10 g/ml CRP or 0.1 mM 
pervanadate for 300 sec and subsequently lysed with NP-40 detergent.  Myc-tagged 
proteins were immunoprecipitated and samples were analysed by SDS-PAGE and 
western blotting for G6f and Myc.  Results are representative of three experiments. 
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5.2.6 Minimal expression of G6f in mouse platelets 
To assess whether G6f is expressed in mouse platelets, I raised an antibody to the 
cytoplasmic tail of mouse G6f (amino acids 259-273, Figure 5.1 a shows a comparison 
of the mouse and human sequence), using the same commercial approach for the anti-
human G6f antibody.  The antibody was validated by cloning mouse G6f into a pEF6 
expression vector (Invitrogen) with a C-terminal Myc tag attached.  When this construct 
was expressed in 293T cells, mouse G6f was immunoprecipitated using the -Myc 
antibody followed by western blotted using serum from the immunised rabbit.  A clear 
band of approximately 45 kDa was observed which was absent in mock transfected 
cells.  Reprobing the membrane for Myc confirmed that the band was mouse G6f 
(Figure 5.6 a).  There was also the presence of a smaller sized protein (~40 kDa) in the 
transfected lysate which did not re-probe for Myc, suggesting either an unrelated protein 
or a break-down product of full length G6f protein. 
 
Several attempts to demonstrate expression of G6f expression in whole cell lysates of 
mouse platelets by a combination of western blotting and immunoprecipitation were 
carried out but failed to provide definitive proof of expression.  Only through the use of 
4G10 to immunoprecipitate tyrosine phosphorylated proteins from basal and CRP 
stimulated mouse platelets was it possible to identify the presence of a weak band of 
approximately 55 kDa in GPVI stimulated platelets using the validated mouse G6f 
antibody (Figure 5.6 b).  However, since this protein is much bigger than predicted 
(although this could be explained by glycosylation), and we were unable to 
immunoprecipitate G6f and detect its presence by western blotting, we suspect that the 
positive band is an unrelated protein that is phosphorylated upon stimulation by CRP.  
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Indeed, a serial analysis of gene expression (SAGE) on mouse megakaryocytes did not 
reveal any tags for mouse G6f (Senis et al, 2007).  Several non-specific bands are also 
seen under both basal and stimulated conditions.  We therefore conclude that G6f is 
absent or below the level of detection in mouse platelets. 
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Figure 5.6 – G6f was not detected in mouse platelets. 
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Figure 5.6 – continued.  a) 293T cells were transfected with mouse G6f or an empty 
vector control and subsequently lysed with NP-40 detergent.  Myc-tagged proteins were 
immunoprecipitated and samples were analysed by SDS-PAGE and western blotting 
with the mouse G6f antibody and reprobed for Myc.  Results are representative of three 
experiments.  b) Washed mouse platelets (5x 10
8
/ml) were stimulated with 10 g/ml 
CRP for 90 sec and subsequently lysed with NP-40 detergent.  Tyrosine phosphorylated 
proteins were immunoprecipitated and samples were analysed by SDS-PAGE and 
western blotting for mouse G6f.  Results are representative of three experiments. 
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5.2.7 Studies on LAT-like proteins reveal the presence of PAG in platelets 
To search for a LAT-like molecule that lies upstream of SLP-76 and PLC2 in platelets, 
we were given access to several knock-out mouse lines in Dr Burkhart Schraven‟s 
laboratory in Magdeburg, Germany.  This approach has a number of benefits over that 
of western blotting of this family of adapters, as antibodies to this group of proteins are 
notoriously poor most likely due to their relatively low levels of expression.  Thus, a 
more definitive guide to the functional presence of one or more LAT-like proteins was 
to investigate a possible phenotype using platelets deficient in one or more of the family 
of membrane adapters. 
 
We were provided with access to platelets deficient in one LAT family protein, namely 
LAT
-/-
, NTAL
-/-
, LAX
-/-
, LIME
-/-
 and PAG
-/- 
or compound knock-out mice, namely 
LAT/NTAL
-/-
, LAT/NTAL/LAX
-/-
 and PAG/LIME
-/-
.  Protein lysates were generated 
from all of these mice and used for western blotting.  Platelet lysates from litter matched 
controls, primary T-cells and in the case of NTAL, primary B cells, were used to verify 
expression in platelets and to verify the efficacy of the antibodies.  Using the specific 
antibodies, all of which were supplied by Dr Schraven, we were able to confirm 
expression of PAG in platelets which runs at approximately 70 kDa in both T-cells and 
in platelets, and which was absent in PAG knock-out platelets (Figure 5.7 a).  On the 
other hand, we were unable to detect the presence of NTAL in platelets although we 
were able to confirm its expression in B cells where it runs as a 30 kDa protein (not 
shown).  We were unable to detect the presence of LIME (Figure 5.7 b) and LAX (not 
shown) in platelets or in the T cell lysates, raising concern over the sensitivity of the 
available antibodies. 
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Figure 5.7 – PAG is expressed in mouse platelets.  Washed platelets (1x 107) from 
wild type (WT) and knock-out mice lysed with SDS sample buffer.  Platelet and T-cell 
lysates were analysed by SDS-PAGE and western blotting for a) PAG and b) LIME.  
Results are representative of two mice. 
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5.2.8 Contribution of LAT-family proteins to GPVI-mediated platelet activation 
We used lysates from the various mutant mice platelets to investigate a possible role for 
the LAT-like adapter proteins in phosphorylation of PLC2 by GPVI.  For these studies, 
washed platelets from WT, PAG
-/-
, LIME
-/- 
and PAG/LIME
-/- 
mice were stimulated with 
collagen (10 g/ml) or CRP (3 g/ml CRP) for 90 sec.  Syk and PLC2 were then 
immunoprecipitated and analysed for tyrosine phosphorylation by western blotting.  
There was no significant difference in tyrosine phosphorylation of Syk or PLC2 by 
CRP or collagen in the absence of any of the above LAT-like adapter proteins, with the 
exception that, in the absence of LIME alone, the CRP response appears slightly low in 
comparison to the other mice (Figure 5.8).  On the other hand, phosphorylation of 
PLC2 was similar to that in the other lysates suggesting that the reduction in Syk may 
reflect loss of sample.  Due to the limited availability of tissue, we were unable to test a 
full dose response curve to CRP or collagen, and to extend this to other agonists such as 
rhodocytin.  We were also unable to monitor aggregation for the same reason. 
 
LAT
-/-
 platelets were also used as control (not shown) and results were similar to those 
seen in Figure 4.4.  Similar experiments were also performed on LAX
-/-
 and NTAL
-/-
 
platelets (not shown) which showed no obvious differences although we were unable to 
confirm or deny their expression in platelets making it difficult to draw any firm 
conclusions.  Likewise, LAT/NTAL
-/-
 and LAT/NTAL/LAX
-/-
 platelets showed no 
obvious difference in comparison to LAT
-/-
 platelets (not shown). 
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Figure 5.8 – Measurement of tyrosine phosphorylation in PAG-/-, LIME-/- and 
PAG/LIME
-/-
 platelets.  Washed platelets (2x 10
8
/ml) were stimulated with 3 g/ml 
CRP for 60 sec or 10 g/ml collagen for 90 sec and subsequently lysed with NP-40 
detergent.  PLC2 and Syk were immunoprecipitated and samples were analysed by 
SDS-PAGE and western blotting for phosphotyrosine (4G10) and reprobed for PLC2, 
and Syk.  Results are representative of studies performed using platelets from two mice. 
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5.3 Discussion 
The transmembrane adaptor protein LAT has previously been shown to be required for 
optimal GPVI and CLEC-2 signalling, but a residual response can be seen in its 
absence.  This raises the possibility of expression of a LAT-like protein in platelets.  
The aim of this chapter was to test several candidate proteins which may have 
redundancy with LAT. 
 
A potential candidate was highlighted by the identification of G6f using proteomics 
(Garcia et al, 2006). G6f is a potential orphan receptor with a single transmembrane 
domain and a cytoplasmic tail containing one tyrosine residue (Ribas et al, 2001).  After 
raising and validating an antibody against human G6f, we were able to confirm its 
presence in human platelets and demonstrate that it undergoes tyrosine phosphorylation 
in response to CRP.  G6f was also robustly phosphorylated by collagen, whereas it was 
only weakly phosphorylated in response to fibrinogen, thrombin and rhodocytin.  The 
weak response to rhodocytin was dependent on the formation of the secondary 
mediators, ADP and thromboxanes, as is the case for phosphorylation of CLEC-2 itself 
and downstream proteins (Pollitt et al, 2010).  These results show that GPVI is the 
major receptor mediating G6f phosphorylation, although other receptors can also 
mediate weak G6f phosphorylation 
 
The single cytoplasmic tyrosine residue, Y281 is in a consensus sequence for Grb2 
binding via its SH2 domain, namely YxN.  In agreement with this, and also with the 
initial study on G6f (De Vet et al, 2003), we were able to confirm a phosphorylation-
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dependent association with Grb2 using CRP-stimulated platelets. In contrast, no 
association with the Grb2 family member Gads was observed.  The functional 
contribution of the G6f-Grb2 association, if any, to platelet activation by GPVI is 
unclear.  However, the observation that G6f was unable to restore the response to 
collagen in GPVI-FcR-transfected LAT-deficient Jurkat T-cells argues against a role in 
the regulation of PLC2.  As a caveat to this experiment, it should be noted that we were 
unable to confirm expression of G6f at the cell surface by flow cytometry due to the 
absence of a suitable antibody.  Following CRP, thrombin and rhodocytin stimulation, 
several larger, unidentified tyrosine phosphorylated proteins were seen to co-precipitate 
with G6f, but their overall level of tyrosine phosphorylation was weak compared to the 
level of G6f phosphorylation.  Identifying these proteins is an interesting line of future 
work on G6f as it is unclear if they are constitutively associated proteins or if they 
associate with G6f following its phosphorylation, and whether this is via Grb2 or an 
independent association. 
 
G6f contains an extracellular Ig domain, thus raising the possibility that it may be a 
novel collagen receptor by analogy to GPVI.  Transfection of DT40 cells with G6f 
however failed to result in a NFAT response to collagen or CRP and nor were we able 
to detect significant tyrosine phosphorylation downstream of GPVI.  Therefore it seems 
likely that G6f is phosphorylated downstream of GPVI in platelets rather than serving as 
a collagen receptor.  The observation that collagen and CRP stimulate robust 
phosphorylation of G6f argues for a potentially important role in mediating platelet 
activation.  However, a functional role for G6f seems less likely following our failure to 
find conclusive evidence for expression of the mouse homologue in mouse platelets, 
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either using a validated antibody or by a SAGE analysis (Senis et al, 2007).  Caution is 
necessary in regard to this conclusion however as the major receptor for thrombin in 
human platelets, PAR-1 is not expressed in mouse platelets, where PAR-4 plays the 
major role.  It is possible that a similar scenario may exist for a putative G6f-like 
protein.  Also, rather than a role as a receptor it may be that G6f acts as an adaptor 
protein for GPVI signalling, however ligand hunting for G6f would be an interesting 
line of future work as it may have a novel ligand for platelet activation. 
 
I also investigated the possible expression of several other LAT-like molecules in 
mouse platelets, thereby able to demonstrate expression of PAG.  I was unable to detect 
the presence of LIME, NTAL or LAX, although concerns remain in regard to the 
efficacy of available antibodies for the latter two adapters.  PAG-deficiency had no 
significant effect on CRP- or collagen-mediated Syk and PLC2 phosphorylation.  In T-
cells, PAG acts as a membrane anchor for the Src family kinase regulatory protein, Csk 
(Brdicka et al, 2000; Kawabuchi et al, 2000).  Csk mediates phosphorylation of Src 
kinases at their inhibitory tyrosines.  The lack of an effect of the absence of PAG on 
platelet activation by GPVI therefore argues against a major role for the membrane 
adapter in regulating Csk in platelets downstream of collagen.   However, extending 
future studies with this knock-out mouse to look at integrin IIb3 signalling would be 
particularly interesting as Csk has been shown to mediate Src family kinases 
downstream of the integrin (Obergfell et al, 2002). 
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The hypothesis that formed much of the basis of the work in this chapter, namely that 
the LAT-independent component of platelet activation by GPVI and CLEC-2 reflects 
the presence of a LAT-like molecule that overlaps with LAT in terms of function, is still 
valid as there are other LAT-like proteins whose expression has yet to be confirmed, as 
well as other potential candidates.  However, the alternative possibility that there is no 
such protein should also be considered, especially given our inability to identify robust 
expression of one or more LAT-like proteins other than that of PAG.  In such a 
scenario, it may be that the role of LAT is to amplify signalling by GPVI but that a 
residual level of activation of PLC2 can occur in its absence.  In a similar argument, 
the role of Gads may be to amplify GPVI signalling but again the pathway can function 
independent of Gads or a related family protein.  Studies on mice deficient in Gads and 
Grb2 are required to investigate this.  Neither LAT nor Gads are required for signalling 
downstream of IIb3 consistent with the localisation of LAT and the integrin to lipids 
rafts and non-raft regions, respectively.  Again, it remains unclear if platelets express 
one or more LAT- and Gads-like proteins that facilitate signalling by the integrin.  
Nevertheless, the much greater level of expression of integrin IIb3 (80,000 – 120,000 
copies in human platelets) relative to GPVI (4,000 – 6,000), and the fact that the latter is 
the more powerful signalling receptor, provides an indirect argument against the 
presence of a LAT-like protein downstream of activation of Syk by the integrin. 
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6.1 Summary of results 
In this thesis I have provided evidence for a unique mode of signalling through Syk and 
a single YxxL sequence via cross-linking of CLEC-2 molecules.  This trans binding is a 
novel mechanism through Syk which until now was thought to activate either through 
cis binding to the dual tyrosines of an ITAM or through a phosphotyrosine independent 
mechanism through integrin IIb3.  I have also shown a minimal role for the adaptor 
protein Gads in both GPVI and CLEC-2 signalling pathways.  It appears that Gads is as 
dispensable for GPVI and CLEC-2 signalling as LAT is, whereas CLEC-2 is capable of 
a small degree of signalling independently of its constitutive binding partner, SLP-76.  I 
have also investigated the possible role of a number of other LAT-like molecules in the 
ITAM signalling pathway, but failed to identify any potential candidates.  In this, the 
final chapter, I will discuss some of the wider aspects of the work. 
 
6.2 The evolution of ITAM receptors and C-type lectins 
After performing numerous database searches with the help of John Herbert we have 
found that orthologs for a number of ITAM proteins can be found as far back as 
zebrafish (Danio rerio).  Due to the size of and divergence of the C-type lectin family, 
only one (CLEC14) was found to have an ortholog in zebrafish.  Other zebrafish C-type 
lectins were too divergent in sequence to be directly linked to a human C-type lectin.  
We were however, able to find a single zebrafish protein which had both a C-type lectin 
domain and a putative ITAM-like sequence (Figure 6.1).  Both Syk and Zap-70 can also 
be found in the zebrafish. 
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Figure 6.1 – Sequence alignment of human CLEC-2 and a hypothetical zebrafish 
C-type lectin LOC564061.  Sequences were aligned using ClustalW web-based 
software. 
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As discussed in Chapter 3, we have found that a number of the ITAM-containing 
proteins have their ITAM sequence split over two exons.  We therefore hypothesised 
that the possibility of gene duplication of the ITAM-like sequence resulted in a protein 
which was able to signal more efficiently due to a higher affinity for Syk.  As the 
known ITAM-like C-type lectins have multiple roles, in haemostasis, lymphatic 
development and in the innate immune system, it is possible that at one time this family 
of proteins mediated many of these responses in a thrombocyte forerunner.  A review by 
Pancer and Cooper discusses the evolution of the adaptive immune system and they 
conclude that this appeared along with the rearrangement of IgG domain receptors in 
jawed fish (Pancer and Cooper, 2006).  The jawless fish have an immune system that 
utilises Leucine-rich-repeat receptors.  This step in evolution from innate towards 
adaptive immunity could be linked to the appearance of the variable IgG receptors and 
possibly the presence of an ITAM.  Before this ITAM-like molecules may have been 
the less efficient mode of signalling used. 
 
The opposite hypothesis to this would be that the ITAM-like molecules may have 
evolved through convergent evolution with ITAM proteins and use a common 
signalling pathway.  This is perhaps the more likely scenario given that ITAMs are 
found mostly on IgG superfamily proteins, whereas the only ITAM-like proteins we 
know of so far are C-type lectins.  Also, the ITAM-like proteins are type II proteins 
whereas the ITAM proteins are type I and are therefore quite different structurally.  
However, the structure and activity of Syk versus Zap-70 is also of interest when 
thinking about the evolution and role of ITAMs and ITAM-like receptors although it is 
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of note that Syk is also able to be activated by a phosphotyrosine independent 
mechanism through integrin IIb3.  
 
Syk is expressed in a number of tissues whereas the expression of Zap-70 is restricted to 
haematopoietic cells, in particular, T-cells and natural killers (NK) cells where its role is 
in ITAM signalling.  In B-cells, platelets, granulocytes and macrophages Syk plays this 
role although Syk is also expressed in thymocytes (a T-cell precursor), but then lost 
following T-cell maturation.  The sequence of Syk and Zap-70 reveals an N-terminal 
SH2 domain, a short inter-domain linker (interdomain A), a C-terminal SH2 domain, a 
SH2-kinase linker (interdomain B), and a kinase domain (Figure 6.2).  A structural 
analysis of inactive Zap-70 shows that these domains are arranged such that the tandem 
SH2 domains present their phosphotyrosine binding pockets in line facing in one 
direction, and the kinase domain presents the active site in the opposite direction 
(Deindl et al, 2007).  This arrangement allows for tight binding to the ITAM sequence 
and therefore, membrane localisation of the kinase domain such that it is orientated to 
phosphorylate its targets. 
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Figure 6.2 – Domain arrangement of Syk and Zap-70.  a) Linear representation of 
the domains and their sizes (in number of amino acid residues) of Syk and Zap-70.  b) 
Colour-coded cartoon representing the 3D arrangement of the domains of Syk and Zap-
70 including the phosphotyrosine binding pockets of the SH2 domains. 
b) 
a) 
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Interestingly, in Syk, the two phosphotyrosine binding pockets are complete, one per 
SH2 domain.  However, Zap-70 is slightly different with one complete binding pocket 
present in the C-SH2 domain, and the second binding pocket is partially formed by both 
SH2 domains.  Therefore, the N-SH2 domain of Zap-70 alone should not be able to bind 
to phosphotyrosine and for Zap-70 to bind to an ITAM, both SH2 domains have to align 
correctly.  In comparison, we have presented data in Chapter 3 confirming that both of 
the single SH2 domains of Syk are capable of phosphotyrosine binding.  A further 
difference between the two kinases is in their kinase domains, with the kinase domain of 
Syk being shown as up 100 times more active than that of Zap-70 in an in vitro kinase 
assay (Latour et al, 1996).  Furthermore, interdomain A in Syk has been shown to be 
more flexible than in Zap-70 suggesting it would be able to accommodate binding 
between two chains much more efficiently than Zap-70. 
 
Therefore, we can hypothesise that ITAM-like molecules came first in evolution, and 
that they were able to mediate a number of functions (haemostasis, innate immunity, 
development) in a generic blood cell.  This is mediated through cross-linking by Syk 
which is made possible due to the ability of both SH2 domains to bind to 
phosphotyrosine residues and the high intrinsic activity of its kinase domain.  The 
appearance of an ITAM could result in a higher affinity interaction with Syk and more 
efficient signalling.  The high activity of Syk would be advantageous in a platelet-like 
cell which is required to activate fully and rapidly in times of vascular damage, 
however, immune cells which evolved for the adaptive immune system, like T-cells, 
have to undergo positive and negative selection and the high activity of Syk could 
possibly affect these processes.  Therefore the use of Zap-70 with its lower intrinsic 
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kinase activity and requirement for binding to an ITAM and not an ITAM-like molecule 
could be a way that evolution refined the ITAM signalling pathway. 
 
Future work on the structure-activity relationship between CLEC-2 and Syk will be 
carried out to investigate these hypotheses by comparing the ability of CLEC-2 to signal 
through Syk compared to Zap-70 using the NFAT-luciferase cell line reporter assay and 
cells deficient in either Syk or Zap-70.  Interestingly, it has previously been published 
that CLEC-2 can signal in a Jurkat T-cell line (Zap-70 expressing) using the NFAT-
luciferase reporter assay, although the increase over basal in these cells is much lower 
than the increases seen in the DT40 B-cell line (Fuller et al, 2007).  Chimeric versions 
of Syk and Zap-70 would also be interesting for further experiments.  Constructs with 
the SH2 domains of Zap-70 and the kinase domain of Syk, and vice versa would allow 
us to investigate if it is the less active kinase domain or the unusual SH2 domains of 
Zap-70 which were the key to any differences found.  Furthermore, the Zap-70 kinase 
domain may become more active when paired with the Syk SH2 domains due to 
intramolecular interactions; however in vitro kinase assays can be used to study this 
also. 
 
Various CLEC-2 mutants can also be investigated looking at the importance of the 
DEDG sequence preceding the YxxL and also CLEC-2/ITAM chimeras to investigate if 
CLEC-2 can signal with two YxxL sequences in its cytoplasmic tail, and would this also 
be possible through Zap-70? 
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It would also be interesting to extend studies into the zebrafish and investigate the 
ITAM-like C-type lectin we found to be expressed there.  Use of in situ hybridisation 
could be used to look at the expression of this protein.  If it were present in 
thrombocytes, cells which play an analogous role to platelets found in birds and fish, it 
would be particularly provocative as it may play a CLEC-2-like role.  Further, the use of 
morpholino knock-down technology could be used to look at the development of the 
fish in the absence of the protein, and also the use of a laser injury model to investigate 
a haemostatic role for the protein.  DT40 cell line studies could also be performed 
following cloning of the zebrafish protein to see if it can signal in a similar fashion to 
CLEC-2. 
 
6.3 Final thoughts 
During the course of this thesis, many new developments for a physiological role of 
CLEC-2 have been published.  While this does not directly influence the work in this 
thesis which has focussed on the downstream signalling pathway it does validate the 
importance of working on the receptor.  Unlike GPVI which has a well defined 
haemostatic role though its interaction with collagen, it seems that the major 
physiological role of CLEC-2 is in development through its interaction with podoplanin.  
This field of work is showing the importance of platelets not only as a means of 
preventing blood loss, but as a crucial cell required for the development of, and 
continued maintenance of the lymphatic system (Carramolino et al, 2010; Uhrin et al, 
2010).  Unpublished, ongoing work in our lab with a recently generated CLEC-2 knock-
out mouse has shown the mutation to be lethal, highlighting the importance of this 
molecule.  Furthermore, radiation chimeric mice have blood filled lymph providing 
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evidence for a continued role of CLEC-2 in the maintenance of the lymphatics in adult 
mice (Hughes, Pollitt, Finney and Watson, Unpublished). 
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I.1 The LAT-family of adaptor proteins 
The members of the family of LAT-like transmembrane adaptor proteins (TRAPs) are 
NTAL, LAX, PAG, LIME, TRIM and SIT (Figure I.1, adapted from (Horejsi et al, 
2004).  All of these family members are structurally related to LAT in that they have a 
short or limited extracellular domain, a transmembrane domain and a tyrosine-rich 
cytoplasmic tail.  LAT has nine tyrosine residues in its cytoplasmic tail which, when 
phosphorylated, enable LAT to act as a protein scaffold to several SH2 domain-
containing proteins including Gads, Grb2 and PLC2.  LAT also contains an inner 
membrane proximal CxxC motif which undergoes palmitoylation and thereby allows 
LAT to integrate into GEMs (glycolipid enriched microdomains, aka lipid rafts).  PAG, 
NTAL and LIME also have a CxxC motif proximal to the membrane which mediates 
their association with GEMs.  SIT, TRIM and LAX are not found associated with 
GEMs and lack this CxxC motif. 
 
Although LAT was first identified in T-cells, it is also found in platelets, NK cells and 
in B-lineage, but not mature B-cells, playing a role downstream of the pre-BCR (Jumaa 
et al, 1999; Minegishi et al, 1999; Pappu et al, 1999; Hayashi et al, 2000; Oya et al, 
2003; Su and Jumaa, 2003).  NTAL (Non-T-cell Activation Linker, also known as LAB, 
Linker for Activation of B-cells) is expressed in B-cells, NK and myeloid cells 
including mast cells.  It contains eight cytoplasmic tyrosine residues which allow 
association with Grb2 but not PLC or SLP-65 and SLP-76 downstream of the BCR or 
Fc receptor (Brdicka et al, 2002; Janssen et al, 2003).  PAG (Protein Associated with 
GEMs, also known as CBP, (CSK Binding Protein)), appears to be ubiquitously 
Appendix I 
Page | 223 
 
expressed and contains nine cytoplasmic tyrosine residues, although the only clearly 
defined binding partner is Csk (c-Src Kinase).  It has been proposed that PAG is a 
membrane anchor for Csk, allowing it to phosphorylate and thereby inhibit Src family 
kinases (Brdicka et al, 2000; Kawabuchi et al, 2000).  LIME (Lck-Interacting 
Membrane Protein) is expressed in T-cells and contains five cytoplasmic tyrosine 
residues.  It has been shown to associate with Lck, Fyn and Csk.  Paradoxically, despite 
the association with Csk, Lck has been demonstrated to have increased activity when 
associated with LIME suggesting it is present in an active conformation (Brdickova et 
al, 2003; Hur et al, 2003). 
 
LAX (Linker for Activation of X cells (where X is an unidentified cell)) has been 
shown to be expressed in T- and B-lymphocytes.  It contains eight cytoplasmic tyrosine 
residues which are able to bind to Gads, Grb2 and PI-3kinase although it is unable to 
reconstitute T-cell receptor signalling in LAT-deficient Jurkat T-cells (Zhu et al, 2002).  
TRIM (T-cell Receptor Interacting Molecule) is expressed in T-cells where it forms a 
disulphide-linked homodimer.  Each monomer contains three cytoplasmic tyrosines and 
the only binding partner described so far is PI-3 kinase.  Over-expression of TRIM in 
Jurkat T-cells was shown to increase, by approximately two-fold, the levels of 
expression of the T-cell receptor on the cell surface and therefore the magnitude of 
TCR-mediated signalling (Bruyns et al, 1998; Kirchgessner et al, 2001).  SIT (SHP2-
Interacting TRAP) is expressed in T-cells where it forms a disulphide-linked 
homodimer.  Each monomer contains five cytoplasmic tyrosines which, following TCR 
mediated activation, allow binding of Grb2, SHP2 and Csk.  The association with SHP2 
and Csk suggests an inhibitory role and indeed this has been shown experimentally by 
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over-expression in Jurkat T-cells (Marie-Cardine et al, 1999; Pfrepper et al, 2001).  
Interestingly, SIT is the only member of this family with an N-linked glycosylation 
group, which is found in the small extracellular domain.  It has been proposed that this 
may be a binding site for an unidentified ligand although there is no direct evidence for 
this (Marie-Cardine et al, 1999). 
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Figure I.1 – Transmembrane adaptor proteins.  Adapted from (Horejsi et al, 2004). 
